metformin has been researched along with Breast Neoplasms in 422 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The MA32 study investigated whether 5 years of metformin (versus placebo) improves invasive disease-free survival in early-stage breast cancer (BC)." | 9.69 | Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). ( Chen, BE; Gelmon, KA; Goodwin, PJ; Hershman, DL; Lemieux, J; Ligibel, JA; Parulekar, WR; Sathe, C; Whelan, TJ, 2023) |
| "Recently, several clinical trials have attempted to find evidence that supports the anticancer use of metformin in breast cancer (BC) patients." | 9.51 | The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. ( Barakat, HE; Elberry, AA; Hussein, RRS; Ramadan, ME; Zaki, MA, 2022) |
| "Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies." | 9.51 | Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. ( Abramson, VG; Bliss, JM; Chen, BE; Ennis, M; Gelmon, KA; Goodwin, PJ; Hershman, DL; Hobday, TJ; Lemieux, J; Ligibel, JA; Mackey, JR; Mayer, IA; Mukherjee, SD; Oja, C; Parulekar, WR; Rabaglio-Poretti, M; Rastogi, P; Rea, DW; Shepherd, LE; Stambolic, V; Stos, PM; Thompson, AM; Wesolowski, R; Whelan, TJ, 2022) |
| "These two meta-analyses can inform decision-making for women with type 2 diabetes regarding their use of metformin and the use of screening mammography for early detection of breast cancer." | 9.41 | Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis. ( Alagoz, O; Cryns, VL; Gangnon, RE; Hajjar, A; Heckman-Stoddard, BM; Lu, Y; Trentham-Dietz, A, 2023) |
| " We will include any randomised clinical trial of metformin for the treatment of breast cancer in adult women, and will not impose restrictions regarding context, language or publication date." | 9.41 | Metformin for the treatment of breast cancer: protocol for a scoping review of randomised clinical trials. ( Araujo, CFM; Bragagnoli, AC; Fukushima, FB; Murta-Nascimento, C; Nunes, LC; Souza, CP; Vidal, EIO, 2021) |
| "We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention." | 9.41 | A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density. ( Algotar, AM; Altbach, M; Centuori, S; Chalasani, P; Chow, HS; Galons, JP; Guillen-Rodriguez, J; Huang, C; Martinez, JA; Pinto, L; Roe, DJ; Tapia, E; Thomson, CA; Trujillo, J; Villa-Guillen, DE, 2021) |
| "In this randomized clinical trial study, eligible women with fibroadenomas were assigned randomly to the metformin (1000 mg daily for six months) or the placebo group." | 9.41 | Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial. ( Abedi, M; Alipour, S; Eslami, B; Faiz, F; Maleki-Hajiagha, A; Saberi, A; Shahsavari, S, 2021) |
| "Thirty-six patients with untreated primary breast cancer were recruited to a window study and transcriptomic profiling of tumour samples carried out before and after metformin treatment." | 9.34 | Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. ( Adams, RF; Buffa, FM; Cheng, WC; Collins, JM; English, R; Fielding, BA; Frezza, C; Gaude, E; Haider, S; Harjes, U; Harris, AL; Hoefler, G; Jha, P; Karpe, F; Lord, SR; Pinnick, KE; Pollak, MN; Roy, PG; Segaran, A; Thompson, AM; Wigfield, S, 2020) |
| " Female patients with early breast cancer (N = 314) will be randomly assigned to two groups (placebo, metformin 2000 mg)." | 9.34 | Metformin intervention against ovarian toxicity during chemotherapy for early breast cancer: Study protocol for a randomized double-blind placebo-controlled trial. ( Cui, P; Jin, Y; Li, X; Li, Y; Liu, R; Ma, X; Ren, W; Wang, B; Wang, S; Zhang, J; Zhang, M; Zhang, P, 2020) |
| "Pre-clinical data suggest metformin might enhance the effect of chemotherapy in breast cancer (BC)." | 9.30 | A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. ( Cescon, D; Chang, MC; Dowling, RJO; Elser, C; Ennis, M; Goodwin, PJ; Hamm, C; Haq, R; Lohmann, AE; Pimentel, I; Potvin, KR; Stambolic, V, 2019) |
| " Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer." | 9.30 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. ( Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ, 2019) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 9.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| "Purpose Previous studies have suggested an association between metformin use and improved outcome in patients with diabetes and breast cancer." | 9.24 | Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. ( Agbor-Tarh, D; Andersson, M; Azim, HA; Bradbury, I; Cufer, T; de Azambuja, E; Di Cosimo, S; Fumagalli, D; Gralow, J; Harris, L; Keane, M; Kroep, J; Moreno-Aspitia, A; Piccart-Gebhart, M; Salman, P; Sarp, S; Simon, SD; Sonnenblick, A; Toi, M; Wolff, AC, 2017) |
| "Fasting plasma samples from 373 overweight or obese breast cancer survivors randomly assigned to metformin (n = 194) or placebo (n = 179) administration were collected at baseline, after 6 months (Reach For Health trial), and after 12 months (MetBreCS trial)." | 9.22 | Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. ( Bellerba, F; Bonanni, B; Chatziioannou, AC; Gandini, S; Hartman, SJ; Jasbi, P; Johansson, H; Keski-Rahkonen, P; Robinot, N; Scalbert, A; Sears, DD; Trolat, A; Vozar, B, 2022) |
| "Previous studies have suggested that metformin might improve survival outcomes in patients with breast cancer." | 9.22 | Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis. ( Kataoka, Y; Kawaguchi-Sakita, N; Kurata, Y; Morio, K; Shiroshita, A, 2022) |
| "Current evidence from phase II clinical trials does not support that additional use of metformin could improve the survival outcome in women with breast cancer." | 9.22 | Metformin and survival of women with breast cancer: A meta-analysis of randomized controlled trials. ( Du, X; Long, J; Ma, X; Mao, H; Pan, B; Wang, Q, 2022) |
| "Weight loss and metformin are hypothesized to improve breast cancer outcomes; however the joint impacts of these treatments have not been investigated." | 9.22 | Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, B; Patterson, RE; Villaseñor, A, 2016) |
| "The study will evaluate whether metformin can result in favorable changes in breast density, select proteins and hormones, products of body metabolism, and body weight and composition." | 9.22 | Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol. ( Altbach, M; Chalasani, P; Chow, HH; Galons, JP; Martinez, JA; Roe, D; Stopeck, A; Thompson, PA; Thomson, CA; Villa-Guillen, DE, 2016) |
| "Metformin has therapeutic potential against breast cancer, but the mechanisms of action in vivo remain uncertain." | 9.20 | Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. ( Chang, MC; Coates, P; Done, SJ; Dowling, RJ; Goodwin, PJ; Hadad, SM; Jordan, LB; Moulder-Thompson, S; Purdie, CA; Stambolic, V; Thompson, AM, 2015) |
| "Previous observational studies have suggested that metformin in diabetes patients may reduce breast cancer risk more than the reductions from other anti-diabetes medications." | 9.20 | Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial. ( Ahn, C; Cho, YM; Han, W; Hwang, Y; Ko, KP; Ma, SH; Noh, DY; Park, BJ; Park, SK; Yang, JJ, 2015) |
| "We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients." | 9.19 | Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. ( Ahmad, A; Cremers, S; Crew, KD; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, M; Refice, S; Taback, B; Wang, A; Xiao, T, 2014) |
| "This study will provide direct evidence of the anti-tumor effect of metformin in non-diabetic, postmenopausal patients with ER-positive breast cancer." | 9.19 | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). ( Ahn, SH; Chae, BJ; Choi, SY; Han, S; Han, W; Jeong, J; Jeong, SS; Jung, SY; Jung, Y; Kang, E; Kang, HS; Kang, T; Kim, EK; Kim, J; Kim, KS; Kim, LS; Kim, MK; Kim, SI; Kim, SW; Kim, TH; Lee, JE; Lim, W; Moon, HG; Nam, SJ; Noh, DY; Paik, NS; Park, CH; Yoo, YB; Yoon, JH; Yu, JH, 2014) |
| "Treatment of diabetics with metformin is associated with decreased breast cancer risk in observational studies, but it remains unclear if this drug has clinical antineoplastic activity." | 9.19 | Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. ( Aristarco, V; Bassi, F; Bonanni, B; Cazzaniga, M; DeCensi, A; Gandini, S; Guerrieri-Gonzaga, A; Hofmann, U; Johansson, HA; Lazzeroni, M; Luini, A; Macis, D; Mora, S; Pollak, MN; Pruneri, G; Puntoni, M; Schwab, M; Serrano, D, 2014) |
| "Metformin has been associated with antitumour activity in breast cancer (BC) but its mechanism remains unclear." | 9.17 | The effect of metformin on apoptosis in a breast cancer presurgical trial. ( Bonanni, B; Bottiglieri, L; Cazzaniga, M; DeCensi, A; Dell'Orto, P; Gentilini, OD; Guerrieri-Gonzaga, A; Lazzeroni, M; Pagani, G; Pruneri, G; Puntoni, M; Serrano, D; Varricchio, C; Viale, G, 2013) |
| " We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer." | 9.17 | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC, 2013) |
| "Metformin is associated with reduced breast cancer risk in observational studies in patients with diabetes, but clinical evidence for antitumor activity is unclear." | 9.16 | Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. ( Aristarco, V; Bassi, F; Bonanni, B; Bruzzi, P; Cazzaniga, M; Decensi, A; Galimberti, V; Gennari, A; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Luini, A; Pruneri, G; Puntoni, M; Serrano, D; Trabacca, MS; Varricchio, C; Veronesi, P; Viale, G, 2012) |
| "This is a randomized controlled trial to test the effect of different doses of metformin in patients with breast cancer and without diabetes, with the aim of modifying the hormonal and metabolic parameters linked to breast cancer prognosis." | 9.16 | Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. ( Abbà, C; Ambroggio, S; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Colombero, R; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2012) |
| "Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women." | 9.15 | Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. ( Baker, L; Bray, S; Deharo, S; Dewar, JA; Hadad, S; Hardie, DG; Iwamoto, T; Jellema, G; Jordan, L; Moulder-Thompson, S; Purdie, C; Pusztai, L; Thompson, AM, 2011) |
| "We administered metformin (1500 mg per day) to 32 women with early breast cancer whose baseline insulin levels were at least 45 pmol/L to determine its effect on insulin levels." | 9.13 | Insulin-lowering effects of metformin in women with early breast cancer. ( Clemons, M; Ennis, M; Fantus, IG; Goodwin, PJ; Graham, M; Pritchard, KI, 2008) |
| "This study aims to determine the efficacy and safety of metformin administration as adjunctive therapy on mortality among females with breast cancer." | 9.12 | A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. ( Eugenio, KPY; Jimeno, CA; Lusica, PMM; Sacdalan, DBL, 2021) |
| "Currently, tamoxifen is the only drug approved for reduction of breast cancer risk in premenopausal women." | 9.05 | Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. ( Dietze, EC; Jones, VC; Jovanovic-Talisman, T; McCune, JS; Seewaldt, VL, 2020) |
| "Breast cancer patients receiving metformin as treatment for diabetes showed significant reduction in levels of insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki-67." | 9.05 | The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials. ( Chhabra, M; Clark, C; Gudi, SK; Manzari, N; Mousavi, SM; Naik, G; Rahmani, J; Thompson, J; Varkaneh, HK; Zhang, Y, 2020) |
| "Observational studies show a beneficial effect of adjuvant metformin therapy on breast cancer survivals, but data from randomized clinical trials are lacking." | 9.01 | The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials. ( Bi, Y; Liu, Y; Wang, C; Yuan, J; Zhang, ZJ, 2019) |
| "Although preclinical work is vital in unraveling the molecular tenets which apply to metformin action in breast cancer, it is by nature unable to capture the host's response to metformin in terms of insulin-mediated effects and related changes in the hormonal and metabolic asset at the systemic level." | 8.91 | Metformin and breast cancer: basic knowledge in clinical context. ( Barba, M; Della Giulia, M; Di Lauro, L; Giordano, A; Marchetti, P; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Vici, P, 2015) |
| "Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pathologic complete response rate than do diabetic patients not receiving metformin, but findings on salvage treatment have been inconsistent." | 8.91 | Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis. ( Chen, K; Dai, Y; Jia, X; Li, D; Mao, Y; Tao, M; Tian, Y; Xie, J; Xu, H, 2015) |
| " The unexpected ability of the anti-type II diabetes drug metformin to inactivate mTOR and decrease p70S6K1 activity further reveals that this biguanide, generally considered non-toxic and remarkably inexpensive, might be considered for new combinatorial lapatinib-based protocols in HER2-overexpressing breast cancer patients." | 8.85 | mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). ( del Barco, S; Martín-Castillo, B; Menéndez, JA; Oliveras-Ferraros, C; Vázquez-Martín, A, 2009) |
| "We aimed at evaluating the effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women." | 8.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "Some studies have shown that metformin inhibits the proliferation of breast cancer (BC) cells via multiple ways." | 8.31 | The efficacy of metformin as adjuvant to chemotherapy on IGF levels in non-diabetic female patients with progressive and non-progressive metastatic breast cancer. ( Alharbi, AA; Boshra, MS; Elgendy, MO; Essa, NM; Gabr, A; Harakeh, S; Mahmoud, MM; Salem, HF; Tashkandi, HM, 2023) |
| "Previous studies assessed the prognostic effect of aspirin, statins, and metformin in breast cancer (BC) patients, with inconclusive results." | 8.31 | Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. ( Andreassen, BK; Botteri, E; Löfling, LL; Støer, NC; Ursin, G, 2023) |
| "In this research we evaluated molecular mechanism of effect of metformin in radio sensitivity of breast cancer cells." | 8.31 | Metformin Caused Radiosensitivity of Breast Cancer Cells through the Expression Modulation of miR-21-5p/SESN1axis. ( Ansari, Y; Moghbelinejad, S; Momeni, A; Ramezani, M; Saffari, F, 2023) |
| "Metformin associated lactic acidosis may potentially occur after combination with ribocilib, an uncommon but lethal complication from the interaction of these drugs, especially in patients who had preexisting renal impairment." | 8.12 | Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report. ( Lagampan, C; Parinyanitikul, N; Poovorawan, N, 2022) |
| "The cytotoxic effects of various concentrations of metformin caprylic acid and metformin hydrochloride (0 to 20 mM) on MCF-7 and MDA-MB-231 breast cancer cells and MCF-10A human mammary epithelial cell line were assessed by the MTT assay." | 8.12 | Replacement of hydrochloride in metformin hydrochloride with caprylic acid to investigate its effects on MCF-7 and MDA-MB-231 breast cancer cell lines. ( Darzi, L; Forouzandeh-Moghdam, M; Mousavi-Koodehi, B; Najafi, F; Sadeghizadeh, M, 2022) |
| " We investigated potential synergy between shikonin and anti-diabetic metformin against tumorigenic properties of breast cancer cell line MCF-7." | 8.12 | Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition. ( Gardaneh, M; Gavidel, P; Sabouni, F; Tabari, AR, 2022) |
| "Whether pioglitazone may affect breast cancer risk in female diabetes patients is not conclusive and has not been investigated in the Asian populations." | 8.12 | Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis. ( Tseng, CH, 2022) |
| "Metformin has demonstrated a chemoprotective effect in breast cancer but there is limited evidence on the effect of cumulative exposure to metformin and the risk of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR + /HER2-) breast cancer." | 8.12 | Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. ( Abughosh, SM; Aparasu, RR; Chikermane, SG; Johnson, ML; Sharma, M; Trivedi, MV, 2022) |
| "Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied." | 8.02 | An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors. ( Bonanni, B; Cardenas, A; Chung, FF; Cuenin, C; Hartman, SJ; Herceg, Z; Hubbard, AE; Johansson, H; Novoloaca, A; Nwanaji-Enwerem, JC; Sears, DD; Smith, MT; Van der Laan, L, 2021) |
| "This study investigated the association of insulin, metformin, and statin use with survival and whether the association was modified by the hormone receptor status of the tumor in patients with breast cancer." | 8.02 | Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients. ( Choi, M; Han, J; Han, W; Im, SA; Jang, MJ; Kim, M; Kim, TY; Lee, DW; Lee, HB; Lee, KH; Moon, HG; Noh, DY; Yang, BR, 2021) |
| "In the present study we aimed to figure out the effect of metformin on the expression of AMPK-alpha, cyclin D1, and Tp53, and apoptosis in primary breast cancer cells (PBCCs)." | 8.02 | Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism ( Beşli, N; Hocaoğlu Emre, FS; Kanıgür, G; Şenol, K; Yaprak Saraç, E; Yenmiş, G, 2021) |
| "Type 2 diabetes (T2D) has been associated with increased breast cancer risk, but commonly prescribed antidiabetic medications such as metformin may reduce risk." | 8.02 | A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. ( Bookwalter, DB; Jackson, CL; O'Brien, KM; Park, YM; Sandler, DP; Weinberg, CR, 2021) |
| "The possible synergistic combination between metformin and tangeretin was initially evaluated using MTT cell viability assay in different breast cancer cell lines (MCF-7, MDA-MB-231, and their resistant phenotype)." | 8.02 | Tangeretin boosts the anticancer activity of metformin in breast cancer cells via curbing the energy production. ( Abdin, SM; Mdkhana, B; Omar, HA; Zaher, DM, 2021) |
| "There are still inconsistencies about the role of metformin on breast cancer." | 8.02 | The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes. ( Behrouzi, B; Emami, AH; Mohagheghi, MA; Sadighi, S; Zokaasadi, M, 2021) |
| " In this in vitro study, we hypothesized that metformin with an effective dose can inhibit tumor cell proliferation and metastasis by modulating the expressions of MMP-2 and -9 and interfering with NF-kB signaling in primary breast cancer cells (PBCCs)." | 8.02 | Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity. ( Besli, N; Dilek Kancagi, D; Ekmekci, CG; Kanigur Sultuybek, G; Karagulle, OO; Ovali, E; Senol, K; Soydas, T; Tastan, C; Tuncdemir, M; Ulutin, T; Yaprak Sarac, E; Yenmis, G; Yilanci, M, 2021) |
| "The relationship between type 2 diabetes (T2D), metformin, and breast cancer is complex." | 8.02 | Making sense of associations between type 2 diabetes, metformin, and breast cancer risk. ( Park, YM; Sandler, DP, 2021) |
| " The main purpose of this study is to strengthen the application of non-oncological drug metformin on breast cancer treatment in the perspective of epigenetics." | 8.02 | lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell. ( Hao, Z; He, Y; Huang, Y; Li, T; Song, Y; Wang, B; Wu, Z; Yuan, K; Zhang, J; Zhao, Q; Zheng, S; Zhou, Z, 2021) |
| "Numerous studies have suggested that metformin treatment can increase breast cancer survival; however, it is unclear whether its effects interact with intrinsic subtype or diabetic status." | 8.02 | Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study. ( Cho, MJ; Kim, BH; Kwon, J, 2021) |
| "Breast cancer cell lines MCF-10, MCF-7 and BT-474 expressing various levels of HER2 were examined for their response to treatment with sulforaphane (SLFN), metformin (MTFN), Nano-MTFN or combinations." | 7.96 | Co-Treatment with Sulforaphane and Nano-Metformin Molecules Accelerates Apoptosis in HER2+ Breast Cancer Cells by Inhibiting Key Molecules. ( Gardaneh, M; Heidari-Keshel, S; Keshandehghan, A; Nikkhah, S; Tahermansouri, H, 2020) |
| "A cell viability assay was utilized to examine the inhibitory effect of metformin on proliferation of breast cancer cells." | 7.96 | Metformin alleviates breast cancer through targeting high-mobility group AT-hook 2. ( Feng, W; Li, Y; Ren, H; Wang, D, 2020) |
| "We studied a large cohort of early-stage, hormone-positive breast cancer patients to determine if there is an association between RS and metformin treatment." | 7.96 | Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients. ( Blanter, J; Cascetta, K; Ru, M; Tharakan, S; Tiersten, A; Zimmerman, B, 2020) |
| "This study confirms that metformin is transported into tumor tissue in women with breast cancer." | 7.96 | Metformin is distributed to tumor tissue in breast cancer patients in vivo: A ( Al-Suliman, N; Frøkiær, J; Gormsen, LC; Jakobsen, S; Jessen, N; Munk, OL; Pedersen, SB; Sundelin, EIO; Vahl, P; Vendelbo, M, 2020) |
| "Metformin use prior to diagnosis of cancer was associated with a decrease in risk of both breast cancer (OR = 0." | 7.96 | Use of metformin and risk of breast and colorectal cancer. ( Gronich, N; Gruber, SB; Pinchev, M; Rennert, G; Rennert, HS, 2020) |
| "Microscopic imaging, the formation of 3D multicellular tumour spheroids, immunocytochemistry, flow cytometry, Annexin V Assay, Caspase 3/7 Apoptosis Assay, tube formation assay and analysis, and WST-1 cell viability assay evaluated the formation of MCTS, morphologic changes, cell viability, apoptosis activity and the expression levels of ALDH1A1, CD44 and CD24 on the cell surface, MDA-MB231 triple-negative breast cancer, tamoxifen (Tmx) resistant variant (MDA-MB-231-TmxR)." | 7.96 | A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. ( Burov, SV; Haq, S; Harless, W; Markvicheva, E; Qorri, B; Sambi, M; Samuel, V; Szewczuk, MR, 2020) |
| "High doses of metformin induces oxidative stress (OS) and transforming growth factor β1 (TGF-β1) in breast cancer cells, which was associated with increased cancer stem cell population, local invasion, liver metastasis and treatment resistance." | 7.96 | Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis. ( Abdelhay, E; Binato, R; Borges, FH; Cecchini, AL; Cecchini, R; L Mencalha, A; Lopes, NMD; Luiz, RC; Marinello, PC; Panis, C; Rodrigues, JA; Silva, TNX, 2020) |
| "ADSCs grown from lipoaspirates were tested for growth-stimulating and migration-controlling activity on breast cancer cell lines after pretreatment with metformin." | 7.96 | Effects of metformin on adipose-derived stromal cell (ADSC) - Breast cancer cell lines interaction. ( Hamilton, G; Huk, I; Nanobashvili, J; Neumayer, C; Plangger, A; Radtke, C; Rath, B; Staud, C; Teufelsbauer, M, 2020) |
| "An efficacious metformin dose for breast cancer varies among tumour subtypes based on cation transporter expression, which provides a useful guide for dose selection." | 7.91 | Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours. ( Cai, H; Everett, RS; Thakker, DR, 2019) |
| " The antidiabetic agent metformin has shown its ability to inhibit tumor angiogenesis in metastatic breast cancer models." | 7.91 | Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation. ( Feng, J; Han, SX; Jiang, YN; Li, GY; Liu, JL; Liu, PJ; Lu, SY; Shen, YW; Sun, X; Wang, B; Wang, JC; Wang, MD; Zhou, C, 2019) |
| "The study was aimed at investigating the synergistic inhibitory effect of unique combinational regimen of nanocapsulated Metformin (Met) and Curcumin (Cur) against T47D breast cancer cells." | 7.88 | Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells. ( Dadashpour, M; Farajzadeh, R; Javidfar, S; Lotfi-Attari, J; Pilehvar-Soltanahmadi, Y; Sadeghzadeh, H; Shafiei-Irannejad, V; Zarghami, N, 2018) |
| "Studies have shown that aspirin and metformin play important roles in chemoprevention and repression of breast cancers, even though the exact mechanism remains unclear." | 7.88 | Aspirin and metformin exhibit antitumor activity in murine breast cancer. ( Du, C; Liu, Y; Luo, F; Wang, Y; Zhang, N; Zhao, M, 2018) |
| "cells were investigated." | 7.88 | Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression ( Rasouli, S; Zarghami, N, 2018) |
| "This study investigated the effects of metformin and weight loss on biomarkers associated with breast cancer prognosis." | 7.88 | The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Laughlin, GA; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, BA; Patterson, RE; Sears, DD; Villaseñor, A, 2018) |
| "Autophagy modulation is a potential therapeutic strategy for breast cancer, and a previous study indicated that metformin exhibits significant anti-carcinogenic activity." | 7.88 | Inhibiting ROS-TFE3-dependent autophagy enhances the therapeutic response to metformin in breast cancer. ( Guo, Q; Huang, Y; Liao, N; Liu, M; Qiu, B; Tan, M; Wang, T; Wu, A; Yi, J; Zhou, W, 2018) |
| "Here, we used an 1-methyl-1-nitrosourea (MNU)-induced mammary tumor rat model of estrogen receptor (ER)-positive postmenopausal breast cancer to evaluate the long-term effects of metformin administration on metabolic and tumor endpoints." | 7.88 | Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. ( Anderson, SM; Edwards, DP; Giles, ED; Jindal, S; MacLean, PS; Schedin, P; Schedin, T; Thor, AD; Wellberg, EA, 2018) |
| "To explore a chemopreventive strategy for improving breast cancer treatment efficacy, the anticancer effects of a combination of Metformin (MET) and Silibinin (SIL) were investigated in T47D breast cancer cells." | 7.88 | Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition. ( Asbaghi, N; Chatran, M; Dadashpour, M; Faramarzi, L; Jafari-Gharabaghlou, D; Pilehvar-Soltanahmadi, Y; Rasouli, S; Zarghami, N, 2018) |
| "We found that metformin inhibited the growth, proliferation and clonogenic potential of the breast cancer-derived cells tested." | 7.88 | Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD). ( Kumar, S; Sharma, P, 2018) |
| "At pharmacologically achievable concentrations, metformin does not drastically impact cell viability, but inhibits inflammatory signaling and metastatic progression in breast cancer cells." | 7.88 | Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells. ( Broussard, K; Ismail, M; Keizerweerd, A; Llopis, S; McAtee, L; McFerrin, H; Onuaguluchi, D; Poché, A; Schexnayder, C; Williams, C, 2018) |
| "Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia." | 7.85 | Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. ( Ariaans, G; Jalving, M; Jong, S; Vries, EG, 2017) |
| " This method was applied to MDA-MB-231 breast cancer cells treated with the antidiabetic drug metformin, which is being repurposed for treatment of triple-negative breast cancer." | 7.85 | Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer. ( Athreya, AP; Cairns, J; Gaglio, AJ; Iyer, RK; Kalari, KR; Niu, N; Wang, L; Weinshilboum, R; Wills, QF, 2017) |
| " Here, we present the important in vitro discovery that the development of MDR (in breast cancer cells) can be prevented, and that established MDR could be resensitized to therapy, by adjunct treatment with metformin." | 7.85 | Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. ( Arnason, T; Bowen, M; Davies, G; Dawicki, W; Gordon, JR; Groot, G; Harkness, T; Lobanova, L, 2017) |
| "In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models." | 7.85 | Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. ( André, N; Baglioni, M; Bondarenko, M; Carré, M; Laluce, NC; Menacho Márquez, M; Rico, M; Rozados, V; Scharovsky, OG, 2017) |
| "Several observational studies have reported that metformin may be associated with reduced risk of breast cancer; however, many of these studies were affected by time-related biases such as immortal time bias and time-window bias." | 7.85 | Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. ( Buse, JB; Henderson, LM; Hong, JL; Jonsson Funk, M; Lund, JL; Pate, V; Stürmer, T, 2017) |
| "The antidiabetic drug metformin exerts antineoplastic effects against breast cancer and other cancers." | 7.83 | Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. ( Cai, H; Everett, RS; Han, TK; Thakker, DR; Zhang, Y, 2016) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 7.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| " Here we show that combining metformin and short-term starvation markedly impairs metabolism and growth of colon and breast cancer." | 7.83 | Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. ( Bianchi, G; Bongioanni, F; Bottoni, G; Bruzzi, P; Buschiazzo, A; Capitanio, S; Emionite, L; Fabbi, M; Garaboldi, L; Inglese, E; Marini, C; Martella, R; Monteverde, E; Orengo, AM; Petretto, A; Raffaghello, L; Ravera, S; Sambuceti, G, 2016) |
| "MDA-MB-468, BT474 and SKBr3 breast cancer cell lines were treated with metformin and [3H-methyl]choline and [14C(U)]glucose incorporation and lipid accumulation determined in the presence and absence of lipase inhibitors." | 7.83 | Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells. ( Phyu, SM; Smith, TA, 2016) |
| "Acquisition of tamoxifen resistance (TR) during anti-estrogenic therapy using tamoxifen is a major obstacle in the treatment of estrogen receptor (ER)-positive breast cancer." | 7.83 | Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. ( Choi, Y; Jang, SY; Kim, A; Kim, C; Kim, J; Lee, J, 2016) |
| "The use of metformin and incretins in women with T2DM and BC may reduce the risk of metastases." | 7.83 | Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. ( Jacob, L; Kalder, M; Kostev, K; Rathmann, W, 2016) |
| "Epidemiological studies indicate that metformin, a widely used type 2 diabetes drug, might reduce breast cancer risk and mortality in patients with type 2 diabetes." | 7.83 | Medium Renewal Blocks Anti-Proliferative Effects of Metformin in Cultured MDA-MB-231 Breast Cancer Cells. ( Dolinar, K; Miš, K; Pavlin, M; Pirkmajer, S; Rajh, M, 2016) |
| "Metformin, a drug approved for diabetes type II treatment, has been associated with a reduction in the incidence of breast cancer and metastasis and increased survival in diabetic breast cancer patients." | 7.83 | The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer. ( Cabello, P; Eroles, P; Lluch, A; Pineda, B; Tormo, E, 2016) |
| "Metformin was demonstrated to have effects on breast cancer, and microRNA-27a (miR-27a) is a prognostic marker for breast cancer progression and patient survival." | 7.83 | miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7. ( Liu, J; Sun, B; Tang, H; Zhang, H; Zhang, X; Zhao, W, 2016) |
| "Metformin, currently undergoing clinical trials as an adjuvant for the treatment of breast cancer, modulates the activity of key intracellular signalling molecules which affect 2-[(18)F]Fluoro-2-deoxy-D-glucose ([(18)F]FDG) incorporation." | 7.81 | Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling. ( Cooper, AC; Fleming, IN; Phyu, SM; Smith, TA, 2015) |
| " The chemopreventive effect of MET against DMBA-induced breast carcinogenesis was evidenced by the capability of MET to restore the induction of the mRNA levels of basic excision repair genes, 8-oxoguanine DNA glycosylase (OGG1) and apurinic/apyrimidinic endonuclease1 (APE1), and the level of 8-hydroxy-2-deoxyguanosine (8-OHdG)." | 7.81 | Metformin inhibits 7,12-dimethylbenz[a]anthracene-induced breast carcinogenesis and adduct formation in human breast cells by inhibiting the cytochrome P4501A1/aryl hydrocarbon receptor signaling pathway. ( Alhaider, AA; Ansari, MA; Denison, MS; El-Kadi, AO; Ghebeh, H; Korashy, HM; Maayah, ZH; Soshilov, AA, 2015) |
| "Evidence has been accumulating for a role for metformin in reducing breast cancer risk in post-menopausal women." | 7.81 | Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells. ( Ahmetaga, A; Bano, G; Mason, HD; Pellat, L; Rice, S; Whitehead, SA, 2015) |
| "We conducted a neoadjuvant, single-arm, "window of opportunity" trial to examine the clinical and biological effects of metformin on patients with breast cancer." | 7.81 | Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. ( Chang, MC; Done, SJ; Dowling, RJ; Ennis, M; Escallon, JM; Goodwin, PJ; Leong, WL; McCready, DR; Niraula, S; Reedijk, M; Stambolic, V, 2015) |
| "Metformin use has recently been observed to decrease both the rate and mortality of breast cancer." | 7.81 | Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. ( Ahn, SH; Kim, HJ; Koh, BS; Kwon, H; Lee, JW; Lee, SB; Lee, Y; Park, HS; Sohn, G; Son, BH; Yu, JH, 2015) |
| "Metformin, a widely prescribed antidiabetic drug, has previously been shown to lower the risk of certain types of cancer, including that of breast cancer, and to improve prognosis." | 7.81 | Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. ( Fan, C; Liu, Z; Sun, Y; Wang, X; Wang, Y; Wei, G; Wei, J, 2015) |
| "Metformin, a diabetes drug with well-established side effect and safety profiles, has been widely studied for its anti-tumor activities in a number of cancers, including breast cancer." | 7.81 | Metformin in breast cancer - an evolving mystery. ( Camacho, L; Dasgupta, A; Jiralerspong, S, 2015) |
| " The tumor inhibitory effect of metformin on p53-mutated breast cancer cells remains unclear." | 7.81 | p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. ( Feng, X; Li, P; Parris, AB; Yang, X; Zhao, M, 2015) |
| "Metformin, an AMPK activator, has been reported to improve pathological response to chemotherapy in diabetic breast cancer patients." | 7.81 | Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. ( Chung, FF; Hii, LW; Ho, GF; Leong, CO; Malik, RA; Ng, CH; See, MH; Soo, JS; Taib, NA; Tan, BS; Tan, SH; Teh, YC; Teo, SH; Yip, CH, 2015) |
| "Our results showed that metformin can induce apoptosis in breast cancer cells when cultured at physiological glucose concentrations and that the pro-apoptotic effect was completely abolished when cells were grown in high glucose/high amino acid medium." | 7.81 | Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions. ( Castagnoli, L; Cesareni, G; Palumbo, F; Paoluzi, S; Pavlidou, T; Posca, D; Rasi, I; Silvestri, A, 2015) |
| "The aim of this study was to compare the effects and mechanisms of action of metformin on estrogen receptor (ER)-positive and ER-negative breast cancer cell lines." | 7.80 | Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. ( Appleyard, V; Hadad, SM; Hardie, DG; Thompson, AM, 2014) |
| " We recently established a pre-clinical model of estrogen-dependent MCF-7 breast cancer cells that were chronically adapted to grow (> 10 months) in the presence of graded, millimolar concentrations of the anti-diabetic biguanide metformin, an AMPK agonist/mTOR inhibitor that has been evaluated in multiple in vitro and in vivo cancer studies and is now being tested in clinical trials." | 7.80 | Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. ( Corominas-Faja, B; Cuyàs, E; Fernández-Arroyo, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Rodríguez-Gallego, E; Vazquez-Martin, A, 2014) |
| "Breast cancer cell lines from luminal A, luminal B, ErbB2 and triple-negative molecular subtypes were treated with a pharmacological concentration of metformin (2mM) at a glucose concentration of 5." | 7.80 | Lack of metformin effects on different molecular subtypes of breast cancer under normoglycemic conditions: an in vitro study. ( Amanpour, S; Behrouzi, B; Khorgami, Z; Muhammadnejad, S; Sadighi, S, 2014) |
| "Whether metformin therapy affects breast cancer risk in Asian patients with type 2 diabetes mellitus (T2DM) has not been investigated." | 7.80 | Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. ( Tseng, CH, 2014) |
| "Observational data suggest that metformin use decreases breast cancer (BC) incidence in women with diabetes; the impact of metformin on BC outcomes in this population is less clear." | 7.80 | The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. ( Eaton, A; King, TA; Oppong, BA; Oskar, S; Patil, S; Pharmer, LA; Stempel, M, 2014) |
| " Here we investigated by 1H-NMR/PCA analysis the metabolic profile of chemoresistant breast cancer cell subpopulations (ALDHbright cells) and their response to metformin, a promising anticancer metabolic modulator." | 7.80 | Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. ( Biagioni, F; Blandino, G; Casadei, L; Cioce, M; Manetti, C; Mori, F; Muti, P; Pulito, C; Sacconi, A; Strano, S; Valerio, M, 2014) |
| " Here we show that low-dose metformin or SN-38 inhibits cell growth or survival in ovarian and breast cancer cells and suppresses their tumor growth in vivo." | 7.80 | Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. ( Berek, JS; Chung, YM; Guan, M; Hu, MC; Hu, T; Ma, J; Ma, M, 2014) |
| " In the present study, we found that metformin inhibited cell migration and invasion of phorbol 12-myristate 13-acetate-induced MCF-7 and tamoxifen-resistant MCF-7 breast cancer cells." | 7.80 | Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells. ( Cho, YH; Jang, SY; Kim, A; Kim, C; Kim, CH; Kim, JH; Kim, JK; Lee, JY, 2014) |
| " Here, we investigated the effects of the anti-diabetes drug metformin on expression of CYP1A1 and CYP1B1 in breast cancer cells under constitutive and inducible conditions." | 7.80 | Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. ( Choi, JH; Chung, YC; Do, MT; Jeong, HG; Jeong, TC; Khanal, T; Kim, HG; Tran, TT, 2014) |
| "Recent population studies provide clues that the use of metformin may be associated with reduced incidence and improved prognosis of breast cancer." | 7.80 | Metformin and survival in diabetic patients with breast cancer. ( El-Benhawy, SA; El-Sheredy, HG, 2014) |
| "Metformin has been associated with a reduction in breast cancer risk and may improve survival after cancer through direct and indirect tumor-suppressing mechanisms." | 7.79 | Association between metformin therapy and mortality after breast cancer: a population-based study. ( Austin, PC; Goodwin, PJ; Gruneir, A; Lega, IC; Lipscombe, LL; Rochon, PA, 2013) |
| "There was a contradictory data with metformin use on breast cancer risk, but there is growing evidence that the use of metformin in diabetic patients was associated with lower risks of breast cancer mortality and incidence." | 7.79 | Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. ( Aksoy, S; Altundag, K; Sendur, MA, 2013) |
| "Metformin treatment has been associated with a decrease in breast cancer risk and improved survival." | 7.79 | Glucose promotes breast cancer aggression and reduces metformin efficacy. ( Anderson, SM; Arnadottir, SS; Deng, XS; Edgerton, SM; Fan, Z; Liu, B; Richer, JK; Thor, AD; Wahdan-Alaswad, R, 2013) |
| "The growth and metastasis of MDA-MB-231 breast cancer may be inhibited by metformin." | 7.79 | Multimodality imaging assessments of response to metformin therapy for breast cancer in nude mice. ( Gao, FB; Mao, Y; Wang, L; Wang, YQ; Xia, R, 2013) |
| "This study was set out to determine whether metformin use influences survival in breast cancer patients treated with antidiabetic drugs as compared to non-users." | 7.79 | Use of metformin and survival of diabetic women with breast cancer. ( Bazelier, MT; De Bruin, ML; de Vries, F; Leufkens, HG; Peeters, PJ; Schmidt, MK; Vestergaard, P, 2013) |
| "Metformin use has been reported to decrease breast cancer incidence and mortality in diabetic patients." | 7.79 | Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. ( Ishibashi, Y; Matsui, T; Takeuchi, M; Yamagishi, S, 2013) |
| "Diabetic patients taking metformin have lower incidence of breast cancer than those taking other anti-diabetic medications." | 7.79 | Metformin induces a senescence-associated gene signature in breast cancer cells. ( Llopis, SD; Singleton, BA; Skripnikova, EV; Williams, CC, 2013) |
| "Thiazolidinediones and metformin users are associated with better clinical outcomes than nonusers in diabetics with stage≥2 HER2+ breast cancer." | 7.78 | Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. ( Ensor, J; Esteva, FJ; He, X; Hortobagyi, GN; Lee, MH; Yeung, SC, 2012) |
| "Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer." | 7.78 | Phenformin as prophylaxis and therapy in breast cancer xenografts. ( Alessi, DR; Appleyard, MV; Bray, SE; Coates, PJ; Fleming, S; Kernohan, NM; Murray, KE; Thompson, AM; Wullschleger, S, 2012) |
| "We tested metformin alone and in combination with RAD001 and/or chemotherapeutic agents (carboplatin, paclitaxel and doxorubicin, respectively) on several human breast cancer cell lines with respect to cell proliferation, apoptosis and autophagy." | 7.78 | Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. ( Eucker, J; Habbel, P; Liu, H; Possinger, K; Regierer, AC; Schefe, JH; Scholz, C; Schulz, CO; Zang, C, 2012) |
| "Emerging evidence suggests that metformin may reduce breast cancer incidence, but reports are mixed and few provide information on tumor characteristics." | 7.78 | Diabetes, metformin, and breast cancer in postmenopausal women. ( Aragaki, AK; Chlebowski, RT; Euhus, DM; Gunter, M; Ipp, E; Kaklamani, VG; Manson, JE; Margolis, K; McTiernan, A; Phillips, LS; Rohan, T; Strickler, H; Vitolins, M; Wactawski-Wende, J; Wallace, R, 2012) |
| "Although there is data suggesting the in vitro inhibition of aromatase in cell lines by antidiabetic biguanide metformin (MF), there is no data on the intratumoral breast cancer (BC) aromatase expression in patients already receiving therapy for type II diabetes." | 7.78 | [Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes]. ( Bershteĭn, LM; Boiarkina, MP; Turkevich, EA, 2012) |
| "Preliminary evidence suggests that metformin may decrease breast cancer risk by decreasing insulin levels and reducing cell proliferation." | 7.77 | Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. ( Antonsen, S; Bosco, JL; Lash, TL; Pedersen, L; Sørensen, HT, 2011) |
| "An unexplored molecular scenario that might explain the inhibitory impact of the anti-diabetic drug metformin on the genesis of breast cancer relates to metformin's ability to modulate the expression status of micro (mi)RNAs." | 7.77 | Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. ( Cufí, S; Del Barco, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Torres-Garcia, VZ; Vazquez-Martin, A, 2011) |
| "We have shown that erbB2 altered breast cancer cells are less sensitive to the anti-proliferative effects of metformin than triple negative cells, and have described the differences of molecular mechanisms of metformin action by tumor subtypes." | 7.77 | Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. ( Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD; Yang, X, 2011) |
| "A decreased risk of breast cancer was observed in female patients with type 2 diabetes using metformin on a long-term basis." | 7.76 | Long-term metformin use is associated with decreased risk of breast cancer. ( Bodmer, M; Jick, SS; Krähenbühl, S; Meier, C; Meier, CR, 2010) |
| "A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer." | 7.76 | Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. ( Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "According to some existing data, unlike sulphonylurea (SU) and insulin derivatives, treatment with biguanide metformin, for reasons still unknown, may diminish breast cancer (BC) morbidity in diabetic females." | 7.76 | [Effect of previous diabetes therapy on tumor receptor phenotype in breast cancer: comparison of metformin and sulphonylurea derivatives]. ( Bershteĭn, LM; Boriakina, MP; Semiglazov, VF; Tsyrlina, EV; Turkevich, EA, 2010) |
| " Earlier studies from our group have revealed that clinically-relevant concentrations of the biguanide derivative metformin, the most widely used oral agent to lower blood glucose concentration in patients with type 2 diabetes and metabolic syndrome, notably decreased both the self-renewal and the proliferation of trastuzumab-refractory breast cancer stem cell populations." | 7.76 | Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. ( Cufí, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "The anti-diabetic drug metformin reduces human cancer incidence and improves the survival of cancer patients, including those with breast cancer." | 7.75 | Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. ( Alimova, IN; Dillon, T; Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD, 2009) |
| "Prompted by the ever-growing scientific rationale for examining the antidiabetic drug metformin as a potential antitumor agent in breast cancer disease, we recently tested the hypothesis that the assessment of metformin-induced global changes in gene expression-as identified using 44 K (double density) Agilent's whole human genome arrays-could reveal gene-expression signatures that would allow proper selection of breast cancer patients who should be considered for metformin-based clinical trials." | 7.75 | Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. ( Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2009) |
| "Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving metformin." | 7.75 | Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. ( Barnett, CM; Giordano, SH; Gonzalez-Angulo, AM; Hortobagyi, GN; Hsu, L; Hung, MC; Jiralerspong, S; Liedtke, C; Meric-Bernstam, F; Palla, SL, 2009) |
| "Metformin, a first line treatment for type 2 diabetes, has been implicated as a potential anti-neoplastic agent for breast cancers as well as other cancers." | 7.75 | Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. ( Claffey, KP; Phoenix, KN; Vumbaca, F, 2009) |
| "Metformin is a biguanide antihyperglycemic agent used as a first-line drug for type II diabetes mellitus." | 7.01 | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications. ( Bashraheel, SS; Khalaf, S; Kheraldine, H; Moustafa, AA, 2023) |
| "Inflammation is one biological mechanism hypothesized to mediate these associations." | 6.94 | Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. ( Abrams, TA; Brown, JC; Campbell, N; Cartmel, B; Douglas, PS; Fuchs, CS; Harrigan, M; Hu, FB; Irwin, ML; Jones, LW; Ligibel, JA; Meyerhardt, JA; Ng, K; Pollak, MN; Sanft, T; Sorrentino, A; Tolaney, SM; Winer, EP; Zhang, S, 2020) |
| "GDF-15 was not associated with type 2 diabetes, glycaemic traits, CAD risk factors or colorectal cancer." | 6.90 | The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study. ( Au Yeung, SL; Luo, S; Schooling, CM, 2019) |
| "Metformin is a challenging anticancer agent in BC cohorts, besides being safe and well-tolerated at antidiabetic doses." | 6.82 | Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis. ( Barakat, HE; Elberry, AA; Elsherbiny Ramadan, M; Hussein, RRS; Zaki, MA, 2022) |
| "Breast cancer is the most prevalent cancer and the leading cause of cancer-related death among women worldwide." | 6.82 | Metformin and Breast Cancer: Where Are We Now? ( Cejuela, M; Martin-Castillo, B; Menendez, JA; Pernas, S, 2022) |
| " We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones." | 6.78 | Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. ( Abbà, C; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Cogliati, P; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2013) |
| " However, unanswered questions remain with regards to areas such as cancer treatment specific therapeutic dosing of metformin, specificity to cancer cells at high concentrations, resistance to metformin therapy, efficacy of combinatory therapeutic approaches, post-therapeutic relapse of the disease, and efficacy in cancer prevention in non-diabetic individuals." | 6.61 | Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. ( Büsselberg, D; Kubatka, P; Samuel, SM; Triggle, CR; Varghese, E, 2019) |
| "Metformin has been the first-line drug for the treatment of type II diabetes mellitus for decades, being presently the most widely prescribed antihyperglycemic drug." | 6.61 | Metformin and Breast Cancer: Molecular Targets. ( Azevedo, A; Faria, J; Martel, F; Negalha, G, 2019) |
| "The heterogeneity of breast cancer, confounded by comorbidity of disease in the elderly population, makes it difficult to determine the actual benefits of metformin therapy." | 6.52 | Recent advances in the use of metformin: can treating diabetes prevent breast cancer? ( Hatoum, D; McGowan, EM, 2015) |
| "However, findings regarding breast cancer have been mixed." | 6.48 | Metformin and breast cancer risk: a meta-analysis and critical literature review. ( Aragaki, AK; Chlebowski, RT; Col, NF; Ochs, L; Springmann, V, 2012) |
| "Metformin is an orally available, biguanide derivative that is widely used in the treatment of Type 2 diabetes." | 6.47 | Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. ( Guppy, A; Jamal-Hanjani, M; Pickering, L, 2011) |
| "Obesity and insulin resistance have been associated with breast cancer risk, and breast cancer outcomes." | 6.47 | Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. ( Goodwin, PJ; Stambolic, V, 2011) |
| "Metformin has been shown to inhibit proliferation, invasion and angiogenesis of neoplastic cells and to overcome resistance of breast cancer to chemotherapy, hormonal therapy and HER2 inhibition." | 6.46 | Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. ( Wierusz-Wysocka, B; Wysocki, PJ, 2010) |
| "Breast cancer is the fifth leading cause of death, worldwide affecting both genders." | 5.91 | Metformin enhances anti-cancer properties of resveratrol in MCF-7 breast cancer cells via induction of apoptosis, autophagy and alteration in cell cycle distribution. ( Akbarizadeh, AR; Fatehi, R; Firouzabadi, N; Rashedinia, M; Zamani, M, 2023) |
| "Metformin (Met) is an anti-hyperglycemic agent whose anti-cancer properties have been formerly reported." | 5.91 | Potentiation of Folate-Functionalized PLGA-PEG nanoparticles loaded with metformin for the treatment of breast Cancer: possible clinical application. ( Dadashpour, M; Jafari-Gharabaghlou, D; Khanghah, OJ; Salmani-Javan, E; Zarghami, N, 2023) |
| "Epithelial breast cancer cells also differentiate into several cell types to meet various demands." | 5.91 | Metformin ameliorates BMP2 induced adipocyte-like property in breast cancer cells. ( Mandal, CC; Soni, S; Yadav, P, 2023) |
| "Metformin can directly inhibit tumorigenesis, although the mechanism responsible for this is not fully understood." | 5.72 | Metformin may induce ferroptosis by inhibiting autophagy via lncRNA H19 in breast cancer. ( Chen, J; Chen, Y; Mao, M; Qin, C; Yang, J; Zhou, Y, 2022) |
| "Compared to breast cancer cell lines (3." | 5.72 | Effects of metformin on human bone-derived mesenchymal stromal cell-breast cancer cell line interactions. ( Hamilton, G; Lang, C; Moser, D; Neumayer, C; Plangger, A; Radtke, C; Rath, B; Staud, C; Teufelsbauer, M, 2022) |
| " However, DOX is known to have many harmful adverse effects including its cardiotoxicity." | 5.72 | Development and Evaluation of Core-Shell Nanocarrier System for Enhancing the Cytotoxicity of Doxorubicin/Metformin Combination Against Breast Cancer Cell Line. ( El-Sherbiny, IM; Ibrahim, A; Khalil, IA, 2022) |
| " The phytochemicals' poor bioavailability and short half-life make them unsuitable as anticancer drugs." | 5.72 | The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action. ( Dadashpour, M; Hassani, N; Jafari-Gharabaghlou, D; Zarghami, N, 2022) |
| "Metformin (MET) is a well-known anti-diabetic drug that also has anti-cancer effects." | 5.72 | MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice. ( Chang, J; He, M; Li, Y; Luo, D; Luo, Y; Ran, L; Wang, H; Wang, X; Zhao, C; Zhong, X, 2022) |
| "The MA32 study investigated whether 5 years of metformin (versus placebo) improves invasive disease-free survival in early-stage breast cancer (BC)." | 5.69 | Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). ( Chen, BE; Gelmon, KA; Goodwin, PJ; Hershman, DL; Lemieux, J; Ligibel, JA; Parulekar, WR; Sathe, C; Whelan, TJ, 2023) |
| " Herein, the impacts of metformin alone and in combination with cimetidine/ibuprofen on some Th1- and regulatory T (Treg) cell-related parameters were evaluated using a breast cancer (BC) model." | 5.62 | Modulatory Effects of Metformin Alone and in Combination with Cimetidine and Ibuprofen on T Cell-related Parameters in a Breast Cancer Model. ( Hassan, ZM; Jafarzadeh, A; Khorramdelazad, H; Masoumi, J; Nemati, M; Oladpour, O; Rezayati, MT; Taghipour, F; Taghipour, Z, 2021) |
| "Metformin may increase the pCR especially in patients with BMI ≥ 25 and patients with triple-positive histology, a larger phase III study is needed to confirm this finding." | 5.62 | The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients. ( Abdallah, D; Abouegylah, M; El-Khayat, SM; Elenbaby, AM; Geweil, AG; Zahra, OS, 2021) |
| "Metformin has been suggested as an anti-cancer agent." | 5.62 | FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling. ( Cheng, Q; Kong, L; Ma, Z; Parris, AB; Shi, Y; Wu, Y; Yang, X, 2021) |
| "Abnormal glucose metabolism in cancer cells causes generation and secretion of excess lactate, which results in acidification of the extracellular microenvironment." | 5.62 | Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter. ( Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV, 2021) |
| "Metastatic breast cancer remains a serious health concern and numerous investigations recommended medicinal plants as a complementary therapy." | 5.62 | Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies. ( Abedini, MR; Arzi, L; Chamani, E; Farahi, A; Farhoudi, R; Hoshyar, R; Javdani, H; Talebloo, N, 2021) |
| "A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled." | 5.62 | Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus. ( Hui, T; Li, R; Shang, C; Song, Z; Wang, M; Yang, L, 2021) |
| "Metformin has long been an attractive therapeutic option for EwS, but hypoxia limits its efficacy." | 5.56 | Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. ( Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H, 2020) |
| "Metformin use has been linked to pathologic complete response (pCR) following neoadjuvant chemotherapy for several malignancies." | 5.56 | Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response. ( Berger, AC; Brenin, DR; Christopher, A; Hassinger, TE; Knisely, AT; Mehaffey, JH; Schroen, AT; Showalter, SL, 2020) |
| "Metformin treatment for T2D during the initial diagnosis of BC may improve outcomes." | 5.56 | Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status. ( Gogineni, K; He, J; Lee, KN; McCullough, LE; Torres, MA; Troeschel, AN, 2020) |
| "Metformin has been suggested to possibly reduce cancer risk." | 5.56 | Influences of preoperative metformin on immunological factors in early breast cancer. ( Doihara, H; Hatono, M; Ikeda, H; Iwamoto, T; Kajihara, Y; Kawada, K; Kochi, M; Shien, T; Suzuki, Y; Taira, N; Tanaka, T; Toyooka, S; Tsukioki, T, 2020) |
| "Human primary breast cancer cells were either cultured alone or co-cultured with autologous MOs before treatment with MET." | 5.56 | Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity. ( Addou-Klouche, L; Aribi, M; Benaissti, MI; Chahinez Djebri, N; Dahmani, Z; Dahou, S; Fernandez, A; Gizard, F; Lamb, NJ; Lefranc, G; Messaoud, A; Miliani, M; Mostefaoui, M; Nouari, W; Terbeche, H, 2020) |
| "Recently, several clinical trials have attempted to find evidence that supports the anticancer use of metformin in breast cancer (BC) patients." | 5.51 | The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. ( Barakat, HE; Elberry, AA; Hussein, RRS; Ramadan, ME; Zaki, MA, 2022) |
| "Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies." | 5.51 | Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. ( Abramson, VG; Bliss, JM; Chen, BE; Ennis, M; Gelmon, KA; Goodwin, PJ; Hershman, DL; Hobday, TJ; Lemieux, J; Ligibel, JA; Mackey, JR; Mayer, IA; Mukherjee, SD; Oja, C; Parulekar, WR; Rabaglio-Poretti, M; Rastogi, P; Rea, DW; Shepherd, LE; Stambolic, V; Stos, PM; Thompson, AM; Wesolowski, R; Whelan, TJ, 2022) |
| "Many breast cancer patients suffer from obvious side effects induced by chemotherapy." | 5.51 | Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro. ( Guo, Y; Ren, Q; Wang, Y; Xin, M, 2019) |
| "Background Breast cancer is highly prevalent among women worldwide." | 5.48 | Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. ( Amaral, MEA; Campos, MM; de Azevedo Junior, WF; Leite, CE; Nery, LR, 2018) |
| "With no sharp cure, breast cancer still be the major and the most serious life-threatening disease worldwide." | 5.48 | Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells ( Abdel-Ghany, SE; El-Zawahry, M; M Said, OA; Mostafa, MA; Sabit, H, 2018) |
| "Triple naegative breast cancer has an increased rate of distant metastasis and consequently poor prognosis." | 5.46 | Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro. ( Bizjak, M; Dolinar, K; Malavašič, P; Pavlin, M; Pirkmajer, S; Pohar, J, 2017) |
| "102 women with newly diagnosed breast cancer were divided into 2 main groups, a control group and a metformin group." | 5.43 | Metformin may protect nondiabetic breast cancer women from metastasis. ( El-Bassiouny, NA; El-Haggar, SM; El-Shitany, NA; Mostafa, MF, 2016) |
| "Metformin, which is a drug commonly prescribed to treat type 2 diabetes, has anti-proliferative effects in cancer cells; however, the molecular mechanisms underlying this effect remain largely unknown." | 5.43 | Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cells. ( Chen, Y; Chung, HT; Joe, Y; Kim, HJ; Pandiri, I; Park, J; Park, JW, 2016) |
| "Metformin, which is a drug commonly used to treat type 2 diabetes, has shown anti-tumor effects in numerous experimental, epidemiologic, observational, and clinical studies." | 5.43 | Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. ( Han, W; Kim, SW; Lee, J; Lee, KM; Lee, M; Moon, HG; Noh, DY, 2016) |
| "Metformin pretreatment for 24 h of HER2+ MDA-MB-361 cells, which were subsequently treated for 48 h with Herceptin, induced additional decline in cell survival." | 5.42 | Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells. ( Abu Rabi, Z; Antić-Stanković, J; Damjanović, A; Damjanović, S; Džodić, R; Juranić, Z; Kanjer, K; Matić, IZ; Milovanović, Z; Nikolić, S; Roki, K; Ðorđić, M; Ðurović, MN, 2015) |
| "These two meta-analyses can inform decision-making for women with type 2 diabetes regarding their use of metformin and the use of screening mammography for early detection of breast cancer." | 5.41 | Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis. ( Alagoz, O; Cryns, VL; Gangnon, RE; Hajjar, A; Heckman-Stoddard, BM; Lu, Y; Trentham-Dietz, A, 2023) |
| "Metformin has been associated with lower breast cancer (BC) risk and improved outcomes in observational studies." | 5.41 | The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. ( Bedard, P; Chen, BE; Dowling, RJO; Ellard, S; Ennis, M; Gelmon, K; Goodwin, PJ; Hershman, DL; Hobday, T; Lemieux, J; Ligibel, J; Lohmann, AE; Mates, M; Mayer, I; Parulekar, W; Pimentel, I; Pitre, L; Rabaglio, M; Rastogi, P; Rea, D; Shepherd, L; Stambolic, V; Thompson, A; Vandenberg, T; Whelan, T, 2021) |
| " We will include any randomised clinical trial of metformin for the treatment of breast cancer in adult women, and will not impose restrictions regarding context, language or publication date." | 5.41 | Metformin for the treatment of breast cancer: protocol for a scoping review of randomised clinical trials. ( Araujo, CFM; Bragagnoli, AC; Fukushima, FB; Murta-Nascimento, C; Nunes, LC; Souza, CP; Vidal, EIO, 2021) |
| "We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention." | 5.41 | A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density. ( Algotar, AM; Altbach, M; Centuori, S; Chalasani, P; Chow, HS; Galons, JP; Guillen-Rodriguez, J; Huang, C; Martinez, JA; Pinto, L; Roe, DJ; Tapia, E; Thomson, CA; Trujillo, J; Villa-Guillen, DE, 2021) |
| "In this randomized clinical trial study, eligible women with fibroadenomas were assigned randomly to the metformin (1000 mg daily for six months) or the placebo group." | 5.41 | Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial. ( Abedi, M; Alipour, S; Eslami, B; Faiz, F; Maleki-Hajiagha, A; Saberi, A; Shahsavari, S, 2021) |
| "Breast cancer is the most frequently diagnosed tumor type and the primary leading cause of cancer deaths in women worldwide and multidrug resistance is the major obstacle for breast cancer treatment improvement." | 5.40 | Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. ( He, Z; Qu, C; Yin, J; Zhang, W; Zhang, Z; Zheng, G, 2014) |
| "Metformin has been reported to activate AMPK, thereby suppressing mTOR, which plays an important role for protein synthesis, cell cycle progression, and cell survival." | 5.40 | Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. ( Choi, BH; Lee, CK; Lee, H; Oh, ET; Park, CS; Park, HJ; Song, CW; Williams, B, 2014) |
| "Co-treatment with metformin and H2O2 increased oxidative stress which was associated with reduced cell number." | 5.40 | Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. ( Barbosa, AM; Dekker, RF; Eichler, R; Forsyth, HL; Fortes, ZB; Khaper, N; Lees, SJ; Puukila, S; Queiroz, EA; Sampaio, SC, 2014) |
| "The unique metabolism of breast cancer cells provides interest in exploiting this phenomenon therapeutically." | 5.40 | Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. ( Coppock, JD; Haugrud, AB; Miskimins, WK; Zhuang, Y, 2014) |
| "Basal-like breast cancers (BBCs) are enriched for increased EGFR expression and decreased expression of PTEN." | 5.40 | Metformin and erlotinib synergize to inhibit basal breast cancer. ( Bessler, E; Cremers, S; Du, X; Hopkins, B; Keniry, M; Lau, YK; Maurer, MA; Parsons, RE; Pires, MM; Rayannavar, V; Shaw, J; Szabolcs, M; Thomas, T, 2014) |
| "Metformin is a well-established diabetes drug that prevents the onset of most types of human cancers in diabetic patients, especially by targeting cancer stem cells." | 5.39 | Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. ( Gandara, R; Howell, A; Hulit, J; Lamb, R; Lisanti, MP; Martinez-Outschoorn, UE; Rubin, E; Sanchez-Alvarez, R; Sartini, M; Sotgia, F, 2013) |
| "Metformin's effects were also studied in sublines with forced over-expression of constitutively active (CA) Stat3, as well as lines with stable knockdown of Stat3." | 5.38 | Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. ( Deng, A; Deng, XS; Edgerton, SM; Lind, SE; Liu, B; Thor, AD; Wahdan-Alaswad, R; Wang, S, 2012) |
| "Trastuzumab-refractory breast cancer stem cells (CSCs) could also explain the high rate of primary resistance to single-agent trastuzumab in HER2 gene-amplified breast cancer patients." | 5.38 | Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. ( Bosch-Barrera, J; Corominas-Faja, B; Cufi, S; Dorca, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2012) |
| "The coexistence of type 2 diabetes with breast cancer may result in poorer cancer-related survival due to a number of mediating factors including an alteration of tumor tissue hormonal sensitivity." | 5.37 | More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. ( Berstein, LM; Boyarkina, MP; Semiglazov, VF; Tsyrlina, EV; Turkevich, EA, 2011) |
| "Metformin treatment dynamically regulated the CD44(pos)CD24(neg/low) breast cancer stem cell immunophenotype, transcriptionally reprogrammed cells through decreased expression of key drivers of the EMT machinery including the transcription factors ZEB1, TWIST1 and SNAI2 (Slug) and the pleiotrophic cytokines TGFβs, and lastly impeded the propensity of breast cancer stem cells to form multicellular "microtumors" in non-adherent and non-differentiating conditions (i." | 5.36 | Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. ( Cufí, S; Del Barco, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "Metformin pre-treatment, before injection of MDA-MB-231 cells, results in a significant decrease in tumor outgrowth and incidence." | 5.35 | Metformin induces unique biological and molecular responses in triple negative breast cancer cells. ( Alimova, IN; Deng, XS; Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD, 2009) |
| "Breast cancer is the most common malignancy diagnosed among women." | 5.35 | Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs. ( Cetinkalp, S; Karaca, B; Uslu, R; Yurekli, BS, 2009) |
| "Thirty-six patients with untreated primary breast cancer were recruited to a window study and transcriptomic profiling of tumour samples carried out before and after metformin treatment." | 5.34 | Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. ( Adams, RF; Buffa, FM; Cheng, WC; Collins, JM; English, R; Fielding, BA; Frezza, C; Gaude, E; Haider, S; Harjes, U; Harris, AL; Hoefler, G; Jha, P; Karpe, F; Lord, SR; Pinnick, KE; Pollak, MN; Roy, PG; Segaran, A; Thompson, AM; Wigfield, S, 2020) |
| " Female patients with early breast cancer (N = 314) will be randomly assigned to two groups (placebo, metformin 2000 mg)." | 5.34 | Metformin intervention against ovarian toxicity during chemotherapy for early breast cancer: Study protocol for a randomized double-blind placebo-controlled trial. ( Cui, P; Jin, Y; Li, X; Li, Y; Liu, R; Ma, X; Ren, W; Wang, B; Wang, S; Zhang, J; Zhang, M; Zhang, P, 2020) |
| "In MCF-7 breast cancer cells, metformin treatment led to a 30% decrease in global protein synthesis." | 5.34 | Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. ( Dowling, RJ; Fantus, IG; Pollak, M; Sonenberg, N; Zakikhani, M, 2007) |
| "Pre-clinical data suggest metformin might enhance the effect of chemotherapy in breast cancer (BC)." | 5.30 | A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. ( Cescon, D; Chang, MC; Dowling, RJO; Elser, C; Ennis, M; Goodwin, PJ; Hamm, C; Haq, R; Lohmann, AE; Pimentel, I; Potvin, KR; Stambolic, V, 2019) |
| " Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer." | 5.30 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. ( Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ, 2019) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 5.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| "Purpose Previous studies have suggested an association between metformin use and improved outcome in patients with diabetes and breast cancer." | 5.24 | Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. ( Agbor-Tarh, D; Andersson, M; Azim, HA; Bradbury, I; Cufer, T; de Azambuja, E; Di Cosimo, S; Fumagalli, D; Gralow, J; Harris, L; Keane, M; Kroep, J; Moreno-Aspitia, A; Piccart-Gebhart, M; Salman, P; Sarp, S; Simon, SD; Sonnenblick, A; Toi, M; Wolff, AC, 2017) |
| "Fasting plasma samples from 373 overweight or obese breast cancer survivors randomly assigned to metformin (n = 194) or placebo (n = 179) administration were collected at baseline, after 6 months (Reach For Health trial), and after 12 months (MetBreCS trial)." | 5.22 | Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials. ( Bellerba, F; Bonanni, B; Chatziioannou, AC; Gandini, S; Hartman, SJ; Jasbi, P; Johansson, H; Keski-Rahkonen, P; Robinot, N; Scalbert, A; Sears, DD; Trolat, A; Vozar, B, 2022) |
| "Based on cohort studies, metformin therapy has potential survival benefits for patients with malignancy, especially with the greatest benefits seen in breast cancer on overall survival, progression-free survival, and cancer-specific survival." | 5.22 | Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies. ( Cao, L; Shen, Y; Yang, H; Yang, J; Yin, Y; Zhu, W, 2022) |
| "Previous studies have suggested that metformin might improve survival outcomes in patients with breast cancer." | 5.22 | Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis. ( Kataoka, Y; Kawaguchi-Sakita, N; Kurata, Y; Morio, K; Shiroshita, A, 2022) |
| "Current evidence from phase II clinical trials does not support that additional use of metformin could improve the survival outcome in women with breast cancer." | 5.22 | Metformin and survival of women with breast cancer: A meta-analysis of randomized controlled trials. ( Du, X; Long, J; Ma, X; Mao, H; Pan, B; Wang, Q, 2022) |
| "Weight loss and metformin are hypothesized to improve breast cancer outcomes; however the joint impacts of these treatments have not been investigated." | 5.22 | Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, B; Patterson, RE; Villaseñor, A, 2016) |
| "The study will evaluate whether metformin can result in favorable changes in breast density, select proteins and hormones, products of body metabolism, and body weight and composition." | 5.22 | Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol. ( Altbach, M; Chalasani, P; Chow, HH; Galons, JP; Martinez, JA; Roe, D; Stopeck, A; Thompson, PA; Thomson, CA; Villa-Guillen, DE, 2016) |
| "Metformin has therapeutic potential against breast cancer, but the mechanisms of action in vivo remain uncertain." | 5.20 | Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. ( Chang, MC; Coates, P; Done, SJ; Dowling, RJ; Goodwin, PJ; Hadad, SM; Jordan, LB; Moulder-Thompson, S; Purdie, CA; Stambolic, V; Thompson, AM, 2015) |
| "Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes." | 5.20 | Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. ( Bernstein, V; Chalchal, HI; Chen, BE; Gelmon, KA; Goodwin, PJ; Hershman, DL; Hobday, TJ; Lemieux, J; Ligibel, JA; Mayer, IA; Mukherjee, SD; Oja, CD; Parulekar, WR; Pritchard, KI; Rastogi, P; Shepherd, LE; Stambolic, V; Thompson, AM; Tonkin, KS; Whelan, TJ, 2015) |
| "Metformin is associated with lower breast cancer risk in epidemiologic studies and showed decreased proliferation in HER2-positive breast cancer in a presurgical trial." | 5.20 | Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial. ( Bonanni, B; Cazzaniga, M; Cuzick, J; DeCensi, A; Gentilini, O; Guerrieri-Gonzaga, A; Lazzeroni, M; Petrera, M; Pruneri, G; Puntoni, M; Serrano, D; Viale, G; Vingiani, A, 2015) |
| "Previous observational studies have suggested that metformin in diabetes patients may reduce breast cancer risk more than the reductions from other anti-diabetes medications." | 5.20 | Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial. ( Ahn, C; Cho, YM; Han, W; Hwang, Y; Ko, KP; Ma, SH; Noh, DY; Park, BJ; Park, SK; Yang, JJ, 2015) |
| "We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients." | 5.19 | Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. ( Ahmad, A; Cremers, S; Crew, KD; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, M; Refice, S; Taback, B; Wang, A; Xiao, T, 2014) |
| "This study will provide direct evidence of the anti-tumor effect of metformin in non-diabetic, postmenopausal patients with ER-positive breast cancer." | 5.19 | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). ( Ahn, SH; Chae, BJ; Choi, SY; Han, S; Han, W; Jeong, J; Jeong, SS; Jung, SY; Jung, Y; Kang, E; Kang, HS; Kang, T; Kim, EK; Kim, J; Kim, KS; Kim, LS; Kim, MK; Kim, SI; Kim, SW; Kim, TH; Lee, JE; Lim, W; Moon, HG; Nam, SJ; Noh, DY; Paik, NS; Park, CH; Yoo, YB; Yoon, JH; Yu, JH, 2014) |
| "Treatment of diabetics with metformin is associated with decreased breast cancer risk in observational studies, but it remains unclear if this drug has clinical antineoplastic activity." | 5.19 | Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. ( Aristarco, V; Bassi, F; Bonanni, B; Cazzaniga, M; DeCensi, A; Gandini, S; Guerrieri-Gonzaga, A; Hofmann, U; Johansson, HA; Lazzeroni, M; Luini, A; Macis, D; Mora, S; Pollak, MN; Pruneri, G; Puntoni, M; Schwab, M; Serrano, D, 2014) |
| "Metformin has been associated with antitumour activity in breast cancer (BC) but its mechanism remains unclear." | 5.17 | The effect of metformin on apoptosis in a breast cancer presurgical trial. ( Bonanni, B; Bottiglieri, L; Cazzaniga, M; DeCensi, A; Dell'Orto, P; Gentilini, OD; Guerrieri-Gonzaga, A; Lazzeroni, M; Pagani, G; Pruneri, G; Puntoni, M; Serrano, D; Varricchio, C; Viale, G, 2013) |
| " We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer." | 5.17 | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC, 2013) |
| "Metformin is associated with reduced breast cancer risk in observational studies in patients with diabetes, but clinical evidence for antitumor activity is unclear." | 5.16 | Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. ( Aristarco, V; Bassi, F; Bonanni, B; Bruzzi, P; Cazzaniga, M; Decensi, A; Galimberti, V; Gennari, A; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Luini, A; Pruneri, G; Puntoni, M; Serrano, D; Trabacca, MS; Varricchio, C; Veronesi, P; Viale, G, 2012) |
| "This is a randomized controlled trial to test the effect of different doses of metformin in patients with breast cancer and without diabetes, with the aim of modifying the hormonal and metabolic parameters linked to breast cancer prognosis." | 5.16 | Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. ( Abbà, C; Ambroggio, S; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Colombero, R; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2012) |
| "Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women." | 5.15 | Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. ( Baker, L; Bray, S; Deharo, S; Dewar, JA; Hadad, S; Hardie, DG; Iwamoto, T; Jellema, G; Jordan, L; Moulder-Thompson, S; Purdie, C; Pusztai, L; Thompson, AM, 2011) |
| "We administered metformin (1500 mg per day) to 32 women with early breast cancer whose baseline insulin levels were at least 45 pmol/L to determine its effect on insulin levels." | 5.13 | Insulin-lowering effects of metformin in women with early breast cancer. ( Clemons, M; Ennis, M; Fantus, IG; Goodwin, PJ; Graham, M; Pritchard, KI, 2008) |
| "This study aims to determine the efficacy and safety of metformin administration as adjunctive therapy on mortality among females with breast cancer." | 5.12 | A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. ( Eugenio, KPY; Jimeno, CA; Lusica, PMM; Sacdalan, DBL, 2021) |
| "The aim of the present study was to evaluate the role of metformin in endometrial cancer (EC), focusing on its potential preventive effect in breast cancer and obese patients and its safety and efficacy when added to progesterone monotherapy in EC patients who wish to preserve their fertility." | 5.12 | The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials. ( Fotiou, A; Iavazzo, C; Lekka, S; Prodromidou, A; Psomiadou, V, 2021) |
| "Currently, tamoxifen is the only drug approved for reduction of breast cancer risk in premenopausal women." | 5.05 | Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. ( Dietze, EC; Jones, VC; Jovanovic-Talisman, T; McCune, JS; Seewaldt, VL, 2020) |
| "Breast cancer patients receiving metformin as treatment for diabetes showed significant reduction in levels of insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki-67." | 5.05 | The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials. ( Chhabra, M; Clark, C; Gudi, SK; Manzari, N; Mousavi, SM; Naik, G; Rahmani, J; Thompson, J; Varkaneh, HK; Zhang, Y, 2020) |
| "Observational studies show a beneficial effect of adjuvant metformin therapy on breast cancer survivals, but data from randomized clinical trials are lacking." | 5.01 | The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials. ( Bi, Y; Liu, Y; Wang, C; Yuan, J; Zhang, ZJ, 2019) |
| " In breast cancer, TGF-β effect on EMT could be potentiated by Fos-related antigen, oncogene HER2, epidermal growth factor, or mitogen-activated protein kinase kinase 5 - extracellular-regulated kinase signaling." | 5.01 | Epithelial mesenchymal transition and resistance in endocrine-related cancers. ( Culig, Z, 2019) |
| "Although preclinical work is vital in unraveling the molecular tenets which apply to metformin action in breast cancer, it is by nature unable to capture the host's response to metformin in terms of insulin-mediated effects and related changes in the hormonal and metabolic asset at the systemic level." | 4.91 | Metformin and breast cancer: basic knowledge in clinical context. ( Barba, M; Della Giulia, M; Di Lauro, L; Giordano, A; Marchetti, P; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Vici, P, 2015) |
| "Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pathologic complete response rate than do diabetic patients not receiving metformin, but findings on salvage treatment have been inconsistent." | 4.91 | Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis. ( Chen, K; Dai, Y; Jia, X; Li, D; Mao, Y; Tao, M; Tian, Y; Xie, J; Xu, H, 2015) |
| " The unexpected ability of the anti-type II diabetes drug metformin to inactivate mTOR and decrease p70S6K1 activity further reveals that this biguanide, generally considered non-toxic and remarkably inexpensive, might be considered for new combinatorial lapatinib-based protocols in HER2-overexpressing breast cancer patients." | 4.85 | mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). ( del Barco, S; Martín-Castillo, B; Menéndez, JA; Oliveras-Ferraros, C; Vázquez-Martín, A, 2009) |
| "We aimed at evaluating the effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women." | 4.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "Some studies have shown that metformin inhibits the proliferation of breast cancer (BC) cells via multiple ways." | 4.31 | The efficacy of metformin as adjuvant to chemotherapy on IGF levels in non-diabetic female patients with progressive and non-progressive metastatic breast cancer. ( Alharbi, AA; Boshra, MS; Elgendy, MO; Essa, NM; Gabr, A; Harakeh, S; Mahmoud, MM; Salem, HF; Tashkandi, HM, 2023) |
| "Previous studies assessed the prognostic effect of aspirin, statins, and metformin in breast cancer (BC) patients, with inconclusive results." | 4.31 | Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. ( Andreassen, BK; Botteri, E; Löfling, LL; Støer, NC; Ursin, G, 2023) |
| "In this research we evaluated molecular mechanism of effect of metformin in radio sensitivity of breast cancer cells." | 4.31 | Metformin Caused Radiosensitivity of Breast Cancer Cells through the Expression Modulation of miR-21-5p/SESN1axis. ( Ansari, Y; Moghbelinejad, S; Momeni, A; Ramezani, M; Saffari, F, 2023) |
| "Metformin associated lactic acidosis may potentially occur after combination with ribocilib, an uncommon but lethal complication from the interaction of these drugs, especially in patients who had preexisting renal impairment." | 4.12 | Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report. ( Lagampan, C; Parinyanitikul, N; Poovorawan, N, 2022) |
| "The cytotoxic effects of various concentrations of metformin caprylic acid and metformin hydrochloride (0 to 20 mM) on MCF-7 and MDA-MB-231 breast cancer cells and MCF-10A human mammary epithelial cell line were assessed by the MTT assay." | 4.12 | Replacement of hydrochloride in metformin hydrochloride with caprylic acid to investigate its effects on MCF-7 and MDA-MB-231 breast cancer cell lines. ( Darzi, L; Forouzandeh-Moghdam, M; Mousavi-Koodehi, B; Najafi, F; Sadeghizadeh, M, 2022) |
| "The nonsteroidal anti-inflammatory drug aspirin is an agent of interest for breast cancer prevention." | 4.12 | Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use. ( Acheampong, T; Agovino, M; Athilat, S; Lee Argov, EJ; Rodriguez, CB; Tehranifar, P; Terry, MB; Wei, Y, 2022) |
| " CMF, the combination of cyclophosphamide (CYP), methotrexate (MTX), and 5-fluorouracil (5-FU), is employed for the treatment of several types of cancers, such as metastatic breast cancer." | 4.12 | Effects of CMF and MET on glutamate and dopamine levels in the brain, and their impact on cognitive function. ( Abdellatif, AAH; Aldubayan, MA; Alhowail, AH; Almogbel, YS; Chigurupati, S; Nemala, RA, 2022) |
| " We investigated potential synergy between shikonin and anti-diabetic metformin against tumorigenic properties of breast cancer cell line MCF-7." | 4.12 | Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition. ( Gardaneh, M; Gavidel, P; Sabouni, F; Tabari, AR, 2022) |
| "Whether pioglitazone may affect breast cancer risk in female diabetes patients is not conclusive and has not been investigated in the Asian populations." | 4.12 | Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis. ( Tseng, CH, 2022) |
| "Metformin has demonstrated a chemoprotective effect in breast cancer but there is limited evidence on the effect of cumulative exposure to metformin and the risk of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR + /HER2-) breast cancer." | 4.12 | Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. ( Abughosh, SM; Aparasu, RR; Chikermane, SG; Johnson, ML; Sharma, M; Trivedi, MV, 2022) |
| "Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied." | 4.02 | An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors. ( Bonanni, B; Cardenas, A; Chung, FF; Cuenin, C; Hartman, SJ; Herceg, Z; Hubbard, AE; Johansson, H; Novoloaca, A; Nwanaji-Enwerem, JC; Sears, DD; Smith, MT; Van der Laan, L, 2021) |
| "This study investigated the association of insulin, metformin, and statin use with survival and whether the association was modified by the hormone receptor status of the tumor in patients with breast cancer." | 4.02 | Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients. ( Choi, M; Han, J; Han, W; Im, SA; Jang, MJ; Kim, M; Kim, TY; Lee, DW; Lee, HB; Lee, KH; Moon, HG; Noh, DY; Yang, BR, 2021) |
| " In the current study, we investigated the effect of metformin on EMT behavior and HOTAIR expression in MDA-MB-231 breast cancer cells." | 4.02 | Metformin modulates oncogenic expression of HOTAIR gene via promoter methylation and reverses epithelial-mesenchymal transition in MDA-MB-231 cells. ( Dashtizad, M; Ghanei, Z; Golshan, M; Jamshidizad, A; Khaleghi, S; Shafiee, SM; Shamsara, M; Valaee, S, 2021) |
| "In the present study we aimed to figure out the effect of metformin on the expression of AMPK-alpha, cyclin D1, and Tp53, and apoptosis in primary breast cancer cells (PBCCs)." | 4.02 | Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism ( Beşli, N; Hocaoğlu Emre, FS; Kanıgür, G; Şenol, K; Yaprak Saraç, E; Yenmiş, G, 2021) |
| "Type 2 diabetes (T2D) has been associated with increased breast cancer risk, but commonly prescribed antidiabetic medications such as metformin may reduce risk." | 4.02 | A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. ( Bookwalter, DB; Jackson, CL; O'Brien, KM; Park, YM; Sandler, DP; Weinberg, CR, 2021) |
| "The possible synergistic combination between metformin and tangeretin was initially evaluated using MTT cell viability assay in different breast cancer cell lines (MCF-7, MDA-MB-231, and their resistant phenotype)." | 4.02 | Tangeretin boosts the anticancer activity of metformin in breast cancer cells via curbing the energy production. ( Abdin, SM; Mdkhana, B; Omar, HA; Zaher, DM, 2021) |
| "There are still inconsistencies about the role of metformin on breast cancer." | 4.02 | The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes. ( Behrouzi, B; Emami, AH; Mohagheghi, MA; Sadighi, S; Zokaasadi, M, 2021) |
| " In this in vitro study, we hypothesized that metformin with an effective dose can inhibit tumor cell proliferation and metastasis by modulating the expressions of MMP-2 and -9 and interfering with NF-kB signaling in primary breast cancer cells (PBCCs)." | 4.02 | Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity. ( Besli, N; Dilek Kancagi, D; Ekmekci, CG; Kanigur Sultuybek, G; Karagulle, OO; Ovali, E; Senol, K; Soydas, T; Tastan, C; Tuncdemir, M; Ulutin, T; Yaprak Sarac, E; Yenmis, G; Yilanci, M, 2021) |
| " Each 10% increase in 1-year adherence to metformin reduced cancer-specific mortality among women with breast cancer (adjusted HR = 0." | 4.02 | Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study. ( Feng, JL; Qin, X, 2021) |
| "The relationship between type 2 diabetes (T2D), metformin, and breast cancer is complex." | 4.02 | Making sense of associations between type 2 diabetes, metformin, and breast cancer risk. ( Park, YM; Sandler, DP, 2021) |
| " Moreover, using clustered regularly interspaced short palindromic repeats/Cas9-engineered ZR75-1 breast cancer cells with different ZNF423 SNP genotypes, striking differences in cellular responses to metformin, either alone or in the combination of tamoxifen, were observed in both cell culture and the mouse xenograft model." | 4.02 | ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion. ( Gao, H; Ingle, JN; Kim, W; Qin, S; Wang, L; Weinshilboum, RM, 2021) |
| " The main purpose of this study is to strengthen the application of non-oncological drug metformin on breast cancer treatment in the perspective of epigenetics." | 4.02 | lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell. ( Hao, Z; He, Y; Huang, Y; Li, T; Song, Y; Wang, B; Wu, Z; Yuan, K; Zhang, J; Zhao, Q; Zheng, S; Zhou, Z, 2021) |
| "Epidemiologic studies in diabetic patients as well as research in model organisms have indicated the potential of metformin as a drug candidate for the treatment of various types of cancer, including breast cancer." | 4.02 | AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism. ( Bonini, MG; Chen, Y; Coelho, DR; Danes, JM; de Abreu, AL; Jones, DP; Karan, U; Miguel, R; Palma, FR; Paviani, V; Ratti, BA; Silva, SO; Silverstein, RL; Zaichik, SV, 2021) |
| "Numerous studies have suggested that metformin treatment can increase breast cancer survival; however, it is unclear whether its effects interact with intrinsic subtype or diabetic status." | 4.02 | Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study. ( Cho, MJ; Kim, BH; Kwon, J, 2021) |
| "Breast cancer cell lines MCF-10, MCF-7 and BT-474 expressing various levels of HER2 were examined for their response to treatment with sulforaphane (SLFN), metformin (MTFN), Nano-MTFN or combinations." | 3.96 | Co-Treatment with Sulforaphane and Nano-Metformin Molecules Accelerates Apoptosis in HER2+ Breast Cancer Cells by Inhibiting Key Molecules. ( Gardaneh, M; Heidari-Keshel, S; Keshandehghan, A; Nikkhah, S; Tahermansouri, H, 2020) |
| "A cell viability assay was utilized to examine the inhibitory effect of metformin on proliferation of breast cancer cells." | 3.96 | Metformin alleviates breast cancer through targeting high-mobility group AT-hook 2. ( Feng, W; Li, Y; Ren, H; Wang, D, 2020) |
| "We studied a large cohort of early-stage, hormone-positive breast cancer patients to determine if there is an association between RS and metformin treatment." | 3.96 | Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients. ( Blanter, J; Cascetta, K; Ru, M; Tharakan, S; Tiersten, A; Zimmerman, B, 2020) |
| "This study confirms that metformin is transported into tumor tissue in women with breast cancer." | 3.96 | Metformin is distributed to tumor tissue in breast cancer patients in vivo: A ( Al-Suliman, N; Frøkiær, J; Gormsen, LC; Jakobsen, S; Jessen, N; Munk, OL; Pedersen, SB; Sundelin, EIO; Vahl, P; Vendelbo, M, 2020) |
| "Metformin use prior to diagnosis of cancer was associated with a decrease in risk of both breast cancer (OR = 0." | 3.96 | Use of metformin and risk of breast and colorectal cancer. ( Gronich, N; Gruber, SB; Pinchev, M; Rennert, G; Rennert, HS, 2020) |
| "Microscopic imaging, the formation of 3D multicellular tumour spheroids, immunocytochemistry, flow cytometry, Annexin V Assay, Caspase 3/7 Apoptosis Assay, tube formation assay and analysis, and WST-1 cell viability assay evaluated the formation of MCTS, morphologic changes, cell viability, apoptosis activity and the expression levels of ALDH1A1, CD44 and CD24 on the cell surface, MDA-MB231 triple-negative breast cancer, tamoxifen (Tmx) resistant variant (MDA-MB-231-TmxR)." | 3.96 | A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer. ( Burov, SV; Haq, S; Harless, W; Markvicheva, E; Qorri, B; Sambi, M; Samuel, V; Szewczuk, MR, 2020) |
| "High doses of metformin induces oxidative stress (OS) and transforming growth factor β1 (TGF-β1) in breast cancer cells, which was associated with increased cancer stem cell population, local invasion, liver metastasis and treatment resistance." | 3.96 | Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis. ( Abdelhay, E; Binato, R; Borges, FH; Cecchini, AL; Cecchini, R; L Mencalha, A; Lopes, NMD; Luiz, RC; Marinello, PC; Panis, C; Rodrigues, JA; Silva, TNX, 2020) |
| "ADSCs grown from lipoaspirates were tested for growth-stimulating and migration-controlling activity on breast cancer cell lines after pretreatment with metformin." | 3.96 | Effects of metformin on adipose-derived stromal cell (ADSC) - Breast cancer cell lines interaction. ( Hamilton, G; Huk, I; Nanobashvili, J; Neumayer, C; Plangger, A; Radtke, C; Rath, B; Staud, C; Teufelsbauer, M, 2020) |
| " We found that gallic acid activated KDM2A to reduce rRNA transcription and cell proliferation in breast cancer MCF-7 cells." | 3.96 | Production of ROS by Gallic Acid Activates KDM2A to Reduce rRNA Transcription. ( Konishi, A; Obinata, H; Tanaka, Y; Tsuneoka, M; Yamagiwa, N, 2020) |
| " Metformin has been reported to have an inhibitory effect on PlGF expression in a breast cancer model." | 3.91 | PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin. ( Duan, P; Feng, J; Gu, JT; Kang, XW; Liu, PJ; Ma, Q; Sun, X; Wang, B; Wang, JC; Yang, L, 2019) |
| "Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6, is indicated for metastatic breast cancer treatment." | 3.91 | Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. ( Bacon, J; Bonventre, JV; Chappell, JC; Chiang, AY; Hall, SD; Kulanthaivel, P; Pak, YA; Royalty, J; Turner, PK, 2019) |
| "To address the possible association between the use of metformin, other forms of antidiabetic medication (ADM) and statins with the incidence of breast cancer in women with type 2 diabetes (T2D)." | 3.91 | Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. ( Arffman, M; Hautakoski, A; Hosio, M; Jukkola, A; Karihtala, P; Läärä, E; Marttila, M; Puistola, U; Sund, R; Urpilainen, E, 2019) |
| "Metformin was shown to sensitize multidrug resistant breast cancer cells; however, the mechanisms involved in this capacity need to be clarified." | 3.91 | Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. ( Abdelhay, E; Binato, R; Cecchini, AL; Cecchini, R; Lopes, NMD; Luiz, RC; Marinello, PC; Mencalha, AL; Panis, C; Rodrigues, JA; Silva, TNX, 2019) |
| "An efficacious metformin dose for breast cancer varies among tumour subtypes based on cation transporter expression, which provides a useful guide for dose selection." | 3.91 | Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours. ( Cai, H; Everett, RS; Thakker, DR, 2019) |
| "The effect of metformin on different breast cancer cell lines, representing the molecular heterogenicity of the disease was investigated using in vitro proliferation and apoptosis assays." | 3.91 | PYK2 promotes HER2-positive breast cancer invasion. ( Al-Juboori, SI; Almshayakhchi, R; Ball, GR; Boocock, DJ; Caraglia, M; Desiderio, V; Idri, S; Miles, AK; Pearson, JR; Regad, T; Vadakekolathu, J; Wagner, S; Zafeiris, D, 2019) |
| " The antidiabetic agent metformin has shown its ability to inhibit tumor angiogenesis in metastatic breast cancer models." | 3.91 | Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation. ( Feng, J; Han, SX; Jiang, YN; Li, GY; Liu, JL; Liu, PJ; Lu, SY; Shen, YW; Sun, X; Wang, B; Wang, JC; Wang, MD; Zhou, C, 2019) |
| "To assess the proportion of members of a private health insurance at the Hospital Italiano de Buenos Aires with primary adherence to, 1) bisphosphonates for secondary prevention of osteoporotic fractures, 2) insulin and metformin in type 2 diabetes, and 3) tamoxifen in the context of treatment of breast cancer." | 3.88 | [Evaluation of primary adherence to medications in patients with chronic conditions: A retrospective cohort study]. ( Esteban, S; Peper, FE; Terrasa, SA, 2018) |
| "The study was aimed at investigating the synergistic inhibitory effect of unique combinational regimen of nanocapsulated Metformin (Met) and Curcumin (Cur) against T47D breast cancer cells." | 3.88 | Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells. ( Dadashpour, M; Farajzadeh, R; Javidfar, S; Lotfi-Attari, J; Pilehvar-Soltanahmadi, Y; Sadeghzadeh, H; Shafiei-Irannejad, V; Zarghami, N, 2018) |
| "Studies have shown that aspirin and metformin play important roles in chemoprevention and repression of breast cancers, even though the exact mechanism remains unclear." | 3.88 | Aspirin and metformin exhibit antitumor activity in murine breast cancer. ( Du, C; Liu, Y; Luo, F; Wang, Y; Zhang, N; Zhao, M, 2018) |
| "cells were investigated." | 3.88 | Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression ( Rasouli, S; Zarghami, N, 2018) |
| "This study investigated the effects of metformin and weight loss on biomarkers associated with breast cancer prognosis." | 3.88 | The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Laughlin, GA; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, BA; Patterson, RE; Sears, DD; Villaseñor, A, 2018) |
| "Autophagy modulation is a potential therapeutic strategy for breast cancer, and a previous study indicated that metformin exhibits significant anti-carcinogenic activity." | 3.88 | Inhibiting ROS-TFE3-dependent autophagy enhances the therapeutic response to metformin in breast cancer. ( Guo, Q; Huang, Y; Liao, N; Liu, M; Qiu, B; Tan, M; Wang, T; Wu, A; Yi, J; Zhou, W, 2018) |
| "Here, we used an 1-methyl-1-nitrosourea (MNU)-induced mammary tumor rat model of estrogen receptor (ER)-positive postmenopausal breast cancer to evaluate the long-term effects of metformin administration on metabolic and tumor endpoints." | 3.88 | Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. ( Anderson, SM; Edwards, DP; Giles, ED; Jindal, S; MacLean, PS; Schedin, P; Schedin, T; Thor, AD; Wellberg, EA, 2018) |
| "To explore a chemopreventive strategy for improving breast cancer treatment efficacy, the anticancer effects of a combination of Metformin (MET) and Silibinin (SIL) were investigated in T47D breast cancer cells." | 3.88 | Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition. ( Asbaghi, N; Chatran, M; Dadashpour, M; Faramarzi, L; Jafari-Gharabaghlou, D; Pilehvar-Soltanahmadi, Y; Rasouli, S; Zarghami, N, 2018) |
| "We found that metformin inhibited the growth, proliferation and clonogenic potential of the breast cancer-derived cells tested." | 3.88 | Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD). ( Kumar, S; Sharma, P, 2018) |
| "At pharmacologically achievable concentrations, metformin does not drastically impact cell viability, but inhibits inflammatory signaling and metastatic progression in breast cancer cells." | 3.88 | Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells. ( Broussard, K; Ismail, M; Keizerweerd, A; Llopis, S; McAtee, L; McFerrin, H; Onuaguluchi, D; Poché, A; Schexnayder, C; Williams, C, 2018) |
| " The present study was aimed at exploring the antiproliferative effects of the commonly studied metformin and the less frequently reported phenformin oral hypoglycemic agents on different molecular subtypes of breast cancer under rich glucose and glucose deprived conditions." | 3.88 | Glucose Deprivation Enhances the Antiproliferative Effects of Oral Hypoglycemic Biguanides in Different Molecular Subtypes of Breast Cancer: an in Vitro Study. ( Aleidi, SM; Alsalamat, HA; Bardaweel, SK; Bashatwah, RM, 2018) |
| "Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia." | 3.85 | Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. ( Ariaans, G; Jalving, M; Jong, S; Vries, EG, 2017) |
| " This method was applied to MDA-MB-231 breast cancer cells treated with the antidiabetic drug metformin, which is being repurposed for treatment of triple-negative breast cancer." | 3.85 | Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer. ( Athreya, AP; Cairns, J; Gaglio, AJ; Iyer, RK; Kalari, KR; Niu, N; Wang, L; Weinshilboum, R; Wills, QF, 2017) |
| "The widely prescribed diabetes medicine metformin has been reported to lower the risk of incident breast cancer, but it is unclear whether it affects malignant progression after diagnosis." | 3.85 | Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. ( Barlow, WE; Boudreau, DM; Chen, L; Chubak, J; Li, CI; Weiss, NS, 2017) |
| " Here, we present the important in vitro discovery that the development of MDR (in breast cancer cells) can be prevented, and that established MDR could be resensitized to therapy, by adjunct treatment with metformin." | 3.85 | Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. ( Arnason, T; Bowen, M; Davies, G; Dawicki, W; Gordon, JR; Groot, G; Harkness, T; Lobanova, L, 2017) |
| " The goal of this study was to assess protein marker changes by RPPA in tumor tissue from a pre-surgical metformin trial in women with operable breast cancer (BC)." | 3.85 | Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial. ( Connolly, E; Crew, KD; Du, X; Feldman, SM; Hershman, DL; Hibshoosh, H; Kalinsky, K; Maurer, MA; Mundi, P; Refice, S; Taback, B; Yang, J; Zheng, T, 2017) |
| " Hazard ratios for breast cancer in the first 3 months following initiation of metformin, sulfonylurea or thiazolidinedione were 0." | 3.85 | Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias. ( Bowker, SL; Eurich, DT; Johnson, JA; Lin, M, 2017) |
| "In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models." | 3.85 | Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. ( André, N; Baglioni, M; Bondarenko, M; Carré, M; Laluce, NC; Menacho Márquez, M; Rico, M; Rozados, V; Scharovsky, OG, 2017) |
| "Several observational studies have reported that metformin may be associated with reduced risk of breast cancer; however, many of these studies were affected by time-related biases such as immortal time bias and time-window bias." | 3.85 | Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. ( Buse, JB; Henderson, LM; Hong, JL; Jonsson Funk, M; Lund, JL; Pate, V; Stürmer, T, 2017) |
| "Considered a popular drug for diabetes in recent years, metformin was determined to have a moderate anti-tumor effect, particularly in breast cancer." | 3.83 | Characterization and evaluation of metformin-loaded solid lipid nanoparticles for celluar and mitochondrial uptake. ( Shen, Q; Xu, Q; Yi, C; Zhu, T, 2016) |
| "The antidiabetic drug metformin exerts antineoplastic effects against breast cancer and other cancers." | 3.83 | Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. ( Cai, H; Everett, RS; Han, TK; Thakker, DR; Zhang, Y, 2016) |
| "Herein two breast cancer cell lines, SKBr3 and BT474, overexpressing human epithelial receptor 2 (HER2), the target of the humanised antibody trastuzumab, were treated with a range of concentrations (20-2000 nM) of doxorubicin with and without trastuzumab in the presence of clinically relevant doses of the ACE inhibitor enalapril, the beta-blocker carvedilol, metformin or dexrazoxane, and cell survival determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay." | 3.83 | Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells. ( Akabuogu, EU; Phyu, SM; Smith, TA, 2016) |
| "Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models." | 3.83 | Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016) |
| " Here we show that combining metformin and short-term starvation markedly impairs metabolism and growth of colon and breast cancer." | 3.83 | Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer. ( Bianchi, G; Bongioanni, F; Bottoni, G; Bruzzi, P; Buschiazzo, A; Capitanio, S; Emionite, L; Fabbi, M; Garaboldi, L; Inglese, E; Marini, C; Martella, R; Monteverde, E; Orengo, AM; Petretto, A; Raffaghello, L; Ravera, S; Sambuceti, G, 2016) |
| "MDA-MB-468, BT474 and SKBr3 breast cancer cell lines were treated with metformin and [3H-methyl]choline and [14C(U)]glucose incorporation and lipid accumulation determined in the presence and absence of lipase inhibitors." | 3.83 | Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells. ( Phyu, SM; Smith, TA, 2016) |
| "Acquisition of tamoxifen resistance (TR) during anti-estrogenic therapy using tamoxifen is a major obstacle in the treatment of estrogen receptor (ER)-positive breast cancer." | 3.83 | Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. ( Choi, Y; Jang, SY; Kim, A; Kim, C; Kim, J; Lee, J, 2016) |
| "Among 10,050 women with diabetes, 57 % used metformin, 43 % used sulfonylureas, 32 % used insulin, and 301 were diagnosed with breast cancer over median follow-up of 6." | 3.83 | Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. ( Boudreau, DM; Calip, GS; Elmore, JG; Yu, O, 2016) |
| "The use of metformin and incretins in women with T2DM and BC may reduce the risk of metastases." | 3.83 | Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. ( Jacob, L; Kalder, M; Kostev, K; Rathmann, W, 2016) |
| "Epidemiological studies indicate that metformin, a widely used type 2 diabetes drug, might reduce breast cancer risk and mortality in patients with type 2 diabetes." | 3.83 | Medium Renewal Blocks Anti-Proliferative Effects of Metformin in Cultured MDA-MB-231 Breast Cancer Cells. ( Dolinar, K; Miš, K; Pavlin, M; Pirkmajer, S; Rajh, M, 2016) |
| "Objective To investigate the effect of metformin, alone or in combination with Lily polysaccharide 1 (LP1), on cell viability and apoptosis in MCF-7 human breast cancer cells." | 3.83 | [Lily polysaccharide 1 enhances the effect of metformin on proliferation and apoptosis of human breast carcinoma cells]. ( Hou, J; Li, F; Li, X; Mei, Q; Mi, M, 2016) |
| "Metformin, a drug approved for diabetes type II treatment, has been associated with a reduction in the incidence of breast cancer and metastasis and increased survival in diabetic breast cancer patients." | 3.83 | The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer. ( Cabello, P; Eroles, P; Lluch, A; Pineda, B; Tormo, E, 2016) |
| "Previous studies have shown that hypoxia can reverse DCA/metformin-induced cell death in breast cancer cells." | 3.83 | TRAIL restores DCA/metformin-mediated cell death in hypoxia. ( An, S; Hong, J; Hong, SE; Hwang, SG; Jin, HO; Kim, CS; Kim, HA; Kim, JI; Lee, JK; Noh, WC; Park, IC; Song, JY, 2016) |
| "Metformin was demonstrated to have effects on breast cancer, and microRNA-27a (miR-27a) is a prognostic marker for breast cancer progression and patient survival." | 3.83 | miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7. ( Liu, J; Sun, B; Tang, H; Zhang, H; Zhang, X; Zhao, W, 2016) |
| "Metformin, currently undergoing clinical trials as an adjuvant for the treatment of breast cancer, modulates the activity of key intracellular signalling molecules which affect 2-[(18)F]Fluoro-2-deoxy-D-glucose ([(18)F]FDG) incorporation." | 3.81 | Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling. ( Cooper, AC; Fleming, IN; Phyu, SM; Smith, TA, 2015) |
| " The chemopreventive effect of MET against DMBA-induced breast carcinogenesis was evidenced by the capability of MET to restore the induction of the mRNA levels of basic excision repair genes, 8-oxoguanine DNA glycosylase (OGG1) and apurinic/apyrimidinic endonuclease1 (APE1), and the level of 8-hydroxy-2-deoxyguanosine (8-OHdG)." | 3.81 | Metformin inhibits 7,12-dimethylbenz[a]anthracene-induced breast carcinogenesis and adduct formation in human breast cells by inhibiting the cytochrome P4501A1/aryl hydrocarbon receptor signaling pathway. ( Alhaider, AA; Ansari, MA; Denison, MS; El-Kadi, AO; Ghebeh, H; Korashy, HM; Maayah, ZH; Soshilov, AA, 2015) |
| "Evidence has been accumulating for a role for metformin in reducing breast cancer risk in post-menopausal women." | 3.81 | Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells. ( Ahmetaga, A; Bano, G; Mason, HD; Pellat, L; Rice, S; Whitehead, SA, 2015) |
| "This study assessed the association between glucose-lowering drug (GLD) use, including metformin, sulphonylurea derivatives and insulin, after breast cancer diagnosis and breast cancer-specific and all-cause mortality." | 3.81 | The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. ( Cardwell, CR; Murray, LJ; Pouwer, F; van de Poll-Franse, LV; Vissers, PA; Young, IS, 2015) |
| "We conducted a neoadjuvant, single-arm, "window of opportunity" trial to examine the clinical and biological effects of metformin on patients with breast cancer." | 3.81 | Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. ( Chang, MC; Done, SJ; Dowling, RJ; Ennis, M; Escallon, JM; Goodwin, PJ; Leong, WL; McCready, DR; Niraula, S; Reedijk, M; Stambolic, V, 2015) |
| "Metformin use has recently been observed to decrease both the rate and mortality of breast cancer." | 3.81 | Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. ( Ahn, SH; Kim, HJ; Koh, BS; Kwon, H; Lee, JW; Lee, SB; Lee, Y; Park, HS; Sohn, G; Son, BH; Yu, JH, 2015) |
| "Metformin, a widely prescribed antidiabetic drug, has previously been shown to lower the risk of certain types of cancer, including that of breast cancer, and to improve prognosis." | 3.81 | Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. ( Fan, C; Liu, Z; Sun, Y; Wang, X; Wang, Y; Wei, G; Wei, J, 2015) |
| "Metformin, a diabetes drug with well-established side effect and safety profiles, has been widely studied for its anti-tumor activities in a number of cancers, including breast cancer." | 3.81 | Metformin in breast cancer - an evolving mystery. ( Camacho, L; Dasgupta, A; Jiralerspong, S, 2015) |
| " The tumor inhibitory effect of metformin on p53-mutated breast cancer cells remains unclear." | 3.81 | p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. ( Feng, X; Li, P; Parris, AB; Yang, X; Zhao, M, 2015) |
| "Metformin, an AMPK activator, has been reported to improve pathological response to chemotherapy in diabetic breast cancer patients." | 3.81 | Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. ( Chung, FF; Hii, LW; Ho, GF; Leong, CO; Malik, RA; Ng, CH; See, MH; Soo, JS; Taib, NA; Tan, BS; Tan, SH; Teh, YC; Teo, SH; Yip, CH, 2015) |
| "Our results showed that metformin can induce apoptosis in breast cancer cells when cultured at physiological glucose concentrations and that the pro-apoptotic effect was completely abolished when cells were grown in high glucose/high amino acid medium." | 3.81 | Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions. ( Castagnoli, L; Cesareni, G; Palumbo, F; Paoluzi, S; Pavlidou, T; Posca, D; Rasi, I; Silvestri, A, 2015) |
| "The aim of this study was to compare the effects and mechanisms of action of metformin on estrogen receptor (ER)-positive and ER-negative breast cancer cell lines." | 3.80 | Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. ( Appleyard, V; Hadad, SM; Hardie, DG; Thompson, AM, 2014) |
| " We recently established a pre-clinical model of estrogen-dependent MCF-7 breast cancer cells that were chronically adapted to grow (> 10 months) in the presence of graded, millimolar concentrations of the anti-diabetic biguanide metformin, an AMPK agonist/mTOR inhibitor that has been evaluated in multiple in vitro and in vivo cancer studies and is now being tested in clinical trials." | 3.80 | Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. ( Corominas-Faja, B; Cuyàs, E; Fernández-Arroyo, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Rodríguez-Gallego, E; Vazquez-Martin, A, 2014) |
| "The efficacy of metformin alone and in combination with tamoxifen against ER-positive breast cancer was analyzed by cell survival, DNA replication activity, plate colony formation, soft-agar, flow cytometry, immunohistochemistry, and nude mice model assays." | 3.80 | Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. ( Chen, S; Guo, Y; Lai, X; Liu, W; Ma, J; Wei, Y; Xue, Y; Yu, S; Zhang, J; Zhang, Y; Zhong, C, 2014) |
| "Breast cancer cell lines from luminal A, luminal B, ErbB2 and triple-negative molecular subtypes were treated with a pharmacological concentration of metformin (2mM) at a glucose concentration of 5." | 3.80 | Lack of metformin effects on different molecular subtypes of breast cancer under normoglycemic conditions: an in vitro study. ( Amanpour, S; Behrouzi, B; Khorgami, Z; Muhammadnejad, S; Sadighi, S, 2014) |
| "Whether metformin therapy affects breast cancer risk in Asian patients with type 2 diabetes mellitus (T2DM) has not been investigated." | 3.80 | Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. ( Tseng, CH, 2014) |
| "We consider that administration of metformin with chemotherapeutic agents could be an effective method in treatment of breast cancer through mechanisms such as reduced resistance to chemotherapy and increased cytotoxic activity." | 3.80 | The relationship between anticancer effect of metformin and the transcriptional regulation of certain genes (CHOP, CAV-1, HO-1, SGK-1 and Par-4) on MCF-7 cell line. ( Alacam, H; Bedir, A; Okuyucu, A; Ozdemir, T; Salis, O, 2014) |
| "Observational data suggest that metformin use decreases breast cancer (BC) incidence in women with diabetes; the impact of metformin on BC outcomes in this population is less clear." | 3.80 | The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. ( Eaton, A; King, TA; Oppong, BA; Oskar, S; Patil, S; Pharmer, LA; Stempel, M, 2014) |
| " Here we investigated by 1H-NMR/PCA analysis the metabolic profile of chemoresistant breast cancer cell subpopulations (ALDHbright cells) and their response to metformin, a promising anticancer metabolic modulator." | 3.80 | Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. ( Biagioni, F; Blandino, G; Casadei, L; Cioce, M; Manetti, C; Mori, F; Muti, P; Pulito, C; Sacconi, A; Strano, S; Valerio, M, 2014) |
| " Here we show that low-dose metformin or SN-38 inhibits cell growth or survival in ovarian and breast cancer cells and suppresses their tumor growth in vivo." | 3.80 | Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. ( Berek, JS; Chung, YM; Guan, M; Hu, MC; Hu, T; Ma, J; Ma, M, 2014) |
| " In the present study, we found that metformin inhibited cell migration and invasion of phorbol 12-myristate 13-acetate-induced MCF-7 and tamoxifen-resistant MCF-7 breast cancer cells." | 3.80 | Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells. ( Cho, YH; Jang, SY; Kim, A; Kim, C; Kim, CH; Kim, JH; Kim, JK; Lee, JY, 2014) |
| " Here, we investigated the effects of the anti-diabetes drug metformin on expression of CYP1A1 and CYP1B1 in breast cancer cells under constitutive and inducible conditions." | 3.80 | Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. ( Choi, JH; Chung, YC; Do, MT; Jeong, HG; Jeong, TC; Khanal, T; Kim, HG; Tran, TT, 2014) |
| "A 74-year-old female patient with a locally recurrent breast cancer developed hyperglycaemia, which started 2 weeks after the initiation of treatment with everolimus 10 mg once daily." | 3.80 | [Hyperglycaemia during treatment with everolimus]. ( Beijnen, JH; Huitema, AD; Opdam, FL; Schellens, JH, 2014) |
| " Neurotensin (NTS) and its high affinity receptor (NTSR1) are up regulated in 20% of breast cancers, and NTSR1 overexpression was shown to predict a poor prognosis for 5 year overall survival in invasive breast carcinomas." | 3.80 | Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. ( Cayre, A; De Wever, O; Doan, VK; Dupouy, S; Forgez, P; Gompel, A; Kouchkar, A; Liu, J; Llorca, FP; Mourra, N; Wu, Z, 2014) |
| "Recent population studies provide clues that the use of metformin may be associated with reduced incidence and improved prognosis of breast cancer." | 3.80 | Metformin and survival in diabetic patients with breast cancer. ( El-Benhawy, SA; El-Sheredy, HG, 2014) |
| "Metformin has been associated with a reduction in breast cancer risk and may improve survival after cancer through direct and indirect tumor-suppressing mechanisms." | 3.79 | Association between metformin therapy and mortality after breast cancer: a population-based study. ( Austin, PC; Goodwin, PJ; Gruneir, A; Lega, IC; Lipscombe, LL; Rochon, PA, 2013) |
| "There was a contradictory data with metformin use on breast cancer risk, but there is growing evidence that the use of metformin in diabetic patients was associated with lower risks of breast cancer mortality and incidence." | 3.79 | Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. ( Aksoy, S; Altundag, K; Sendur, MA, 2013) |
| "Metformin treatment has been associated with a decrease in breast cancer risk and improved survival." | 3.79 | Glucose promotes breast cancer aggression and reduces metformin efficacy. ( Anderson, SM; Arnadottir, SS; Deng, XS; Edgerton, SM; Fan, Z; Liu, B; Richer, JK; Thor, AD; Wahdan-Alaswad, R, 2013) |
| "The growth and metastasis of MDA-MB-231 breast cancer may be inhibited by metformin." | 3.79 | Multimodality imaging assessments of response to metformin therapy for breast cancer in nude mice. ( Gao, FB; Mao, Y; Wang, L; Wang, YQ; Xia, R, 2013) |
| "This study was set out to determine whether metformin use influences survival in breast cancer patients treated with antidiabetic drugs as compared to non-users." | 3.79 | Use of metformin and survival of diabetic women with breast cancer. ( Bazelier, MT; De Bruin, ML; de Vries, F; Leufkens, HG; Peeters, PJ; Schmidt, MK; Vestergaard, P, 2013) |
| "Metformin use has been reported to decrease breast cancer incidence and mortality in diabetic patients." | 3.79 | Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. ( Ishibashi, Y; Matsui, T; Takeuchi, M; Yamagishi, S, 2013) |
| "Metformin, the first-line drug for treating diabetes, inhibits cellular transformation and selectively kills cancer stem cells in breast cancer cell lines." | 3.79 | Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. ( Hirsch, HA; Iliopoulos, D; Struhl, K, 2013) |
| "Diabetic patients taking metformin have lower incidence of breast cancer than those taking other anti-diabetic medications." | 3.79 | Metformin induces a senescence-associated gene signature in breast cancer cells. ( Llopis, SD; Singleton, BA; Skripnikova, EV; Williams, CC, 2013) |
| "Thiazolidinediones and metformin users are associated with better clinical outcomes than nonusers in diabetics with stage≥2 HER2+ breast cancer." | 3.78 | Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. ( Ensor, J; Esteva, FJ; He, X; Hortobagyi, GN; Lee, MH; Yeung, SC, 2012) |
| "Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer." | 3.78 | Phenformin as prophylaxis and therapy in breast cancer xenografts. ( Alessi, DR; Appleyard, MV; Bray, SE; Coates, PJ; Fleming, S; Kernohan, NM; Murray, KE; Thompson, AM; Wullschleger, S, 2012) |
| "We tested metformin alone and in combination with RAD001 and/or chemotherapeutic agents (carboplatin, paclitaxel and doxorubicin, respectively) on several human breast cancer cell lines with respect to cell proliferation, apoptosis and autophagy." | 3.78 | Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. ( Eucker, J; Habbel, P; Liu, H; Possinger, K; Regierer, AC; Schefe, JH; Scholz, C; Schulz, CO; Zang, C, 2012) |
| "In a retrospective controlled study, a tumor-protective effect, regarding breast cancer, was determined for the medicines metformin and glitazone (anti-diabetics), bisoprolol, and propranolol (cardioselective β1 adrenoceptor antagonists)." | 3.78 | A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer. ( Briese, V; Richter, C; Richter, DU; Szewczyk, M, 2012) |
| "Emerging evidence suggests that metformin may reduce breast cancer incidence, but reports are mixed and few provide information on tumor characteristics." | 3.78 | Diabetes, metformin, and breast cancer in postmenopausal women. ( Aragaki, AK; Chlebowski, RT; Euhus, DM; Gunter, M; Ipp, E; Kaklamani, VG; Manson, JE; Margolis, K; McTiernan, A; Phillips, LS; Rohan, T; Strickler, H; Vitolins, M; Wactawski-Wende, J; Wallace, R, 2012) |
| "Although there is data suggesting the in vitro inhibition of aromatase in cell lines by antidiabetic biguanide metformin (MF), there is no data on the intratumoral breast cancer (BC) aromatase expression in patients already receiving therapy for type II diabetes." | 3.78 | [Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes]. ( Bershteĭn, LM; Boiarkina, MP; Turkevich, EA, 2012) |
| "Metabolomic fingerprint of breast cancer cells treated with the antidiabetic drug metformin revealed a significant accumulation of 5-formimino-tetrahydrofolate, one of the tetrahydrofolate forms carrying activated one-carbon units that are essential for the de novo synthesis of purines and pyrimidines." | 3.78 | Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. ( Corominas-Faja, B; Cufí, S; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Quirantes-Piné, R; Segura-Carretero, A; Vazquez-Martin, A, 2012) |
| "Resistance to tamoxifen (TAM) and aromatase inhibitors represents a major drawback to the treatment of hormone-dependent breast cancer, and strategies to overcome this problem are urgently needed." | 3.77 | Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. ( Berstein, LM; Santen, RJ; Wang, JP; Yue, W, 2011) |
| "Preliminary evidence suggests that metformin may decrease breast cancer risk by decreasing insulin levels and reducing cell proliferation." | 3.77 | Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. ( Antonsen, S; Bosco, JL; Lash, TL; Pedersen, L; Sørensen, HT, 2011) |
| " We found that in LKB1-null A549 lung adenocarcinoma cells, an AMPK activator, metformin, failed to block the nuclear export of PTEN, and the reintroduction of functional LKB1 into these cells restored the metformin-mediated inhibition of the nuclear export of PTEN." | 3.77 | AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. ( Gallick, GE; Liu, JL; Mao, Z; Yung, WK, 2011) |
| "An unexplored molecular scenario that might explain the inhibitory impact of the anti-diabetic drug metformin on the genesis of breast cancer relates to metformin's ability to modulate the expression status of micro (mi)RNAs." | 3.77 | Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. ( Cufí, S; Del Barco, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Torres-Garcia, VZ; Vazquez-Martin, A, 2011) |
| "Metformin, the first-line drug for treating diabetes, selectively kills the chemotherapy resistant subpopulation of cancer stem cells (CSC) in genetically distinct types of breast cancer cell lines." | 3.77 | Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. ( Hirsch, HA; Iliopoulos, D; Struhl, K, 2011) |
| "We have shown that erbB2 altered breast cancer cells are less sensitive to the anti-proliferative effects of metformin than triple negative cells, and have described the differences of molecular mechanisms of metformin action by tumor subtypes." | 3.77 | Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. ( Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD; Yang, X, 2011) |
| "Metformin, a Type II diabetic treatment drug, which inhibits transcription of gluconeogenesis genes, has recently been shown to lower the risk of some diabetes-related tumors, including breast cancer." | 3.77 | Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. ( Jung, JW; Kang, KS; Lee, SJ; Park, SB; Seo, MS; Trosko, JE, 2011) |
| "A decreased risk of breast cancer was observed in female patients with type 2 diabetes using metformin on a long-term basis." | 3.76 | Long-term metformin use is associated with decreased risk of breast cancer. ( Bodmer, M; Jick, SS; Krähenbühl, S; Meier, C; Meier, CR, 2010) |
| "Lung, prostate, and breast cancer cells were treated with IR (2-8 Gy) after incubation with either ATM or AMPK inhibitors or the AMPK activator metformin." | 3.76 | Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. ( Bristow, RG; Cutz, JC; Harding, S; Liu, C; Rashid, A; Sanli, T; Singh, G; Tsakiridis, T; Wright, J, 2010) |
| "A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer." | 3.76 | Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. ( Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "According to some existing data, unlike sulphonylurea (SU) and insulin derivatives, treatment with biguanide metformin, for reasons still unknown, may diminish breast cancer (BC) morbidity in diabetic females." | 3.76 | [Effect of previous diabetes therapy on tumor receptor phenotype in breast cancer: comparison of metformin and sulphonylurea derivatives]. ( Bershteĭn, LM; Boriakina, MP; Semiglazov, VF; Tsyrlina, EV; Turkevich, EA, 2010) |
| " Earlier studies from our group have revealed that clinically-relevant concentrations of the biguanide derivative metformin, the most widely used oral agent to lower blood glucose concentration in patients with type 2 diabetes and metabolic syndrome, notably decreased both the self-renewal and the proliferation of trastuzumab-refractory breast cancer stem cell populations." | 3.76 | Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. ( Cufí, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "Population studies have revealed that treatment with the antidiabetic drug metformin significantly associates with reduced breast cancer risk." | 3.75 | The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. ( Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2009) |
| "The anti-diabetic drug metformin reduces human cancer incidence and improves the survival of cancer patients, including those with breast cancer." | 3.75 | Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. ( Alimova, IN; Dillon, T; Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD, 2009) |
| "Prompted by the ever-growing scientific rationale for examining the antidiabetic drug metformin as a potential antitumor agent in breast cancer disease, we recently tested the hypothesis that the assessment of metformin-induced global changes in gene expression-as identified using 44 K (double density) Agilent's whole human genome arrays-could reveal gene-expression signatures that would allow proper selection of breast cancer patients who should be considered for metformin-based clinical trials." | 3.75 | Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. ( Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2009) |
| "Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving metformin." | 3.75 | Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. ( Barnett, CM; Giordano, SH; Gonzalez-Angulo, AM; Hortobagyi, GN; Hsu, L; Hung, MC; Jiralerspong, S; Liedtke, C; Meric-Bernstam, F; Palla, SL, 2009) |
| " Here, we show that low doses of metformin, a standard drug for diabetes, inhibits cellular transformation and selectively kills cancer stem cells in four genetically different types of breast cancer." | 3.75 | Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. ( Hirsch, HA; Iliopoulos, D; Struhl, K; Tsichlis, PN, 2009) |
| "Metformin, a first line treatment for type 2 diabetes, has been implicated as a potential anti-neoplastic agent for breast cancers as well as other cancers." | 3.75 | Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. ( Claffey, KP; Phoenix, KN; Vumbaca, F, 2009) |
| "The effect of the biguanide metformin (dimethyl-biguanide) on insulin binding in vitro to IM-9 lymphocytes and MCF-7 human breast cancer cells was studied." | 3.66 | Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells. ( Pezzino, V; Purrello, F; Trischitta, V; Vigneri, R, 1982) |
| "Metformin is a biguanide antihyperglycemic agent used as a first-line drug for type II diabetes mellitus." | 3.01 | Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications. ( Bashraheel, SS; Khalaf, S; Kheraldine, H; Moustafa, AA, 2023) |
| "Inflammation is one biological mechanism hypothesized to mediate these associations." | 2.94 | Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. ( Abrams, TA; Brown, JC; Campbell, N; Cartmel, B; Douglas, PS; Fuchs, CS; Harrigan, M; Hu, FB; Irwin, ML; Jones, LW; Ligibel, JA; Meyerhardt, JA; Ng, K; Pollak, MN; Sanft, T; Sorrentino, A; Tolaney, SM; Winer, EP; Zhang, S, 2020) |
| "GDF-15 was not associated with type 2 diabetes, glycaemic traits, CAD risk factors or colorectal cancer." | 2.90 | The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study. ( Au Yeung, SL; Luo, S; Schooling, CM, 2019) |
| "Metformin is a challenging anticancer agent in BC cohorts, besides being safe and well-tolerated at antidiabetic doses." | 2.82 | Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis. ( Barakat, HE; Elberry, AA; Elsherbiny Ramadan, M; Hussein, RRS; Zaki, MA, 2022) |
| "Breast cancer is the most prevalent cancer and the leading cause of cancer-related death among women worldwide." | 2.82 | Metformin and Breast Cancer: Where Are We Now? ( Cejuela, M; Martin-Castillo, B; Menendez, JA; Pernas, S, 2022) |
| " We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones." | 2.78 | Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. ( Abbà, C; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Cogliati, P; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2013) |
| "Breast cancer is the most ubiquitous type of neoplasms among women worldwide." | 2.66 | Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions. ( Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K, 2020) |
| " However, unanswered questions remain with regards to areas such as cancer treatment specific therapeutic dosing of metformin, specificity to cancer cells at high concentrations, resistance to metformin therapy, efficacy of combinatory therapeutic approaches, post-therapeutic relapse of the disease, and efficacy in cancer prevention in non-diabetic individuals." | 2.61 | Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. ( Büsselberg, D; Kubatka, P; Samuel, SM; Triggle, CR; Varghese, E, 2019) |
| "Metformin has been the first-line drug for the treatment of type II diabetes mellitus for decades, being presently the most widely prescribed antihyperglycemic drug." | 2.61 | Metformin and Breast Cancer: Molecular Targets. ( Azevedo, A; Faria, J; Martel, F; Negalha, G, 2019) |
| "Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy." | 2.53 | Repurposing metformin for cancer treatment: current clinical studies. ( Altman, JK; Arya, A; Carneiro, B; Chae, YK; Chandra, S; Giles, F; Kalyan, A; Kaplan, J; Malecek, MK; Platanias, L; Shin, DS, 2016) |
| "Breast cancer is the most common cancer in women worldwide." | 2.52 | Update on breast cancer risk prediction and prevention. ( Cuzick, J; Sestak, I, 2015) |
| "The heterogeneity of breast cancer, confounded by comorbidity of disease in the elderly population, makes it difficult to determine the actual benefits of metformin therapy." | 2.52 | Recent advances in the use of metformin: can treating diabetes prevent breast cancer? ( Hatoum, D; McGowan, EM, 2015) |
| "Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer." | 2.52 | Obesity and cancer: mechanistic insights from transdisciplinary studies. ( Allott, EH; Hursting, SD, 2015) |
| "As the incidence of obesity is increasing worldwide, there is an urgent need for adequate preclinical models and preclinical and clinical studies designed to investigate how to inhibit the tumor-promoting activity of the adipose tissue." | 2.52 | Mechanisms of obesity in the development of breast cancer. ( Bertolini, F; Orecchioni, S; Reggiani, F; Talarico, G, 2015) |
| "Metformin is a biguanide drug, typically used for diabetes treatment, currently being studied to evaluate its role in the treatment and prevention of gynecologic cancers." | 2.50 | Metformin and gynecologic cancers. ( Bae-Jump, V; Stine, JE, 2014) |
| "Most breast cancer studies have focused on the intrinsic characteristics of breast tumor cells, including altered growth, proliferation, and metabolism." | 2.48 | Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. ( Claerhout, S; Mills, GB; Mitra, S; Stemke-Hale, K, 2012) |
| "The objective was to review type 2 diabetes as a risk factor for breast cancer, its influence on tumor aggressiveness and prognosis, and the interactions with obesity." | 2.48 | Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. ( Rose, DP; Vona-Davis, L, 2012) |
| "Metformin also plays a direct inhibition of cancer cell growth via the inhibitory effects of AMP-activated protein kinase on the mTOR pathway, which regulates cell growth and proliferation." | 2.48 | Does use of metformin protect against cancer in Type 2 diabetes mellitus? ( Benso, A; Bo, S; Durazzo, M; Ghigo, E, 2012) |
| "However, findings regarding breast cancer have been mixed." | 2.48 | Metformin and breast cancer risk: a meta-analysis and critical literature review. ( Aragaki, AK; Chlebowski, RT; Col, NF; Ochs, L; Springmann, V, 2012) |
| "Preclinical data suggest that current breast cancer treatment strategies lead to CSC enrichment, contributing to chemotherapy and radiotherapy resistance, although a strong correlation with clinical parameters and prognosis is yet to be established." | 2.48 | The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. ( Economopoulou, P; Kaklamani, VG; Siziopikou, K, 2012) |
| "Results from breast cancer treatment trials suggest that aromatase inhibitors may be even more effective in preventing breast cancer than SERMs." | 2.47 | Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. ( Brown, PH; Uray, IP, 2011) |
| "In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeutic interventions." | 2.47 | Preventive therapy for breast cancer: a consensus statement. ( Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H, 2011) |
| "Metformin is an orally available, biguanide derivative that is widely used in the treatment of Type 2 diabetes." | 2.47 | Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. ( Guppy, A; Jamal-Hanjani, M; Pickering, L, 2011) |
| "Obesity and insulin resistance have been associated with breast cancer risk, and breast cancer outcomes." | 2.47 | Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. ( Goodwin, PJ; Stambolic, V, 2011) |
| "Metformin has been shown to inhibit proliferation, invasion and angiogenesis of neoplastic cells and to overcome resistance of breast cancer to chemotherapy, hormonal therapy and HER2 inhibition." | 2.46 | Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. ( Wierusz-Wysocka, B; Wysocki, PJ, 2010) |
| "Breast cancer is the fifth leading cause of death, worldwide affecting both genders." | 1.91 | Metformin enhances anti-cancer properties of resveratrol in MCF-7 breast cancer cells via induction of apoptosis, autophagy and alteration in cell cycle distribution. ( Akbarizadeh, AR; Fatehi, R; Firouzabadi, N; Rashedinia, M; Zamani, M, 2023) |
| "Metformin (Met) is an anti-hyperglycemic agent whose anti-cancer properties have been formerly reported." | 1.91 | Potentiation of Folate-Functionalized PLGA-PEG nanoparticles loaded with metformin for the treatment of breast Cancer: possible clinical application. ( Dadashpour, M; Jafari-Gharabaghlou, D; Khanghah, OJ; Salmani-Javan, E; Zarghami, N, 2023) |
| "Epithelial breast cancer cells also differentiate into several cell types to meet various demands." | 1.91 | Metformin ameliorates BMP2 induced adipocyte-like property in breast cancer cells. ( Mandal, CC; Soni, S; Yadav, P, 2023) |
| "Metformin can directly inhibit tumorigenesis, although the mechanism responsible for this is not fully understood." | 1.72 | Metformin may induce ferroptosis by inhibiting autophagy via lncRNA H19 in breast cancer. ( Chen, J; Chen, Y; Mao, M; Qin, C; Yang, J; Zhou, Y, 2022) |
| "Compared to breast cancer cell lines (3." | 1.72 | Effects of metformin on human bone-derived mesenchymal stromal cell-breast cancer cell line interactions. ( Hamilton, G; Lang, C; Moser, D; Neumayer, C; Plangger, A; Radtke, C; Rath, B; Staud, C; Teufelsbauer, M, 2022) |
| "Obesity is associated with an increased incidence and aggressiveness of breast cancer and is estimated to increment the development of this tumor by 50 to 86%." | 1.72 | Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model. ( Cabrera-Quintero, AJ; Flores-García, LC; García-García, E; Hernández-Juárez, AJ; Méndez, JP; Meraz-Cruz, N; Naranjo-Meneses, MA; Pedraza-Sánchez, S; Ramírez-Ruíz, A; Romero-Córdoba, SL; Vadillo-Ortega, F; Ventura-Gallegos, JL; Zentella-Dehesa, A, 2022) |
| " However, DOX is known to have many harmful adverse effects including its cardiotoxicity." | 1.72 | Development and Evaluation of Core-Shell Nanocarrier System for Enhancing the Cytotoxicity of Doxorubicin/Metformin Combination Against Breast Cancer Cell Line. ( El-Sherbiny, IM; Ibrahim, A; Khalil, IA, 2022) |
| " The phytochemicals' poor bioavailability and short half-life make them unsuitable as anticancer drugs." | 1.72 | The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action. ( Dadashpour, M; Hassani, N; Jafari-Gharabaghlou, D; Zarghami, N, 2022) |
| "Multi-drug resistance (MDR) in breast cancer poses a great threat to chemotherapy." | 1.72 | Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy. ( Gu, M; Liu, Y; Ma, L; Mu, C; Qian, K; Shi, J; Tan, H; Xiong, Y; Xu, L; Xu, S; Yu, J; Zhang, H; Zhao, Y, 2022) |
| "Metformin (MET) is a well-known anti-diabetic drug that also has anti-cancer effects." | 1.72 | MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice. ( Chang, J; He, M; Li, Y; Luo, D; Luo, Y; Ran, L; Wang, H; Wang, X; Zhao, C; Zhong, X, 2022) |
| " Herein, the impacts of metformin alone and in combination with cimetidine/ibuprofen on some Th1- and regulatory T (Treg) cell-related parameters were evaluated using a breast cancer (BC) model." | 1.62 | Modulatory Effects of Metformin Alone and in Combination with Cimetidine and Ibuprofen on T Cell-related Parameters in a Breast Cancer Model. ( Hassan, ZM; Jafarzadeh, A; Khorramdelazad, H; Masoumi, J; Nemati, M; Oladpour, O; Rezayati, MT; Taghipour, F; Taghipour, Z, 2021) |
| "Metformin may increase the pCR especially in patients with BMI ≥ 25 and patients with triple-positive histology, a larger phase III study is needed to confirm this finding." | 1.62 | The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients. ( Abdallah, D; Abouegylah, M; El-Khayat, SM; Elenbaby, AM; Geweil, AG; Zahra, OS, 2021) |
| "Metformin has been suggested as an anti-cancer agent." | 1.62 | FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling. ( Cheng, Q; Kong, L; Ma, Z; Parris, AB; Shi, Y; Wu, Y; Yang, X, 2021) |
| "Abnormal glucose metabolism in cancer cells causes generation and secretion of excess lactate, which results in acidification of the extracellular microenvironment." | 1.62 | Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter. ( Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV, 2021) |
| "KRas is frequently mutated in pancreatic cancers." | 1.62 | GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021) |
| "Metastatic breast cancer remains a serious health concern and numerous investigations recommended medicinal plants as a complementary therapy." | 1.62 | Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies. ( Abedini, MR; Arzi, L; Chamani, E; Farahi, A; Farhoudi, R; Hoshyar, R; Javdani, H; Talebloo, N, 2021) |
| "A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled." | 1.62 | Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus. ( Hui, T; Li, R; Shang, C; Song, Z; Wang, M; Yang, L, 2021) |
| "Metformin treatment of the diabetic/obese mice effectively normalized glucose levels, reconfigured the mammary tumor milieu, and decreased metastatic seeding." | 1.62 | Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding. ( Alsheikh, HAM; Ha, CM; Hinshaw, DC; Kammerud, SC; Lama-Sherpa, T; Metge, BJ; Mota, MSV; Samant, RS; Sharafeldin, N; Shevde, LA; Wende, AR, 2021) |
| "Breast cancer is the most common malignancy in women worldwide." | 1.62 | Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: an experimental study. ( Burade, V; Goswami, S; Pateliya, B, 2021) |
| "Metformin has long been an attractive therapeutic option for EwS, but hypoxia limits its efficacy." | 1.56 | Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. ( Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H, 2020) |
| "Metformin use has been linked to pathologic complete response (pCR) following neoadjuvant chemotherapy for several malignancies." | 1.56 | Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response. ( Berger, AC; Brenin, DR; Christopher, A; Hassinger, TE; Knisely, AT; Mehaffey, JH; Schroen, AT; Showalter, SL, 2020) |
| "Dormant breast cancer cells exhibited upregulated 5' adenosine monophosphate-activated protein kinase (AMPK) levels and activity, and upregulated fatty acid oxidation." | 1.56 | AMPK Activation by Metformin Promotes Survival of Dormant ER ( Demidenko, E; Dillon, LM; Fields, JL; Goen, AE; Hampsch, RA; Huang, YH; Kinlaw, WB; Lewis, LD; Marotti, JD; McCleery, CF; Miller, TW; Pooler, DB; Shee, K; Traphagen, NA; Wells, JD, 2020) |
| "Metformin treatment for T2D during the initial diagnosis of BC may improve outcomes." | 1.56 | Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status. ( Gogineni, K; He, J; Lee, KN; McCullough, LE; Torres, MA; Troeschel, AN, 2020) |
| "Metformin has been suggested to possibly reduce cancer risk." | 1.56 | Influences of preoperative metformin on immunological factors in early breast cancer. ( Doihara, H; Hatono, M; Ikeda, H; Iwamoto, T; Kajihara, Y; Kawada, K; Kochi, M; Shien, T; Suzuki, Y; Taira, N; Tanaka, T; Toyooka, S; Tsukioki, T, 2020) |
| "Metformin use was associated with lower PD and higher non-dense area (NDA), but associations were attenuated by co-medication with statins." | 1.56 | Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density. ( Acheampong, T; Agovino, M; Athilat, S; Lee Argov, EJ; Rodriguez, CB; Tehranifar, P; Terry, MB; Wei, Y, 2020) |
| "Human primary breast cancer cells were either cultured alone or co-cultured with autologous MOs before treatment with MET." | 1.56 | Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity. ( Addou-Klouche, L; Aribi, M; Benaissti, MI; Chahinez Djebri, N; Dahmani, Z; Dahou, S; Fernandez, A; Gizard, F; Lamb, NJ; Lefranc, G; Messaoud, A; Miliani, M; Mostefaoui, M; Nouari, W; Terbeche, H, 2020) |
| "Metformin (MET) was effectively encapsulated into O-carboxymethyl chitosan (O-CMC) polymeric formulation using an experimental design method." | 1.51 | Implementation of two different experimental designs for screening and optimization of process parameters for metformin-loaded carboxymethyl chitosan formulation. ( De, A; Jaiswal, A; Kuppuswamy, G, 2019) |
| "HER2-positive breast tumors are found in 25-30% of patients with breast cancer and are characterized by aggressive course and reduced sensitivity to both chemotherapy and hormone therapy." | 1.51 | Enchancement of Toremifene Anti-Tumor Action by Metformin and Unusual Side Effect of Toremifene in Male Transgenic Mice with HER2-Positive Breast Tumor. ( Alexandrov, VA; Baranenko, DA; Bespalov, VG; Filatova, LV; Osipov, MA; Panchenko, AV; Semenov, AL; Semiglazova, TY; Stukov, AN; Tyndyk, ML; Yurova, MN, 2019) |
| "Glycemic traits and type 2 diabetes unlikely cause breast and prostate cancer." | 1.51 | Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study. ( Au Yeung, SL; Schooling, CM, 2019) |
| "Many breast cancer patients suffer from obvious side effects induced by chemotherapy." | 1.51 | Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro. ( Guo, Y; Ren, Q; Wang, Y; Xin, M, 2019) |
| "Background Breast cancer is highly prevalent among women worldwide." | 1.48 | Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes. ( Amaral, MEA; Campos, MM; de Azevedo Junior, WF; Leite, CE; Nery, LR, 2018) |
| "Metformin is an antidiabetic drug which possesses antiproliferative activity in cancer cells when administered at high doses, due to its unfavorable pharmacokinetics." | 1.48 | Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects. ( Baldassari, S; Barbieri, F; Caviglioli, G; Daga, A; Drava, G; Ferrari, A; Florio, T; Fucile, C; Marini, V; Mattioli, F; Pastorino, S; Pattarozzi, A; Ratto, A; Solari, A; Zuccari, G, 2018) |
| "Obesity is associated with hypoxic adipose tissues, including those in the breast, resulting in increased production of some of the aforementioned factors." | 1.48 | Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. ( Ancukiewicz, M; Babykutty, S; Boucher, Y; Chin, SM; Duda, DG; Fukumura, D; Gomes-Santos, IL; Hoffmman, U; Huang, Y; Incio, J; Jain, RK; Jung, K; Kawaguchi, K; Krop, IE; Ligibel, JA; McManus, DT; Pinter, M; Puchner, SB; Rahbari, NN; Roberge, S; Schlett, CL; Suboj, P; Tolaney, SM; Vardam, TD; Wang, D, 2018) |
| "Women with type 2 diabetes have a higher risk of developing breast cancer." | 1.48 | Chinese herbal products and the reduction of risk of breast cancer among females with type 2 diabetes in Taiwan: A case-control study. ( Fu, SL; Lai, JN; Lin, JG; Tsai, YT; Wu, CT, 2018) |
| "With no sharp cure, breast cancer still be the major and the most serious life-threatening disease worldwide." | 1.48 | Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells ( Abdel-Ghany, SE; El-Zawahry, M; M Said, OA; Mostafa, MA; Sabit, H, 2018) |
| "Metformin initiators were more likely to receive screening mammograms than sulfonylurea initiators pre- and post-initiation, indicating possible detection bias due to differential screening mammography." | 1.46 | Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. ( Buse, JB; Henderson, LM; Hong, JL; Jonsson Funk, M; Lund, JL; Pate, V; Stürmer, T, 2017) |
| "Metformin has demonstrated anti-tumorigenic effect both in vivo and in vitro in different cancer types." | 1.46 | Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway. ( Abo Mansour, HE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, NF, 2017) |
| "Triple naegative breast cancer has an increased rate of distant metastasis and consequently poor prognosis." | 1.46 | Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro. ( Bizjak, M; Dolinar, K; Malavašič, P; Pavlin, M; Pirkmajer, S; Pohar, J, 2017) |
| "Herein, we reveal that breast cancer cells that preferentially metastasize to the lung or bone display relatively high expression of PGC-1α compared with those that metastasize to the liver." | 1.46 | PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. ( Andrzejewski, S; Annis, MG; Chénard, V; Johnson, RM; Klimcakova, E; McGuirk, S; Northey, JJ; Papadopoli, DJ; Siegel, PM; Sriram, U; St-Pierre, J; Tabariès, S, 2017) |
| "Metformin treatment reduces the risk of cancer in type 2 diabetes patients." | 1.46 | Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes. ( Junik, R; Muszyńska-Ogłaza, A; Olejniczak, H; Polaszewska-Muszyńska, M; Zarzycka-Lindner, G, 2017) |
| "Breast tumors were classified into hormone receptor positive (ER+ or PR+), HER2+ and triple negative (TN)." | 1.43 | Association of diabetes and diabetes treatment with incidence of breast cancer. ( Altzibar, JM; Amiano, P; Aragonés, N; Caballero, FJ; Castaño-Vinyals, G; Dierssen-Sotos, T; García-Esquinas, E; Guevara, M; Guinó, E; Kogevinas, M; Llorca, J; Martín, V; Moreno, V; Moreno-Iribas, C; Pastor-Barriuso, R; Peiró-Pérez, R; Pérez-Gómez, B; Pollán, M; Puig-Vives, M; Sala, M; Salas, D; Tardón, A; Villa, TF, 2016) |
| "Although obesity is associated with increased systemic levels of placental growth factor (PlGF), the role of PlGF in obesity-induced tumor progression is not known." | 1.43 | PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. ( Ancukiewicz, M; Babykutty, S; Batista, A; Carmeliet, P; Chin, SM; Duda, DG; Fukumura, D; Hato, T; Hoffmman, U; Incio, J; Jain, RK; Jung, K; Khachatryan, A; Krop, IE; Ligibel, JA; McManus, DT; Puchner, SB; Rahbari, NN; Schlett, CL; Shibuya, M; Soares, R; Suboj, P; Tam, J; Vardam, TD, 2016) |
| "102 women with newly diagnosed breast cancer were divided into 2 main groups, a control group and a metformin group." | 1.43 | Metformin may protect nondiabetic breast cancer women from metastasis. ( El-Bassiouny, NA; El-Haggar, SM; El-Shitany, NA; Mostafa, MF, 2016) |
| "Metformin, which is a drug commonly prescribed to treat type 2 diabetes, has anti-proliferative effects in cancer cells; however, the molecular mechanisms underlying this effect remain largely unknown." | 1.43 | Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cells. ( Chen, Y; Chung, HT; Joe, Y; Kim, HJ; Pandiri, I; Park, J; Park, JW, 2016) |
| "Metformin, which is a drug commonly used to treat type 2 diabetes, has shown anti-tumor effects in numerous experimental, epidemiologic, observational, and clinical studies." | 1.43 | Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. ( Han, W; Kim, SW; Lee, J; Lee, KM; Lee, M; Moon, HG; Noh, DY, 2016) |
| "Metformin pretreatment for 24 h of HER2+ MDA-MB-361 cells, which were subsequently treated for 48 h with Herceptin, induced additional decline in cell survival." | 1.42 | Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells. ( Abu Rabi, Z; Antić-Stanković, J; Damjanović, A; Damjanović, S; Džodić, R; Juranić, Z; Kanjer, K; Matić, IZ; Milovanović, Z; Nikolić, S; Roki, K; Ðorđić, M; Ðurović, MN, 2015) |
| "Medical records of 1087 patients with type 2 diabetes were retrospectively analyzed and a group of 74 (6." | 1.42 | [Obesity as a factor in the development of cancer in type 2 diabetes]. ( Chodorowska, M; Jakubowska, I; Łukasiewicz, D, 2015) |
| "Metformin use was associated with lower all-cause mortality (HR = 0." | 1.42 | Associations between diabetes medication use and risk of second breast cancer events and mortality. ( Boudreau, DM; Calip, GS; Hoskins, KF; Yu, O, 2015) |
| " Our aim in this research was to study the effects of vitamin D3 combined with metformin on the apoptosis induction and its mechanisms in the human breast cancer cell line MDA-MB-231." | 1.42 | Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways. ( Chen, J; Gao, JM; Gao, MT; Guo, LS; Li, CY; Li, HX; Liang, JQ; Wang, QL; Wu, YJ; Zhang, SY, 2015) |
| "Metformin pretreatment significantly suppressed tumor paracrine signaling-induced angiogenic promotion even in the presence of heregulin (HRG)-β1 (a co-activator of HER2) pretreatment of HER2+ tumor cells." | 1.42 | Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis. ( Bao, G; Feng, X; Li, G; Li, P; Li, Y; Liu, P; Mao, X; Sun, X; Tang, S; Wang, J; Wang, M; Wang, Y, 2015) |
| "This study selected luminal-type breast cancer patients as the study subjects." | 1.40 | Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. ( Hao, X; Hou, G; Xiao, Y; Zhang, J; Zhang, S; Zhang, X, 2014) |
| "Breast cancer is the most frequently diagnosed tumor type and the primary leading cause of cancer deaths in women worldwide and multidrug resistance is the major obstacle for breast cancer treatment improvement." | 1.40 | Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. ( He, Z; Qu, C; Yin, J; Zhang, W; Zhang, Z; Zheng, G, 2014) |
| "Metformin-cytotoxicity was mainly dependent on glucose availability and reducing power generated by pentose phosphate pathway, whereas DCA cotreatment enhanced metformin-cytotoxicity via reprogramming glucose metabolism by inhibiting PDK and increasing mitochondrial respiration." | 1.40 | Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells. ( Choi, YW; Lim, IK, 2014) |
| "Metformin has been reported to activate AMPK, thereby suppressing mTOR, which plays an important role for protein synthesis, cell cycle progression, and cell survival." | 1.40 | Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. ( Choi, BH; Lee, CK; Lee, H; Oh, ET; Park, CS; Park, HJ; Song, CW; Williams, B, 2014) |
| "Co-treatment with metformin and H2O2 increased oxidative stress which was associated with reduced cell number." | 1.40 | Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. ( Barbosa, AM; Dekker, RF; Eichler, R; Forsyth, HL; Fortes, ZB; Khaper, N; Lees, SJ; Puukila, S; Queiroz, EA; Sampaio, SC, 2014) |
| "Metformin suppress adipocyte-induced cell proliferation and adipocyte-secreted adipokines in vitro." | 1.40 | Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. ( Carlock, C; Chen, J; Chen, JS; Choi, HH; Chou, PC; Ensor, J; Esteva, FJ; Fraser Symmans, W; Fuentes-Mattei, E; Gully, C; Hortobagyi, GN; Lee, MH; Luo, Y; McKeehan, WL; Phan, L; Pusztai, L; Qi, Y; Shin, JH; Velazquez-Torres, G; Wu, Y; Yeung, SC; Zhang, F; Zhang, Y; Zhao, R, 2014) |
| "The unique metabolism of breast cancer cells provides interest in exploiting this phenomenon therapeutically." | 1.40 | Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. ( Coppock, JD; Haugrud, AB; Miskimins, WK; Zhuang, Y, 2014) |
| "Basal-like breast cancers (BBCs) are enriched for increased EGFR expression and decreased expression of PTEN." | 1.40 | Metformin and erlotinib synergize to inhibit basal breast cancer. ( Bessler, E; Cremers, S; Du, X; Hopkins, B; Keniry, M; Lau, YK; Maurer, MA; Parsons, RE; Pires, MM; Rayannavar, V; Shaw, J; Szabolcs, M; Thomas, T, 2014) |
| "Analyses were focused on breast and prostate cancer to reflect the most common cancers in women and men, respectively." | 1.39 | Breast and prostate cancer survivors in a diabetic cohort: results from the Living with Diabetes Study. ( Doi, SA; Donald, M; Engel, JM; Onitilo, AA; Stankowski, RV; Williams, G, 2013) |
| "Metformin treatment via the i." | 1.39 | Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. ( Bonavia, R; Corominas-Faja, B; Cufí, S; Cuyàs, E; Dorca, J; Fernández, SD; Joven, J; López, IÁ; López, NB; Lopez-Bonet, E; Martin-Castillo, B; Martínez, S; Menendez, JA; Pernas, S; Quirantes-Piné, R; Rodríguez-Gallego, E; Segura-Carretero, A; Visa, J, 2013) |
| "New diagnoses of cancer, including malignant solid tumours and haematological malignancies, occurring during the follow-up were identified from the cohort." | 1.39 | Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. ( Berlin, JA; Demissie, K; Marcella, SW; Qiu, H; Rhoads, GG, 2013) |
| "Metformin is a well-established diabetes drug that prevents the onset of most types of human cancers in diabetic patients, especially by targeting cancer stem cells." | 1.39 | Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. ( Gandara, R; Howell, A; Hulit, J; Lamb, R; Lisanti, MP; Martinez-Outschoorn, UE; Rubin, E; Sanchez-Alvarez, R; Sartini, M; Sotgia, F, 2013) |
| "Hematogeneous metastasis can occur via a cascade of circulating tumor cell adhesion events to the endothelial lining of the vasculature, i." | 1.39 | Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. ( Chandrasekaran, S; Geng, Y; Gidwani, M; Hsu, JW; Hughes, AD; King, MR, 2013) |
| "Metformin's effects were also studied in sublines with forced over-expression of constitutively active (CA) Stat3, as well as lines with stable knockdown of Stat3." | 1.38 | Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. ( Deng, A; Deng, XS; Edgerton, SM; Lind, SE; Liu, B; Thor, AD; Wahdan-Alaswad, R; Wang, S, 2012) |
| "Metformin was associated with survival benefit both in comparison with other treatments for diabetes and in comparison with a nondiabetic population." | 1.38 | Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. ( Currie, CJ; Gale, EA; Jenkins-Jones, S; Johnson, JA; Morgan, CL; Poole, CD, 2012) |
| "Metformin exposure was found to dose-dependently increase the expression levels of cytochrome c oxidase I and mitochondrial succinate dehydrogenase, which are encoded by mitochondrial and nuclear DNA, respectively." | 1.38 | Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. ( Bosch-Barrera, J; Cufí, S; Joven, J; Martin-Castillo, B; Menendez, JA; Menendez, OJ; Oliveras-Ferraros, C; Vazquez-Martin, A, 2012) |
| "Trastuzumab-refractory breast cancer stem cells (CSCs) could also explain the high rate of primary resistance to single-agent trastuzumab in HER2 gene-amplified breast cancer patients." | 1.38 | Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. ( Bosch-Barrera, J; Corominas-Faja, B; Cufi, S; Dorca, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2012) |
| "Metformin use lead to lower MBD in 4 of 14 (28." | 1.38 | [The influence of metformin and N-acetylcysteine on mammographic density in postmenopausal women]. ( Bershteĭn, LM; Boiarkina, MP; Kisel'nikov, KS; Kovalenko, IG; Poroshina, TE; Vasil'ev, DA; Zaĭtsev, AN, 2012) |
| "Women with breast cancer and pre-existing diabetes had a 49 % (95 % CI: 1." | 1.38 | Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. ( Ben-Shlomo, Y; Jeffreys, M; Martin, RM; May, MT; Redaniel, MT, 2012) |
| "The coexistence of type 2 diabetes with breast cancer may result in poorer cancer-related survival due to a number of mediating factors including an alteration of tumor tissue hormonal sensitivity." | 1.37 | More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. ( Berstein, LM; Boyarkina, MP; Semiglazov, VF; Tsyrlina, EV; Turkevich, EA, 2011) |
| "To research different effects of human breast carcinoma cells with different estrogen receptor expressing by antidiabetic drug metformin, and preliminary explore the possible underlying molecular mechanisms." | 1.37 | [Effects of antidiabetic drug metformin on human breast carcinoma cells with different estrogen receptor expressing in vitro]. ( Cai, H; Duan, XY; Ermek, T; Wang, JS; Wang, Y; Wang, YN; Zhang, MX; Zhou, SN, 2011) |
| "We also immuno-stained human breast cancers for a series of well-established protein biomarkers of metabolism." | 1.37 | Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. ( Birbe, RC; Broda, P; Ertel, A; Flomenberg, N; Howell, A; Lisanti, MP; Martinez-Outschoorn, UE; Minetti, C; Pavlides, S; Pestell, RG; Sotgia, F; Tsirigos, A; Whitaker-Menezes, D; Witkiewicz, AK, 2011) |
| "Metformin treatment dynamically regulated the CD44(pos)CD24(neg/low) breast cancer stem cell immunophenotype, transcriptionally reprogrammed cells through decreased expression of key drivers of the EMT machinery including the transcription factors ZEB1, TWIST1 and SNAI2 (Slug) and the pleiotrophic cytokines TGFβs, and lastly impeded the propensity of breast cancer stem cells to form multicellular "microtumors" in non-adherent and non-differentiating conditions (i." | 1.36 | Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. ( Cufí, S; Del Barco, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "Metformin pre-treatment, before injection of MDA-MB-231 cells, results in a significant decrease in tumor outgrowth and incidence." | 1.35 | Metformin induces unique biological and molecular responses in triple negative breast cancer cells. ( Alimova, IN; Deng, XS; Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD, 2009) |
| "Breast cancer is the most common malignancy diagnosed among women." | 1.35 | Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs. ( Cetinkalp, S; Karaca, B; Uslu, R; Yurekli, BS, 2009) |
| "In MCF-7 breast cancer cells, metformin treatment led to a 30% decrease in global protein synthesis." | 1.34 | Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. ( Dowling, RJ; Fantus, IG; Pollak, M; Sonenberg, N; Zakikhani, M, 2007) |
| "Metformin was also effective in significantly enhancing insulin binding in both IM-9 and MCF-7 cells." | 1.26 | Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding of its receptors in target cells. ( Goldfine, ID; Pezzino, V; Vigneri, R; Wong, KY, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.71) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (6.16) | 29.6817 |
| 2010's | 266 (63.03) | 24.3611 |
| 2020's | 127 (30.09) | 2.80 |
| Authors | Studies |
|---|---|
| Goodwin, PJ | 21 |
| Dowling, RJO | 3 |
| Ennis, M | 8 |
| Chen, BE | 8 |
| Parulekar, WR | 7 |
| Shepherd, LE | 6 |
| Gelmon, KA | 7 |
| Whelan, TJ | 7 |
| Ligibel, JA | 12 |
| Hershman, DL | 11 |
| Mayer, IA | 6 |
| Hobday, TJ | 6 |
| Rastogi, P | 7 |
| Rabaglio-Poretti, M | 3 |
| Lemieux, J | 8 |
| Thompson, AM | 15 |
| Rea, DW | 3 |
| Stambolic, V | 15 |
| Lusica, PMM | 1 |
| Eugenio, KPY | 1 |
| Sacdalan, DBL | 1 |
| Jimeno, CA | 1 |
| Zhang, Z | 3 |
| Zeng, D | 1 |
| Zhang, W | 2 |
| Chen, A | 1 |
| Lei, J | 2 |
| Liu, F | 1 |
| Deng, B | 1 |
| Zhuo, J | 1 |
| He, B | 1 |
| Yan, M | 1 |
| Lei, X | 2 |
| Wang, S | 6 |
| Lam, EW | 1 |
| Liu, Q | 2 |
| Wang, Z | 2 |
| Chen, J | 4 |
| Qin, C | 1 |
| Zhou, Y | 3 |
| Chen, Y | 7 |
| Mao, M | 2 |
| Yang, J | 4 |
| Taghipour, F | 1 |
| Oladpour, O | 1 |
| Rezayati, MT | 1 |
| Khorramdelazad, H | 1 |
| Nemati, M | 1 |
| Taghipour, Z | 1 |
| Masoumi, J | 1 |
| Hassan, ZM | 1 |
| Jafarzadeh, A | 1 |
| Zhang, X | 10 |
| Ogihara, T | 1 |
| Zhu, M | 1 |
| Gantumur, D | 1 |
| Li, Y | 12 |
| Mizoi, K | 1 |
| Kamioka, H | 1 |
| Tsushima, Y | 1 |
| Lagampan, C | 1 |
| Poovorawan, N | 1 |
| Parinyanitikul, N | 1 |
| El-Khayat, SM | 1 |
| Abouegylah, M | 1 |
| Abdallah, D | 1 |
| Geweil, AG | 1 |
| Elenbaby, AM | 1 |
| Zahra, OS | 1 |
| Scott, NP | 1 |
| Teoh, EJ | 2 |
| Flight, H | 1 |
| Jones, BE | 1 |
| Niederer, J | 1 |
| Mustata, L | 1 |
| MacLean, GM | 1 |
| Roy, PG | 3 |
| Remoundos, DD | 1 |
| Snell, C | 2 |
| Liu, C | 5 |
| Gleeson, FV | 1 |
| Harris, AL | 5 |
| Lord, SR | 4 |
| McGowan, DR | 2 |
| Nwanaji-Enwerem, JC | 1 |
| Chung, FF | 2 |
| Van der Laan, L | 1 |
| Novoloaca, A | 1 |
| Cuenin, C | 1 |
| Johansson, H | 3 |
| Bonanni, B | 8 |
| Hubbard, AE | 1 |
| Smith, MT | 1 |
| Hartman, SJ | 5 |
| Cardenas, A | 1 |
| Sears, DD | 3 |
| Herceg, Z | 1 |
| Huynh, TYL | 1 |
| Oscilowska, I | 1 |
| Sáiz, J | 1 |
| Nizioł, M | 1 |
| Baszanowska, W | 1 |
| Barbas, C | 1 |
| Palka, J | 1 |
| Markowicz-Piasecka, M | 1 |
| Huttunen, J | 1 |
| Zajda, A | 1 |
| Sikora, J | 1 |
| Huttunen, KM | 1 |
| Mousavi-Koodehi, B | 1 |
| Darzi, L | 1 |
| Sadeghizadeh, M | 1 |
| Najafi, F | 1 |
| Forouzandeh-Moghdam, M | 1 |
| Acheampong, T | 2 |
| Lee Argov, EJ | 2 |
| Terry, MB | 2 |
| Rodriguez, CB | 2 |
| Agovino, M | 2 |
| Wei, Y | 5 |
| Athilat, S | 2 |
| Tehranifar, P | 2 |
| Hao, Q | 1 |
| Huang, Z | 2 |
| Li, Q | 2 |
| Liu, D | 3 |
| Wang, P | 1 |
| Wang, K | 1 |
| Li, J | 11 |
| Cao, W | 1 |
| Deng, W | 1 |
| Wu, K | 2 |
| Su, R | 1 |
| Liu, Z | 5 |
| Vadgama, J | 1 |
| Wu, Y | 4 |
| Teufelsbauer, M | 2 |
| Lang, C | 1 |
| Plangger, A | 2 |
| Rath, B | 2 |
| Moser, D | 1 |
| Staud, C | 2 |
| Radtke, C | 2 |
| Neumayer, C | 2 |
| Hamilton, G | 2 |
| Alhowail, AH | 2 |
| Almogbel, YS | 2 |
| Abdellatif, AAH | 2 |
| Aldubayan, MA | 2 |
| Almami, IS | 1 |
| Barakat, HE | 2 |
| Hussein, RRS | 2 |
| Elberry, AA | 2 |
| Zaki, MA | 2 |
| Elsherbiny Ramadan, M | 1 |
| Cejuela, M | 1 |
| Martin-Castillo, B | 21 |
| Menendez, JA | 25 |
| Pernas, S | 3 |
| Flores-García, LC | 1 |
| Ventura-Gallegos, JL | 1 |
| Romero-Córdoba, SL | 1 |
| Hernández-Juárez, AJ | 1 |
| Naranjo-Meneses, MA | 1 |
| García-García, E | 1 |
| Méndez, JP | 1 |
| Cabrera-Quintero, AJ | 1 |
| Ramírez-Ruíz, A | 1 |
| Pedraza-Sánchez, S | 1 |
| Meraz-Cruz, N | 1 |
| Vadillo-Ortega, F | 1 |
| Zentella-Dehesa, A | 1 |
| Chigurupati, S | 1 |
| Nemala, RA | 1 |
| Tabari, AR | 1 |
| Gavidel, P | 1 |
| Sabouni, F | 1 |
| Gardaneh, M | 2 |
| Ramadan, ME | 1 |
| Gant, DMA | 1 |
| Parris, AB | 3 |
| Yang, X | 7 |
| Tseng, CH | 2 |
| Bliss, JM | 2 |
| Mukherjee, SD | 3 |
| Mackey, JR | 1 |
| Abramson, VG | 1 |
| Oja, C | 1 |
| Wesolowski, R | 1 |
| Stos, PM | 2 |
| Ibrahim, A | 1 |
| Khalil, IA | 1 |
| El-Sherbiny, IM | 1 |
| Scordamaglia, D | 1 |
| Cirillo, F | 1 |
| Talia, M | 1 |
| Santolla, MF | 1 |
| Rigiracciolo, DC | 1 |
| Muglia, L | 1 |
| Zicarelli, A | 1 |
| De Rosis, S | 1 |
| Giordano, F | 1 |
| Miglietta, AM | 1 |
| De Francesco, EM | 1 |
| Vella, V | 1 |
| Belfiore, A | 1 |
| Lappano, R | 1 |
| Maggiolini, M | 1 |
| Hassani, N | 1 |
| Jafari-Gharabaghlou, D | 3 |
| Dadashpour, M | 4 |
| Zarghami, N | 6 |
| Gallagher, EJ | 1 |
| Kase, NG | 1 |
| Bickell, NA | 1 |
| LeRoith, D | 1 |
| Zhang, H | 3 |
| Yu, J | 1 |
| Ma, L | 1 |
| Zhao, Y | 4 |
| Xu, S | 1 |
| Shi, J | 1 |
| Qian, K | 1 |
| Gu, M | 1 |
| Tan, H | 2 |
| Xu, L | 1 |
| Liu, Y | 9 |
| Mu, C | 1 |
| Xiong, Y | 2 |
| Cuyàs, E | 7 |
| Chikermane, SG | 1 |
| Sharma, M | 1 |
| Abughosh, SM | 1 |
| Aparasu, RR | 1 |
| Trivedi, MV | 1 |
| Johnson, ML | 2 |
| Jahani, Z | 1 |
| Davoodi, J | 1 |
| Geldhof, V | 1 |
| de Rooij, LPMH | 1 |
| Sokol, L | 1 |
| Amersfoort, J | 1 |
| De Schepper, M | 1 |
| Rohlenova, K | 1 |
| Hoste, G | 1 |
| Vanderstichele, A | 1 |
| Delsupehe, AM | 1 |
| Isnaldi, E | 1 |
| Dai, N | 1 |
| Taverna, F | 1 |
| Khan, S | 1 |
| Truong, AK | 1 |
| Teuwen, LA | 1 |
| Richard, F | 1 |
| Treps, L | 1 |
| Smeets, A | 1 |
| Nevelsteen, I | 1 |
| Weynand, B | 1 |
| Vinckier, S | 1 |
| Schoonjans, L | 1 |
| Kalucka, J | 1 |
| Desmedt, C | 1 |
| Neven, P | 1 |
| Mazzone, M | 1 |
| Floris, G | 1 |
| Punie, K | 1 |
| Dewerchin, M | 1 |
| Eelen, G | 1 |
| Wildiers, H | 1 |
| Li, X | 13 |
| Luo, Y | 3 |
| Carmeliet, P | 2 |
| Gales, L | 1 |
| Forsea, L | 1 |
| Mitrea, D | 1 |
| Stefanica, I | 1 |
| Stanculescu, I | 1 |
| Mitrica, R | 1 |
| Georgescu, M | 1 |
| Trifanescu, O | 1 |
| Anghel, R | 1 |
| Serbanescu, L | 1 |
| Postlewait, LM | 1 |
| Waissengrin, B | 3 |
| Zahavi, T | 3 |
| Salmon-Divon, M | 3 |
| Goldberg, A | 5 |
| Wolf, I | 3 |
| Rubinek, T | 3 |
| Winkler, T | 3 |
| Farkash, O | 3 |
| Grinshpun, A | 3 |
| Zubkov, A | 3 |
| Khatib, M | 3 |
| Shachar, SS | 3 |
| Keren, N | 3 |
| Carmi-Levy, I | 3 |
| Ben-David, U | 3 |
| Sonnenblick, A | 4 |
| Verdura, S | 4 |
| Lu, Y | 2 |
| Hajjar, A | 1 |
| Cryns, VL | 1 |
| Trentham-Dietz, A | 1 |
| Gangnon, RE | 1 |
| Heckman-Stoddard, BM | 1 |
| Alagoz, O | 1 |
| El-Attar, AA | 1 |
| Ibrahim, OM | 1 |
| Alhassanin, SA | 1 |
| Essa, ES | 1 |
| Mostafa, TM | 1 |
| Bellerba, F | 1 |
| Chatziioannou, AC | 1 |
| Jasbi, P | 1 |
| Robinot, N | 1 |
| Keski-Rahkonen, P | 1 |
| Trolat, A | 1 |
| Vozar, B | 1 |
| Scalbert, A | 1 |
| Gandini, S | 3 |
| Yang, H | 3 |
| Cao, L | 1 |
| Yin, Y | 1 |
| Shen, Y | 3 |
| Zhu, W | 1 |
| Fatehi, R | 1 |
| Rashedinia, M | 1 |
| Akbarizadeh, AR | 1 |
| Zamani, M | 1 |
| Firouzabadi, N | 1 |
| Xu, Y | 2 |
| Cai, H | 4 |
| Tang, L | 1 |
| Li, L | 2 |
| Zhang, L | 4 |
| Yang, Y | 3 |
| Lin, L | 1 |
| Huang, J | 2 |
| Khanghah, OJ | 1 |
| Salmani-Javan, E | 1 |
| Kumar, V | 2 |
| Sharma, K | 1 |
| Sachan, R | 1 |
| Alhayyani, S | 1 |
| Al-Abbasi, FA | 1 |
| Singh, R | 1 |
| Anwar, F | 1 |
| Gholami, M | 1 |
| Klashami, ZN | 1 |
| Ebrahimi, P | 1 |
| Mahboobipour, AA | 1 |
| Farid, AS | 1 |
| Vahidi, A | 1 |
| Zoughi, M | 1 |
| Asadi, M | 1 |
| Amoli, MM | 1 |
| Saleem, MB | 1 |
| Fatima, S | 1 |
| Khan, ZA | 1 |
| Bashraheel, SS | 1 |
| Kheraldine, H | 1 |
| Khalaf, S | 1 |
| Moustafa, AA | 1 |
| Siddiqui, T | 1 |
| Doultani, PR | 1 |
| Sathe, C | 1 |
| Yu, OHY | 1 |
| Suissa, S | 1 |
| Essa, NM | 1 |
| Elgendy, MO | 1 |
| Gabr, A | 1 |
| Mahmoud, MM | 1 |
| Alharbi, AA | 1 |
| Tashkandi, HM | 1 |
| Salem, HF | 1 |
| Harakeh, S | 1 |
| Boshra, MS | 1 |
| de Andrade Mesquita, L | 1 |
| Wayerbacher, LF | 1 |
| Schwartsmann, G | 1 |
| Gerchman, F | 1 |
| Soni, S | 1 |
| Yadav, P | 1 |
| Mandal, CC | 2 |
| Osataphan, N | 1 |
| Phrommintikul, A | 1 |
| Leemasawat, K | 1 |
| Somwangprasert, A | 1 |
| Apaijai, N | 1 |
| Suksai, S | 1 |
| Sirikul, W | 1 |
| Gunaparn, S | 1 |
| Chattipakorn, SC | 1 |
| Chattipakorn, N | 1 |
| Drzał, A | 1 |
| Dziurman, G | 1 |
| Hoła, P | 1 |
| Lechowski, J | 1 |
| Delalande, A | 1 |
| Swakoń, J | 1 |
| Pichon, C | 1 |
| Elas, M | 1 |
| Löfling, LL | 1 |
| Støer, NC | 1 |
| Andreassen, BK | 1 |
| Ursin, G | 1 |
| Botteri, E | 1 |
| Saffari, F | 1 |
| Momeni, A | 1 |
| Ramezani, M | 1 |
| Ansari, Y | 1 |
| Moghbelinejad, S | 1 |
| Bens, A | 1 |
| Langballe, R | 1 |
| Bernstein, JL | 1 |
| Cronin-Fenton, D | 1 |
| Friis, S | 1 |
| Mellemkjaer, L | 1 |
| Pimentel, I | 3 |
| Lohmann, AE | 5 |
| Cescon, D | 1 |
| Elser, C | 1 |
| Potvin, KR | 1 |
| Haq, R | 1 |
| Hamm, C | 1 |
| Chang, MC | 4 |
| Keshandehghan, A | 1 |
| Nikkhah, S | 1 |
| Tahermansouri, H | 1 |
| Heidari-Keshel, S | 1 |
| De, A | 2 |
| Kuppuswamy, G | 1 |
| Jaiswal, A | 1 |
| Stukov, AN | 1 |
| Osipov, MA | 1 |
| Semiglazova, TY | 1 |
| Filatova, LV | 1 |
| Alexandrov, VA | 1 |
| Bespalov, VG | 1 |
| Semenov, AL | 1 |
| Tyndyk, ML | 1 |
| Yurova, MN | 1 |
| Panchenko, AV | 1 |
| Baranenko, DA | 1 |
| Ma, Q | 2 |
| Gu, JT | 1 |
| Wang, B | 4 |
| Feng, J | 4 |
| Yang, L | 3 |
| Kang, XW | 1 |
| Duan, P | 1 |
| Sun, X | 4 |
| Liu, PJ | 2 |
| Wang, JC | 2 |
| Nan, X | 1 |
| Wang, J | 7 |
| Cheng, H | 1 |
| Yin, Z | 2 |
| Sheng, J | 1 |
| Qiu, B | 2 |
| Lau, CC | 1 |
| Yustein, JT | 1 |
| Zhao, H | 3 |
| Wong, STC | 1 |
| Carvalho, MJ | 1 |
| Subtil, S | 1 |
| Rodrigues, Â | 1 |
| Oliveira, J | 1 |
| Figueiredo-Dias, M | 1 |
| Hassinger, TE | 1 |
| Berger, AC | 1 |
| Christopher, A | 1 |
| Knisely, AT | 1 |
| Mehaffey, JH | 1 |
| Brenin, DR | 1 |
| Schroen, AT | 1 |
| Showalter, SL | 1 |
| Collins, JM | 1 |
| Cheng, WC | 2 |
| Haider, S | 2 |
| Wigfield, S | 2 |
| Gaude, E | 2 |
| Fielding, BA | 1 |
| Pinnick, KE | 1 |
| Harjes, U | 1 |
| Segaran, A | 1 |
| Jha, P | 1 |
| Hoefler, G | 1 |
| Pollak, MN | 4 |
| English, R | 2 |
| Adams, RF | 2 |
| Frezza, C | 2 |
| Buffa, FM | 2 |
| Karpe, F | 2 |
| Samuel, SM | 1 |
| Varghese, E | 1 |
| Kubatka, P | 1 |
| Triggle, CR | 1 |
| Büsselberg, D | 1 |
| Au Yeung, SL | 2 |
| Schooling, CM | 2 |
| Wang, D | 2 |
| Ren, H | 1 |
| Feng, W | 1 |
| Tharakan, S | 1 |
| Zimmerman, B | 1 |
| Ru, M | 1 |
| Blanter, J | 1 |
| Cascetta, K | 1 |
| Tiersten, A | 1 |
| Cole, AJ | 1 |
| Fayomi, AP | 1 |
| Anyaeche, VI | 1 |
| Bai, S | 1 |
| Buckanovich, RJ | 1 |
| Sundelin, EIO | 1 |
| Al-Suliman, N | 1 |
| Vahl, P | 1 |
| Vendelbo, M | 1 |
| Munk, OL | 1 |
| Jakobsen, S | 1 |
| Pedersen, SB | 1 |
| Frøkiær, J | 1 |
| Gormsen, LC | 1 |
| Jessen, N | 1 |
| Liu, J | 4 |
| Chen, H | 2 |
| Wang, R | 1 |
| Li, P | 5 |
| Miao, Y | 1 |
| Liu, P | 2 |
| Wang, X | 9 |
| Ding, X | 1 |
| Yu, B | 1 |
| Cong, H | 1 |
| Hampsch, RA | 1 |
| Wells, JD | 1 |
| Traphagen, NA | 1 |
| McCleery, CF | 1 |
| Fields, JL | 1 |
| Shee, K | 1 |
| Dillon, LM | 1 |
| Pooler, DB | 1 |
| Lewis, LD | 1 |
| Demidenko, E | 1 |
| Huang, YH | 1 |
| Marotti, JD | 1 |
| Goen, AE | 1 |
| Kinlaw, WB | 1 |
| Miller, TW | 1 |
| Lee, KN | 1 |
| Torres, MA | 1 |
| Troeschel, AN | 1 |
| He, J | 1 |
| Gogineni, K | 1 |
| McCullough, LE | 1 |
| Ponnusamy, L | 1 |
| Natarajan, SR | 1 |
| Thangaraj, K | 1 |
| Manoharan, R | 1 |
| Rennert, G | 1 |
| Rennert, HS | 1 |
| Gronich, N | 1 |
| Pinchev, M | 1 |
| Gruber, SB | 1 |
| Hosio, M | 2 |
| Urpilainen, E | 3 |
| Hautakoski, A | 2 |
| Marttila, M | 2 |
| Arffman, M | 2 |
| Sund, R | 2 |
| Ahtikoski, A | 1 |
| Puistola, U | 3 |
| Karihtala, P | 3 |
| Jukkola, A | 2 |
| Läärä, E | 2 |
| Zhang, J | 7 |
| Ma, X | 4 |
| Liu, R | 1 |
| Zhang, P | 3 |
| Ren, W | 1 |
| Cui, P | 1 |
| Zhang, M | 5 |
| Jin, Y | 1 |
| Tsukioki, T | 1 |
| Shien, T | 1 |
| Tanaka, T | 1 |
| Suzuki, Y | 1 |
| Kajihara, Y | 1 |
| Hatono, M | 1 |
| Kawada, K | 1 |
| Kochi, M | 1 |
| Iwamoto, T | 2 |
| Ikeda, H | 1 |
| Taira, N | 1 |
| Doihara, H | 1 |
| Toyooka, S | 1 |
| Sambi, M | 1 |
| Samuel, V | 1 |
| Qorri, B | 1 |
| Haq, S | 1 |
| Burov, SV | 1 |
| Markvicheva, E | 1 |
| Harless, W | 1 |
| Szewczuk, MR | 1 |
| Bai, L | 1 |
| Yi, W | 1 |
| Sun, T | 1 |
| Tian, Y | 2 |
| Si, J | 1 |
| Hou, X | 1 |
| Hou, J | 3 |
| Shao, S | 1 |
| Zhao, L | 1 |
| An, G | 1 |
| Jing, X | 1 |
| Luo, M | 1 |
| Li, W | 3 |
| Meng, D | 1 |
| Ning, Q | 2 |
| Zhao, X | 1 |
| Marinello, PC | 2 |
| Panis, C | 2 |
| Silva, TNX | 2 |
| Binato, R | 2 |
| Abdelhay, E | 2 |
| Rodrigues, JA | 2 |
| L Mencalha, A | 1 |
| Lopes, NMD | 2 |
| Borges, FH | 1 |
| Luiz, RC | 2 |
| Cecchini, R | 2 |
| Cecchini, AL | 2 |
| Brown, JC | 1 |
| Zhang, S | 4 |
| Irwin, ML | 1 |
| Jones, LW | 1 |
| Campbell, N | 1 |
| Sorrentino, A | 1 |
| Cartmel, B | 1 |
| Harrigan, M | 1 |
| Tolaney, SM | 2 |
| Winer, EP | 1 |
| Ng, K | 1 |
| Abrams, TA | 1 |
| Sanft, T | 1 |
| Douglas, PS | 1 |
| Hu, FB | 1 |
| Fuchs, CS | 1 |
| Meyerhardt, JA | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 6 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 2 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 5 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 2 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 3 |
| Dong, X | 1 |
| Tang, S | 2 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 2 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 4 |
| Chen, L | 6 |
| Shan, A | 1 |
| Wu, M | 2 |
| Zhang, E | 1 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 3 |
| Yan, Z | 2 |
| Wang, Y | 9 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 1 |
| Ren, Y | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 7 |
| Zhou, X | 2 |
| Wang, W | 2 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 5 |
| Zhu, J | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 2 |
| Hu, W | 1 |
| Zhang, Y | 10 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 2 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 2 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 2 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 2 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 2 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 2 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liang, C | 1 |
| Song, Y | 2 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Qian, J | 2 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 3 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 3 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 1 |
| Qi, Y | 2 |
| Lu, H | 2 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 2 |
| Ying, S | 1 |
| Tan, M | 2 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 4 |
| Fu, D | 1 |
| Li, Z | 3 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Xi, J | 1 |
| Li, C | 3 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 2 |
| Wei, H | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 2 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 2 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 3 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 2 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 2 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 2 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 2 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 3 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 2 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 2 |
| He, Z | 2 |
| Chen, B | 1 |
| Wu, J | 2 |
| Du, X | 4 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 2 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 3 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 2 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 2 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 2 |
| Cao, P | 1 |
| Gu, S | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 2 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 2 |
| Hou, G | 2 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 2 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Qian, Y | 1 |
| Cheng, Q | 2 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 2 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Nanobashvili, J | 1 |
| Huk, I | 1 |
| Yu, S | 2 |
| Lan, Y | 1 |
| Liang, Q | 1 |
| Cao, A | 1 |
| Choi, M | 1 |
| Han, J | 1 |
| Yang, BR | 1 |
| Jang, MJ | 1 |
| Kim, M | 1 |
| Lee, DW | 1 |
| Kim, TY | 1 |
| Im, SA | 1 |
| Lee, HB | 1 |
| Moon, HG | 3 |
| Han, W | 4 |
| Noh, DY | 4 |
| Lee, KH | 1 |
| Kawakita, E | 1 |
| Yang, F | 1 |
| Kumagai, A | 1 |
| Takagaki, Y | 1 |
| Kitada, M | 1 |
| Yoshitomi, Y | 1 |
| Ikeda, T | 1 |
| Nakamura, Y | 1 |
| Ishigaki, Y | 1 |
| Kanasaki, K | 1 |
| Koya, D | 1 |
| Ma, Z | 1 |
| Kong, L | 1 |
| Tanaka, Y | 1 |
| Obinata, H | 1 |
| Konishi, A | 1 |
| Yamagiwa, N | 1 |
| Tsuneoka, M | 1 |
| Dahmani, Z | 1 |
| Addou-Klouche, L | 1 |
| Gizard, F | 1 |
| Dahou, S | 1 |
| Messaoud, A | 1 |
| Chahinez Djebri, N | 1 |
| Benaissti, MI | 1 |
| Mostefaoui, M | 1 |
| Terbeche, H | 1 |
| Nouari, W | 1 |
| Miliani, M | 1 |
| Lefranc, G | 1 |
| Fernandez, A | 1 |
| Lamb, NJ | 1 |
| Aribi, M | 1 |
| Golshan, M | 1 |
| Khaleghi, S | 1 |
| Shafiee, SM | 1 |
| Valaee, S | 1 |
| Ghanei, Z | 1 |
| Jamshidizad, A | 1 |
| Dashtizad, M | 1 |
| Shamsara, M | 1 |
| Jones, VC | 1 |
| Dietze, EC | 1 |
| Jovanovic-Talisman, T | 1 |
| McCune, JS | 1 |
| Seewaldt, VL | 1 |
| Fahim, SM | 1 |
| Hsu, CH | 1 |
| Lin, FJ | 1 |
| Chou, C | 1 |
| Singh, SV | 1 |
| Chaube, B | 1 |
| Mayengbam, SS | 1 |
| Malvi, P | 1 |
| Mohammad, N | 1 |
| Deb, A | 1 |
| Bhat, MK | 1 |
| Yenmiş, G | 2 |
| Beşli, N | 2 |
| Yaprak Saraç, E | 2 |
| Hocaoğlu Emre, FS | 1 |
| Şenol, K | 2 |
| Kanıgür, G | 1 |
| Cai, S | 1 |
| Chen, Z | 2 |
| Wang, M | 3 |
| Tong, Y | 1 |
| Lu, C | 1 |
| Park, YM | 2 |
| Bookwalter, DB | 1 |
| O'Brien, KM | 1 |
| Jackson, CL | 1 |
| Weinberg, CR | 1 |
| Sandler, DP | 2 |
| Mdkhana, B | 1 |
| Zaher, DM | 1 |
| Abdin, SM | 1 |
| Omar, HA | 1 |
| Ligibel, J | 1 |
| Shepherd, L | 1 |
| Whelan, T | 1 |
| Mayer, I | 1 |
| Hobday, T | 1 |
| Thompson, A | 1 |
| Gelmon, K | 1 |
| Rea, D | 1 |
| Rabaglio, M | 1 |
| Ellard, S | 1 |
| Mates, M | 1 |
| Bedard, P | 1 |
| Pitre, L | 1 |
| Vandenberg, T | 1 |
| Parulekar, W | 1 |
| Behrouzi, B | 2 |
| Zokaasadi, M | 1 |
| Mohagheghi, MA | 1 |
| Emami, AH | 1 |
| Sadighi, S | 2 |
| Soydas, T | 1 |
| Tastan, C | 1 |
| Dilek Kancagi, D | 1 |
| Yilanci, M | 1 |
| Karagulle, OO | 1 |
| Ekmekci, CG | 1 |
| Ovali, E | 1 |
| Tuncdemir, M | 1 |
| Ulutin, T | 1 |
| Kanigur Sultuybek, G | 1 |
| Feng, JL | 1 |
| Qin, X | 1 |
| Abrams, SL | 1 |
| Akula, SM | 1 |
| Meher, AK | 1 |
| Steelman, LS | 1 |
| Gizak, A | 1 |
| Duda, P | 1 |
| Rakus, D | 1 |
| Martelli, AM | 1 |
| Ratti, S | 1 |
| Cocco, L | 1 |
| Montalto, G | 1 |
| Cervello, M | 1 |
| Ruvolo, P | 1 |
| Libra, M | 1 |
| Falzone, L | 1 |
| Candido, S | 1 |
| McCubrey, JA | 1 |
| Farahi, A | 1 |
| Abedini, MR | 1 |
| Javdani, H | 1 |
| Arzi, L | 1 |
| Chamani, E | 1 |
| Farhoudi, R | 1 |
| Talebloo, N | 1 |
| Hoshyar, R | 1 |
| Hui, T | 1 |
| Shang, C | 1 |
| Li, R | 1 |
| Song, Z | 1 |
| Prodromidou, A | 1 |
| Lekka, S | 1 |
| Fotiou, A | 1 |
| Psomiadou, V | 1 |
| Iavazzo, C | 1 |
| Qin, S | 1 |
| Ingle, JN | 1 |
| Kim, W | 1 |
| Gao, H | 1 |
| Weinshilboum, RM | 1 |
| Alsheikh, HAM | 1 |
| Metge, BJ | 1 |
| Ha, CM | 1 |
| Hinshaw, DC | 1 |
| Mota, MSV | 1 |
| Kammerud, SC | 1 |
| Lama-Sherpa, T | 1 |
| Sharafeldin, N | 1 |
| Wende, AR | 1 |
| Samant, RS | 1 |
| Shevde, LA | 1 |
| Pateliya, B | 1 |
| Burade, V | 1 |
| Goswami, S | 1 |
| Morio, K | 1 |
| Kurata, Y | 1 |
| Kawaguchi-Sakita, N | 1 |
| Shiroshita, A | 1 |
| Kataoka, Y | 1 |
| Hyun Kim, J | 1 |
| Ofori, S | 1 |
| Mertens, RT | 1 |
| Parkin, S | 1 |
| Awuah, SG | 1 |
| Chen, C | 1 |
| Huang, A | 1 |
| Khan, NUH | 1 |
| Zhou, J | 1 |
| Zhou, Z | 1 |
| Hao, Z | 1 |
| Wu, Z | 2 |
| Yuan, K | 1 |
| Zheng, S | 1 |
| Li, T | 1 |
| Qiu, Y | 1 |
| Cheng, L | 1 |
| Luo, D | 1 |
| Zhong, X | 1 |
| Chang, J | 1 |
| He, M | 1 |
| Zhao, C | 1 |
| Ran, L | 1 |
| Palma, FR | 1 |
| Ratti, BA | 1 |
| Paviani, V | 1 |
| Coelho, DR | 1 |
| Miguel, R | 1 |
| Danes, JM | 1 |
| Zaichik, SV | 1 |
| de Abreu, AL | 1 |
| Silva, SO | 1 |
| Silverstein, RL | 1 |
| Karan, U | 1 |
| Jones, DP | 1 |
| Bonini, MG | 1 |
| Araujo, CFM | 1 |
| Nunes, LC | 1 |
| Murta-Nascimento, C | 1 |
| Souza, CP | 1 |
| Bragagnoli, AC | 1 |
| Fukushima, FB | 1 |
| Vidal, EIO | 1 |
| Kim, BH | 2 |
| Cho, MJ | 1 |
| Kwon, J | 1 |
| Tapia, E | 1 |
| Villa-Guillen, DE | 2 |
| Chalasani, P | 2 |
| Centuori, S | 1 |
| Roe, DJ | 1 |
| Guillen-Rodriguez, J | 1 |
| Huang, C | 1 |
| Galons, JP | 2 |
| Thomson, CA | 2 |
| Altbach, M | 2 |
| Trujillo, J | 1 |
| Pinto, L | 1 |
| Martinez, JA | 2 |
| Algotar, AM | 1 |
| Chow, HS | 1 |
| Long, J | 1 |
| Pan, B | 1 |
| Mao, H | 1 |
| Alipour, S | 1 |
| Abedi, M | 1 |
| Saberi, A | 1 |
| Maleki-Hajiagha, A | 1 |
| Faiz, F | 1 |
| Shahsavari, S | 1 |
| Ariaans, G | 1 |
| Jalving, M | 1 |
| Vries, EG | 1 |
| Jong, S | 1 |
| Bradley, CA | 1 |
| Hong, JL | 2 |
| Henderson, LM | 2 |
| Jonsson Funk, M | 2 |
| Lund, JL | 2 |
| Buse, JB | 2 |
| Pate, V | 2 |
| Stürmer, T | 2 |
| Agbor-Tarh, D | 1 |
| Bradbury, I | 1 |
| Di Cosimo, S | 1 |
| Azim, HA | 1 |
| Fumagalli, D | 1 |
| Sarp, S | 1 |
| Wolff, AC | 1 |
| Andersson, M | 1 |
| Kroep, J | 1 |
| Cufer, T | 1 |
| Simon, SD | 1 |
| Salman, P | 1 |
| Toi, M | 1 |
| Harris, L | 1 |
| Gralow, J | 1 |
| Keane, M | 1 |
| Moreno-Aspitia, A | 1 |
| Piccart-Gebhart, M | 1 |
| de Azambuja, E | 1 |
| Athreya, AP | 1 |
| Kalari, KR | 1 |
| Cairns, J | 1 |
| Gaglio, AJ | 1 |
| Wills, QF | 1 |
| Niu, N | 1 |
| Weinshilboum, R | 1 |
| Iyer, RK | 1 |
| Liebman, MF | 1 |
| Brien, W | 1 |
| Pritchard, KI | 5 |
| Chalchal, HI | 2 |
| Bernstein, V | 2 |
| El-Ashmawy, NE | 1 |
| Khedr, NF | 1 |
| El-Bahrawy, HA | 1 |
| Abo Mansour, HE | 1 |
| Bizjak, M | 1 |
| Malavašič, P | 1 |
| Dolinar, K | 2 |
| Pohar, J | 1 |
| Pirkmajer, S | 2 |
| Pavlin, M | 2 |
| Peper, FE | 1 |
| Esteban, S | 1 |
| Terrasa, SA | 1 |
| Farajzadeh, R | 1 |
| Pilehvar-Soltanahmadi, Y | 2 |
| Javidfar, S | 1 |
| Lotfi-Attari, J | 1 |
| Sadeghzadeh, H | 1 |
| Shafiei-Irannejad, V | 2 |
| Chubak, J | 1 |
| Boudreau, DM | 3 |
| Barlow, WE | 1 |
| Weiss, NS | 1 |
| Li, CI | 1 |
| Andrzejewski, S | 1 |
| Klimcakova, E | 1 |
| Johnson, RM | 1 |
| Tabariès, S | 1 |
| Annis, MG | 1 |
| McGuirk, S | 1 |
| Northey, JJ | 1 |
| Chénard, V | 1 |
| Sriram, U | 1 |
| Papadopoli, DJ | 1 |
| Siegel, PM | 1 |
| St-Pierre, J | 1 |
| Muszyńska-Ogłaza, A | 1 |
| Zarzycka-Lindner, G | 1 |
| Olejniczak, H | 1 |
| Polaszewska-Muszyńska, M | 1 |
| Junik, R | 1 |
| Fernández-Arroyo, S | 3 |
| García, RÁ | 1 |
| Stursa, J | 1 |
| Werner, L | 1 |
| Blanco-González, E | 1 |
| Montes-Bayón, M | 1 |
| Joven, J | 9 |
| Viollet, B | 1 |
| Neuzil, J | 1 |
| Davies, G | 1 |
| Lobanova, L | 1 |
| Dawicki, W | 1 |
| Groot, G | 1 |
| Gordon, JR | 1 |
| Bowen, M | 1 |
| Harkness, T | 1 |
| Arnason, T | 1 |
| Zhao, M | 2 |
| Du, C | 1 |
| Zhang, N | 1 |
| Luo, F | 1 |
| Amaral, MEA | 1 |
| Nery, LR | 1 |
| Leite, CE | 1 |
| de Azevedo Junior, WF | 1 |
| Campos, MM | 1 |
| Dogan Turacli, I | 1 |
| Umudum, H | 1 |
| Pampal, A | 1 |
| Candar, T | 1 |
| Kavasoglu, L | 1 |
| Sari, Y | 1 |
| Baldassari, S | 1 |
| Solari, A | 1 |
| Zuccari, G | 1 |
| Drava, G | 1 |
| Pastorino, S | 1 |
| Fucile, C | 2 |
| Marini, V | 2 |
| Daga, A | 2 |
| Pattarozzi, A | 2 |
| Ratto, A | 2 |
| Ferrari, A | 2 |
| Mattioli, F | 2 |
| Barbieri, F | 2 |
| Caviglioli, G | 1 |
| Florio, T | 2 |
| Chung, YC | 2 |
| Chang, CM | 1 |
| Wei, WC | 1 |
| Chang, TW | 1 |
| Chang, KJ | 1 |
| Chao, WT | 1 |
| Incio, J | 2 |
| McManus, DT | 2 |
| Suboj, P | 2 |
| Jung, K | 2 |
| Kawaguchi, K | 1 |
| Pinter, M | 1 |
| Babykutty, S | 2 |
| Chin, SM | 2 |
| Vardam, TD | 2 |
| Rahbari, NN | 2 |
| Roberge, S | 1 |
| Gomes-Santos, IL | 1 |
| Puchner, SB | 2 |
| Schlett, CL | 2 |
| Hoffmman, U | 2 |
| Ancukiewicz, M | 2 |
| Krop, IE | 2 |
| Duda, DG | 2 |
| Boucher, Y | 1 |
| Fukumura, D | 2 |
| Jain, RK | 2 |
| Tang, GH | 1 |
| Satkunam, M | 1 |
| Pond, GR | 1 |
| Steinberg, GR | 1 |
| Blandino, G | 4 |
| Schünemann, HJ | 1 |
| Muti, P | 5 |
| Samadi, N | 1 |
| Salehi, R | 1 |
| Yousefi, B | 1 |
| Rahimi, M | 1 |
| Akbarzadeh, A | 1 |
| Rasouli, S | 2 |
| Lu, Z | 1 |
| Long, Y | 1 |
| Cun, X | 1 |
| Mei, L | 1 |
| He, Q | 1 |
| Patterson, RE | 3 |
| Marinac, CR | 3 |
| Kerr, J | 2 |
| Cadmus-Bertram, L | 2 |
| Villaseñor, A | 2 |
| Flatt, SW | 2 |
| Godbole, S | 2 |
| Laughlin, GA | 1 |
| Oratowski-Coleman, J | 2 |
| Parker, BA | 2 |
| Natarajan, L | 3 |
| Wu, A | 1 |
| Liao, N | 1 |
| Liu, M | 1 |
| Guo, Q | 1 |
| Yi, J | 1 |
| Zhou, W | 1 |
| Xiao, Y | 2 |
| Zong, Q | 1 |
| Giles, ED | 1 |
| Jindal, S | 1 |
| Wellberg, EA | 1 |
| Schedin, T | 1 |
| Anderson, SM | 2 |
| Thor, AD | 6 |
| Edwards, DP | 1 |
| MacLean, PS | 1 |
| Schedin, P | 1 |
| Chatran, M | 1 |
| Faramarzi, L | 1 |
| Asbaghi, N | 1 |
| Tsai, YT | 1 |
| Lin, JG | 1 |
| Fu, SL | 1 |
| Lai, JN | 1 |
| Sharma, P | 1 |
| Kumar, S | 1 |
| Banala, VT | 1 |
| Sharma, S | 1 |
| Barnwal, P | 1 |
| Urandur, S | 1 |
| Shukla, RP | 1 |
| Ahmad, N | 1 |
| Mittapelly, N | 1 |
| Pandey, G | 1 |
| Dwivedi, M | 1 |
| Kalleti, N | 1 |
| Mitra, K | 1 |
| Rath, SK | 1 |
| Trivedi, R | 1 |
| Mishra, PR | 1 |
| Metcalf, T | 1 |
| Patel, N | 2 |
| Gleeson, F | 2 |
| Bradley, K | 1 |
| Zois, C | 1 |
| Ah-See, ML | 1 |
| Sharma, A | 2 |
| Bidaut, L | 1 |
| Pollak, M | 4 |
| James, T | 1 |
| Campo, L | 1 |
| Ayers, L | 1 |
| Roxanis, I | 1 |
| Fenwick, JD | 1 |
| Morris, A | 1 |
| Sabit, H | 1 |
| Abdel-Ghany, SE | 1 |
| M Said, OA | 1 |
| Mostafa, MA | 1 |
| El-Zawahry, M | 1 |
| Mormile, R | 1 |
| Chappell, JC | 1 |
| Turner, PK | 1 |
| Pak, YA | 1 |
| Bacon, J | 1 |
| Chiang, AY | 1 |
| Royalty, J | 1 |
| Hall, SD | 1 |
| Kulanthaivel, P | 1 |
| Bonventre, JV | 1 |
| Schexnayder, C | 1 |
| Broussard, K | 1 |
| Onuaguluchi, D | 1 |
| Poché, A | 1 |
| Ismail, M | 1 |
| McAtee, L | 1 |
| Llopis, S | 1 |
| Keizerweerd, A | 1 |
| McFerrin, H | 1 |
| Williams, C | 1 |
| Xin, M | 1 |
| Ren, Q | 1 |
| Guo, Y | 2 |
| Scheen, AJ | 1 |
| Philips, JC | 1 |
| Kridelka, F | 1 |
| Yam, C | 1 |
| Esteva, FJ | 4 |
| Patel, MM | 1 |
| Raghavendra, AS | 1 |
| Ueno, NT | 1 |
| Moulder, SL | 2 |
| Hess, KR | 1 |
| Shroff, GS | 1 |
| Hodge, S | 1 |
| Koenig, KH | 1 |
| Chavez Mac Gregor, M | 1 |
| Griner, RL | 1 |
| Yeung, SJ | 1 |
| Hortobagyi, GN | 6 |
| Valero, V | 1 |
| Bandyopadhayaya, S | 1 |
| Chowdhury, K | 1 |
| Sharma, T | 1 |
| Maheshwari, R | 1 |
| Das, A | 1 |
| Chakrabarti, G | 1 |
| Zhang, ZJ | 2 |
| Yuan, J | 1 |
| Bi, Y | 1 |
| Kangaskokko, J | 1 |
| Faria, J | 1 |
| Negalha, G | 1 |
| Azevedo, A | 1 |
| Martel, F | 1 |
| Mencalha, AL | 1 |
| Rahmani, J | 1 |
| Manzari, N | 1 |
| Thompson, J | 1 |
| Gudi, SK | 1 |
| Chhabra, M | 1 |
| Naik, G | 1 |
| Mousavi, SM | 1 |
| Varkaneh, HK | 1 |
| Clark, C | 1 |
| Everett, RS | 2 |
| Thakker, DR | 2 |
| Buxó, M | 1 |
| Dorca, J | 4 |
| Álvarez, I | 1 |
| Martínez, S | 2 |
| Pérez-Garcia, JM | 1 |
| Batista-López, N | 1 |
| Rodríguez-Sánchez, CA | 1 |
| Amillano, K | 1 |
| Domínguez, S | 1 |
| Luque, M | 1 |
| Morilla, I | 1 |
| Stradella, A | 1 |
| Viñas, G | 1 |
| Cortés, J | 1 |
| Brunet, J | 1 |
| López-Bonet, E | 4 |
| Garcia, M | 2 |
| Saidani, S | 1 |
| Luo, J | 1 |
| Lin, MT | 1 |
| Zhi, P | 1 |
| Guo, WW | 1 |
| Han, M | 1 |
| You, J | 1 |
| Gao, JQ | 1 |
| Culig, Z | 1 |
| Al-Juboori, SI | 1 |
| Vadakekolathu, J | 1 |
| Idri, S | 1 |
| Wagner, S | 1 |
| Zafeiris, D | 1 |
| Pearson, JR | 1 |
| Almshayakhchi, R | 1 |
| Caraglia, M | 1 |
| Desiderio, V | 1 |
| Miles, AK | 1 |
| Boocock, DJ | 1 |
| Ball, GR | 1 |
| Regad, T | 1 |
| Nelson, SH | 1 |
| Luo, S | 1 |
| Li, GY | 1 |
| Han, SX | 1 |
| Jiang, YN | 1 |
| Shen, YW | 1 |
| Zhou, C | 1 |
| Lu, SY | 1 |
| Liu, JL | 2 |
| Wang, MD | 1 |
| Kuppusamy, G | 1 |
| Bardaweel, SK | 1 |
| Alsalamat, HA | 1 |
| Aleidi, SM | 1 |
| Bashatwah, RM | 1 |
| Esparza-López, J | 1 |
| Alvarado-Muñoz, JF | 1 |
| Escobar-Arriaga, E | 1 |
| Ulloa-Aguirre, A | 1 |
| de Jesús Ibarra-Sánchez, M | 1 |
| Mlakar, V | 1 |
| Marc, J | 1 |
| Chlebowski, RR | 1 |
| Aragaki, AK | 3 |
| McTiernan, A | 2 |
| Lega, IC | 1 |
| Austin, PC | 1 |
| Gruneir, A | 1 |
| Rochon, PA | 1 |
| Lipscombe, LL | 1 |
| Aksoy, S | 1 |
| Sendur, MA | 1 |
| Altundag, K | 1 |
| Onitilo, AA | 1 |
| Donald, M | 1 |
| Stankowski, RV | 1 |
| Engel, JM | 1 |
| Williams, G | 1 |
| Doi, SA | 1 |
| Strickler, HD | 1 |
| Cufí, S | 11 |
| Corominas-Faja, B | 5 |
| Bonavia, R | 1 |
| López, IÁ | 1 |
| López, NB | 1 |
| Fernández, SD | 1 |
| Visa, J | 1 |
| Rodríguez-Gallego, E | 2 |
| Quirantes-Piné, R | 2 |
| Segura-Carretero, A | 2 |
| Gadéa, É | 1 |
| Thivat, É | 1 |
| Wang-Lopez, Q | 1 |
| Viala, M | 1 |
| Paulon, R | 1 |
| Planchat, É | 1 |
| Chadeyras, JB | 1 |
| Merlin, C | 1 |
| Coudert, B | 1 |
| Bignon, YJ | 1 |
| Morio, B | 1 |
| Durando, X | 1 |
| Hao, X | 1 |
| Qu, C | 1 |
| Zheng, G | 1 |
| Yin, J | 1 |
| Wahdan-Alaswad, R | 2 |
| Fan, Z | 4 |
| Edgerton, SM | 5 |
| Liu, B | 5 |
| Deng, XS | 3 |
| Arnadottir, SS | 1 |
| Richer, JK | 1 |
| Mao, Y | 2 |
| Xia, R | 1 |
| Wang, YQ | 1 |
| Gao, FB | 1 |
| Cazzaniga, M | 6 |
| DeCensi, A | 7 |
| Pruneri, G | 4 |
| Puntoni, M | 5 |
| Bottiglieri, L | 1 |
| Varricchio, C | 2 |
| Guerrieri-Gonzaga, A | 6 |
| Gentilini, OD | 1 |
| Pagani, G | 1 |
| Dell'Orto, P | 1 |
| Lazzeroni, M | 4 |
| Serrano, D | 4 |
| Viale, G | 3 |
| Vestergaard, P | 2 |
| Peeters, PJ | 1 |
| Bazelier, MT | 1 |
| Leufkens, HG | 1 |
| Schmidt, MK | 1 |
| de Vries, F | 1 |
| De Bruin, ML | 1 |
| Campagnoli, C | 2 |
| Berrino, F | 3 |
| Venturelli, E | 2 |
| Abbà, C | 2 |
| Biglia, N | 3 |
| Brucato, T | 2 |
| Cogliati, P | 1 |
| Danese, S | 2 |
| Donadio, M | 2 |
| Zito, G | 2 |
| Pasanisi, P | 2 |
| Hadad, SM | 4 |
| Hardie, DG | 2 |
| Appleyard, V | 2 |
| Buac, D | 1 |
| Kona, FR | 1 |
| Seth, AK | 1 |
| Dou, QP | 1 |
| Choi, YW | 1 |
| Lim, IK | 1 |
| Lee, H | 1 |
| Park, CS | 1 |
| Oh, ET | 1 |
| Choi, BH | 1 |
| Williams, B | 1 |
| Lee, CK | 1 |
| Song, CW | 1 |
| Oliveras-Ferraros, C | 18 |
| Vazquez-Martin, A | 18 |
| Kalinsky, K | 3 |
| Crew, KD | 2 |
| Refice, S | 2 |
| Xiao, T | 1 |
| Wang, A | 1 |
| Feldman, SM | 2 |
| Taback, B | 2 |
| Ahmad, A | 1 |
| Cremers, S | 2 |
| Hibshoosh, H | 2 |
| Maurer, M | 1 |
| Kim, J | 3 |
| Lim, W | 1 |
| Kim, EK | 1 |
| Kim, MK | 1 |
| Paik, NS | 1 |
| Jeong, SS | 1 |
| Yoon, JH | 1 |
| Park, CH | 1 |
| Ahn, SH | 2 |
| Kim, LS | 1 |
| Han, S | 1 |
| Nam, SJ | 1 |
| Kang, HS | 1 |
| Kim, SI | 1 |
| Yoo, YB | 1 |
| Jeong, J | 1 |
| Kim, TH | 1 |
| Kang, T | 1 |
| Kim, SW | 2 |
| Jung, Y | 1 |
| Lee, JE | 1 |
| Kim, KS | 1 |
| Yu, JH | 2 |
| Chae, BJ | 1 |
| Jung, SY | 1 |
| Kang, E | 1 |
| Choi, SY | 1 |
| Ma, J | 2 |
| Zhong, C | 1 |
| Xue, Y | 1 |
| Lai, X | 1 |
| Liu, W | 1 |
| Amanpour, S | 1 |
| Khorgami, Z | 1 |
| Muhammadnejad, S | 1 |
| Queiroz, EA | 1 |
| Puukila, S | 1 |
| Eichler, R | 1 |
| Sampaio, SC | 1 |
| Forsyth, HL | 1 |
| Lees, SJ | 1 |
| Barbosa, AM | 1 |
| Dekker, RF | 1 |
| Fortes, ZB | 1 |
| Khaper, N | 1 |
| Salis, O | 1 |
| Bedir, A | 1 |
| Ozdemir, T | 1 |
| Okuyucu, A | 1 |
| Alacam, H | 1 |
| Oppong, BA | 1 |
| Pharmer, LA | 1 |
| Oskar, S | 1 |
| Eaton, A | 1 |
| Stempel, M | 1 |
| King, TA | 1 |
| Fuentes-Mattei, E | 1 |
| Velazquez-Torres, G | 1 |
| Phan, L | 1 |
| Chou, PC | 1 |
| Shin, JH | 1 |
| Choi, HH | 1 |
| Chen, JS | 1 |
| Zhao, R | 1 |
| Gully, C | 1 |
| Carlock, C | 1 |
| McKeehan, WL | 1 |
| Ensor, J | 3 |
| Pusztai, L | 2 |
| Fraser Symmans, W | 1 |
| Lee, MH | 3 |
| Yeung, SC | 3 |
| Cioce, M | 2 |
| Valerio, M | 2 |
| Casadei, L | 2 |
| Pulito, C | 2 |
| Sacconi, A | 2 |
| Mori, F | 2 |
| Biagioni, F | 2 |
| Manetti, C | 2 |
| Strano, S | 3 |
| Hu, T | 1 |
| Chung, YM | 1 |
| Guan, M | 1 |
| Berek, JS | 1 |
| Hu, MC | 1 |
| Jang, SY | 2 |
| Kim, A | 3 |
| Kim, JK | 1 |
| Kim, C | 3 |
| Cho, YH | 1 |
| Kim, JH | 1 |
| Kim, CH | 1 |
| Lee, JY | 1 |
| Do, MT | 1 |
| Kim, HG | 2 |
| Tran, TT | 1 |
| Khanal, T | 1 |
| Choi, JH | 2 |
| Jeong, TC | 2 |
| Jeong, HG | 2 |
| Opdam, FL | 1 |
| Huitema, AD | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Stine, JE | 1 |
| Bae-Jump, V | 1 |
| Orecchioni, S | 3 |
| Reggiani, F | 3 |
| Talarico, G | 3 |
| Mancuso, P | 2 |
| Calleri, A | 2 |
| Gregato, G | 2 |
| Labanca, V | 2 |
| Noonan, DM | 2 |
| Dallaglio, K | 2 |
| Albini, A | 2 |
| Bertolini, F | 3 |
| Haugrud, AB | 1 |
| Zhuang, Y | 2 |
| Coppock, JD | 1 |
| Miskimins, WK | 2 |
| Dupouy, S | 1 |
| Doan, VK | 1 |
| Mourra, N | 1 |
| De Wever, O | 1 |
| Llorca, FP | 1 |
| Cayre, A | 1 |
| Kouchkar, A | 1 |
| Gompel, A | 1 |
| Forgez, P | 1 |
| Johansson, HA | 1 |
| Schwab, M | 1 |
| Hofmann, U | 1 |
| Mora, S | 1 |
| Aristarco, V | 2 |
| Macis, D | 1 |
| Bassi, F | 2 |
| Luini, A | 2 |
| Damjanović, A | 1 |
| Matić, IZ | 1 |
| Ðorđić, M | 1 |
| Ðurović, MN | 1 |
| Nikolić, S | 1 |
| Roki, K | 1 |
| Milovanović, Z | 1 |
| Antić-Stanković, J | 1 |
| Džodić, R | 1 |
| Damjanović, S | 1 |
| Kanjer, K | 1 |
| Abu Rabi, Z | 1 |
| Juranić, Z | 1 |
| Lau, YK | 1 |
| Rayannavar, V | 1 |
| Hopkins, B | 1 |
| Shaw, J | 1 |
| Bessler, E | 1 |
| Thomas, T | 1 |
| Pires, MM | 1 |
| Keniry, M | 1 |
| Parsons, RE | 1 |
| Szabolcs, M | 1 |
| Maurer, MA | 2 |
| Storr, SJ | 1 |
| Johnson, K | 1 |
| Green, AR | 1 |
| Rakha, EA | 1 |
| Ellis, IO | 1 |
| Morgan, DA | 1 |
| Martin, SG | 1 |
| Sestak, I | 1 |
| Cuzick, J | 3 |
| El-Benhawy, SA | 1 |
| El-Sheredy, HG | 1 |
| Cooper, AC | 1 |
| Fleming, IN | 1 |
| Phyu, SM | 3 |
| Smith, TA | 3 |
| Coates, P | 1 |
| Jordan, LB | 1 |
| Dowling, RJ | 4 |
| Done, SJ | 3 |
| Purdie, CA | 1 |
| Moulder-Thompson, S | 2 |
| Maayah, ZH | 1 |
| Ghebeh, H | 1 |
| Alhaider, AA | 1 |
| El-Kadi, AO | 1 |
| Soshilov, AA | 1 |
| Denison, MS | 1 |
| Ansari, MA | 1 |
| Korashy, HM | 1 |
| Rice, S | 1 |
| Pellat, L | 1 |
| Ahmetaga, A | 1 |
| Bano, G | 1 |
| Mason, HD | 1 |
| Whitehead, SA | 1 |
| Oja, CD | 1 |
| Tonkin, KS | 1 |
| Vissers, PA | 1 |
| Cardwell, CR | 1 |
| van de Poll-Franse, LV | 1 |
| Young, IS | 1 |
| Pouwer, F | 1 |
| Murray, LJ | 1 |
| Łukasiewicz, D | 1 |
| Chodorowska, M | 1 |
| Jakubowska, I | 1 |
| Pizzuti, L | 1 |
| Vici, P | 1 |
| Di Lauro, L | 1 |
| Sergi, D | 1 |
| Della Giulia, M | 1 |
| Marchetti, P | 1 |
| Maugeri-Saccà, M | 1 |
| Giordano, A | 1 |
| Barba, M | 3 |
| Topcul, M | 1 |
| Cetin, I | 1 |
| Niraula, S | 2 |
| McCready, DR | 2 |
| Leong, WL | 2 |
| Escallon, JM | 1 |
| Reedijk, M | 2 |
| Hatoum, D | 1 |
| McGowan, EM | 1 |
| Gao, S | 1 |
| Kong, D | 1 |
| Thellung, S | 1 |
| Carra, E | 1 |
| Bajetto, A | 1 |
| Würth, R | 1 |
| Gatti, M | 1 |
| Campanella, C | 1 |
| Vito, G | 1 |
| Pagano, A | 1 |
| García-Esquinas, E | 1 |
| Guinó, E | 1 |
| Castaño-Vinyals, G | 1 |
| Pérez-Gómez, B | 1 |
| Llorca, J | 1 |
| Altzibar, JM | 1 |
| Peiró-Pérez, R | 1 |
| Martín, V | 1 |
| Moreno-Iribas, C | 1 |
| Tardón, A | 1 |
| Caballero, FJ | 1 |
| Puig-Vives, M | 1 |
| Guevara, M | 1 |
| Villa, TF | 1 |
| Salas, D | 1 |
| Amiano, P | 1 |
| Dierssen-Sotos, T | 1 |
| Pastor-Barriuso, R | 1 |
| Sala, M | 1 |
| Kogevinas, M | 1 |
| Aragonés, N | 1 |
| Moreno, V | 1 |
| Pollán, M | 1 |
| Kim, HJ | 3 |
| Kwon, H | 1 |
| Lee, JW | 1 |
| Park, HS | 1 |
| Sohn, G | 1 |
| Lee, Y | 1 |
| Koh, BS | 1 |
| Son, BH | 1 |
| Calip, GS | 2 |
| Yu, O | 2 |
| Hoskins, KF | 1 |
| Gu, C | 1 |
| Xia, J | 1 |
| Guo, LS | 1 |
| Li, HX | 1 |
| Li, CY | 1 |
| Zhang, SY | 1 |
| Wang, QL | 1 |
| Gao, JM | 1 |
| Liang, JQ | 1 |
| Gao, MT | 1 |
| Wu, YJ | 1 |
| Fan, C | 2 |
| Wei, G | 1 |
| Wei, J | 2 |
| Fenwick, J | 1 |
| Buffa, F | 1 |
| Camacho, L | 1 |
| Dasgupta, A | 1 |
| Jiralerspong, S | 3 |
| Kowall, B | 1 |
| Stang, A | 1 |
| Rathmann, W | 2 |
| Kostev, K | 2 |
| Xu, Q | 1 |
| Zhu, T | 1 |
| Yi, C | 1 |
| Shen, Q | 1 |
| Soo, JS | 1 |
| Ng, CH | 1 |
| Tan, SH | 1 |
| Malik, RA | 1 |
| Teh, YC | 1 |
| Tan, BS | 1 |
| Ho, GF | 1 |
| See, MH | 1 |
| Taib, NA | 1 |
| Yip, CH | 1 |
| Hii, LW | 1 |
| Teo, SH | 1 |
| Leong, CO | 1 |
| Vingiani, A | 1 |
| Gentilini, O | 1 |
| Petrera, M | 1 |
| Silvestri, A | 2 |
| Palumbo, F | 1 |
| Rasi, I | 1 |
| Posca, D | 2 |
| Pavlidou, T | 1 |
| Paoluzi, S | 1 |
| Castagnoli, L | 2 |
| Cesareni, G | 2 |
| Ko, KP | 1 |
| Ma, SH | 1 |
| Yang, JJ | 1 |
| Hwang, Y | 1 |
| Ahn, C | 1 |
| Cho, YM | 1 |
| Park, BJ | 1 |
| Park, SK | 1 |
| Allott, EH | 1 |
| Hursting, SD | 1 |
| Xu, H | 1 |
| Jia, X | 1 |
| Dai, Y | 1 |
| Xie, J | 1 |
| Tao, M | 1 |
| Lee, J | 3 |
| Choi, J | 1 |
| Bao, G | 1 |
| Mao, X | 1 |
| Han, TK | 1 |
| Parker, B | 1 |
| Li, NS | 1 |
| Zou, JR | 1 |
| Lin, H | 1 |
| Ke, R | 1 |
| He, XL | 1 |
| Xiao, L | 1 |
| Huang, D | 1 |
| Lv, N | 1 |
| Akabuogu, EU | 1 |
| Rossi, T | 1 |
| Marini, C | 1 |
| Bianchi, G | 1 |
| Buschiazzo, A | 1 |
| Ravera, S | 1 |
| Martella, R | 1 |
| Bottoni, G | 1 |
| Petretto, A | 1 |
| Emionite, L | 1 |
| Monteverde, E | 1 |
| Capitanio, S | 1 |
| Inglese, E | 1 |
| Fabbi, M | 1 |
| Bongioanni, F | 1 |
| Garaboldi, L | 1 |
| Bruzzi, P | 2 |
| Orengo, AM | 1 |
| Raffaghello, L | 1 |
| Sambuceti, G | 1 |
| Tandon, M | 1 |
| Othman, AH | 1 |
| Pratap, J | 1 |
| Tam, J | 1 |
| Batista, A | 1 |
| Khachatryan, A | 1 |
| Hato, T | 1 |
| Shibuya, M | 1 |
| Soares, R | 1 |
| El-Haggar, SM | 1 |
| El-Shitany, NA | 1 |
| Mostafa, MF | 1 |
| El-Bassiouny, NA | 1 |
| Pandiri, I | 1 |
| Joe, Y | 1 |
| Park, J | 1 |
| Chung, HT | 1 |
| Park, JW | 1 |
| Choi, Y | 1 |
| Chae, YK | 1 |
| Arya, A | 1 |
| Malecek, MK | 1 |
| Shin, DS | 1 |
| Carneiro, B | 1 |
| Chandra, S | 1 |
| Kaplan, J | 1 |
| Kalyan, A | 1 |
| Altman, JK | 1 |
| Platanias, L | 1 |
| Giles, F | 1 |
| Elmore, JG | 1 |
| Jacob, L | 1 |
| Kalder, M | 1 |
| Sacco, F | 1 |
| Pirrò, S | 1 |
| Gherardini, PF | 1 |
| Mann, M | 1 |
| Rajh, M | 1 |
| Miš, K | 1 |
| Lee, KM | 1 |
| Lee, M | 1 |
| Zheng, T | 1 |
| Mundi, P | 1 |
| Connolly, E | 1 |
| Mei, Q | 1 |
| Mi, M | 1 |
| Gadducci, A | 1 |
| Tana, R | 1 |
| Cosio, S | 1 |
| Gallo, M | 1 |
| Shatova, OP | 1 |
| Butenko, EV | 1 |
| Khomutov, EV | 1 |
| Kaplun, DS | 1 |
| Sedakov, IE | 1 |
| Zinkovych, II | 1 |
| Roe, D | 1 |
| Stopeck, A | 1 |
| Thompson, PA | 1 |
| Chow, HH | 1 |
| Cabello, P | 1 |
| Pineda, B | 1 |
| Tormo, E | 1 |
| Lluch, A | 1 |
| Eroles, P | 1 |
| Hong, SE | 1 |
| Kim, CS | 1 |
| An, S | 1 |
| Kim, HA | 1 |
| Hwang, SG | 1 |
| Song, JY | 1 |
| Lee, JK | 1 |
| Hong, J | 1 |
| Kim, JI | 1 |
| Noh, WC | 1 |
| Jin, HO | 1 |
| Park, IC | 1 |
| Alalem, M | 1 |
| Ray, A | 1 |
| Ray, BK | 1 |
| Zimmermann, M | 1 |
| Arachchige-Don, AP | 1 |
| Donaldson, MS | 1 |
| Patriarchi, T | 1 |
| Horne, MC | 1 |
| Zhao, W | 1 |
| Tang, H | 1 |
| Bowker, SL | 1 |
| Lin, M | 1 |
| Eurich, DT | 1 |
| Johnson, JA | 2 |
| Rico, M | 1 |
| Baglioni, M | 1 |
| Bondarenko, M | 1 |
| Laluce, NC | 1 |
| Rozados, V | 1 |
| André, N | 1 |
| Carré, M | 1 |
| Scharovsky, OG | 1 |
| Menacho Márquez, M | 1 |
| Xue, C | 1 |
| Meng, Q | 1 |
| Huo, X | 1 |
| Sun, P | 1 |
| Peng, J | 1 |
| Liu, K | 1 |
| Curry, A | 1 |
| Khatri, I | 1 |
| Kos, O | 1 |
| Zhu, F | 1 |
| Gorczynski, R | 1 |
| Clemons, M | 1 |
| Graham, M | 1 |
| Fantus, IG | 4 |
| Alimova, IN | 2 |
| Dillon, T | 1 |
| Lind, SE | 4 |
| Palla, SL | 1 |
| Giordano, SH | 1 |
| Meric-Bernstam, F | 3 |
| Liedtke, C | 1 |
| Barnett, CM | 1 |
| Hsu, L | 2 |
| Hung, MC | 2 |
| Gonzalez-Angulo, AM | 5 |
| Yurekli, BS | 1 |
| Karaca, B | 1 |
| Cetinkalp, S | 1 |
| Uslu, R | 1 |
| Krogh, V | 1 |
| Villarini, A | 1 |
| del Barco, S | 7 |
| Hirsch, HA | 3 |
| Iliopoulos, D | 3 |
| Tsichlis, PN | 1 |
| Struhl, K | 3 |
| Memmott, RM | 1 |
| Dennis, PA | 1 |
| Grenader, T | 1 |
| Shavit, L | 1 |
| Garcia, A | 1 |
| Tisman, G | 1 |
| Rigla Cros, M | 1 |
| Zakikhani, M | 4 |
| Blouin, MJ | 2 |
| Piura, E | 1 |
| Phoenix, KN | 2 |
| Vumbaca, F | 2 |
| Fox, MM | 1 |
| Evans, R | 1 |
| Claffey, KP | 2 |
| Bodmer, M | 1 |
| Meier, C | 1 |
| Krähenbühl, S | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| Nicolucci, A | 1 |
| Berstein, LM | 3 |
| Koskela, A | 1 |
| Boyarkina, MP | 2 |
| Adlercreutz, H | 1 |
| Wysocki, PJ | 1 |
| Wierusz-Wysocka, B | 1 |
| Tsyrlina, EV | 2 |
| Turkevich, EA | 3 |
| Semiglazov, VF | 3 |
| Sanli, T | 1 |
| Rashid, A | 1 |
| Harding, S | 1 |
| Bristow, RG | 1 |
| Cutz, JC | 1 |
| Singh, G | 1 |
| Wright, J | 1 |
| Tsakiridis, T | 1 |
| Yue, W | 1 |
| Wang, JP | 1 |
| Santen, RJ | 1 |
| Bershteĭn, LM | 5 |
| Boriakina, MP | 1 |
| Hien, TT | 1 |
| Han, EH | 1 |
| Hwang, YP | 1 |
| Kwon, KI | 1 |
| Kim, SK | 1 |
| Song, GY | 1 |
| Bosco, JL | 1 |
| Antonsen, S | 1 |
| Sørensen, HT | 1 |
| Pedersen, L | 1 |
| Lash, TL | 1 |
| Mao, Z | 1 |
| Gallick, GE | 1 |
| Yung, WK | 1 |
| Uray, IP | 1 |
| Brown, PH | 2 |
| Torres-Garcia, VZ | 1 |
| Vasil'ev, DA | 2 |
| Poroshina, TE | 2 |
| Kovalenko, IG | 2 |
| Boiarkina, MP | 3 |
| Revskoĭ, SIu | 1 |
| Kovalevskiĭ, AIu | 1 |
| Zhang, MX | 1 |
| Duan, XY | 1 |
| Zhou, SN | 1 |
| Ermek, T | 1 |
| Wang, YN | 1 |
| Wang, JS | 1 |
| Arun, B | 1 |
| Castiglione, M | 1 |
| Dunn, B | 1 |
| Forbes, JF | 1 |
| Glaus, A | 1 |
| Howell, A | 5 |
| von Minckwitz, G | 1 |
| Vogel, V | 1 |
| Zwierzina, H | 1 |
| Vellon, L | 1 |
| Hadad, S | 1 |
| Jordan, L | 1 |
| Purdie, C | 1 |
| Bray, S | 1 |
| Baker, L | 1 |
| Jellema, G | 1 |
| Deharo, S | 1 |
| Dewar, JA | 1 |
| Guppy, A | 1 |
| Jamal-Hanjani, M | 1 |
| Pickering, L | 1 |
| Schott, S | 1 |
| Bierhaus, A | 1 |
| Schuetz, F | 1 |
| Beckhove, P | 1 |
| Schneeweiss, A | 1 |
| Sohn, C | 1 |
| Domschke, C | 1 |
| Malki, A | 1 |
| Youssef, A | 1 |
| Bayraktar, S | 1 |
| Hernadez-Aya, LF | 1 |
| Litton, JK | 1 |
| Dool, CJ | 1 |
| Mashhedi, H | 1 |
| David, S | 1 |
| Birman, E | 1 |
| Carboni, JM | 1 |
| Gottardis, M | 1 |
| Martinez-Outschoorn, UE | 3 |
| Lin, Z | 1 |
| Ko, YH | 1 |
| Flomenberg, N | 2 |
| Pavlides, S | 2 |
| Pestell, RG | 2 |
| Sotgia, F | 4 |
| Lisanti, MP | 4 |
| Wu, L | 1 |
| Huang, XJ | 1 |
| Yang, CH | 1 |
| Deng, SS | 1 |
| Qian, M | 1 |
| Zang, Y | 1 |
| Jung, JW | 1 |
| Park, SB | 1 |
| Lee, SJ | 1 |
| Seo, MS | 1 |
| Trosko, JE | 1 |
| Kang, KS | 1 |
| Whitaker-Menezes, D | 2 |
| Birbe, RC | 1 |
| Witkiewicz, AK | 1 |
| Tsirigos, A | 1 |
| Ertel, A | 1 |
| Broda, P | 1 |
| Minetti, C | 1 |
| Mitra, S | 1 |
| Stemke-Hale, K | 1 |
| Mills, GB | 1 |
| Claerhout, S | 1 |
| Deng, A | 1 |
| Currie, CJ | 1 |
| Poole, CD | 1 |
| Jenkins-Jones, S | 1 |
| Gale, EA | 1 |
| Morgan, CL | 1 |
| Vona-Davis, L | 1 |
| Rose, DP | 1 |
| Menendez, OJ | 1 |
| Bosch-Barrera, J | 2 |
| Appleyard, MV | 1 |
| Murray, KE | 1 |
| Coates, PJ | 1 |
| Wullschleger, S | 1 |
| Bray, SE | 1 |
| Kernohan, NM | 1 |
| Fleming, S | 2 |
| Alessi, DR | 1 |
| Bo, S | 1 |
| Benso, A | 1 |
| Durazzo, M | 1 |
| Ghigo, E | 1 |
| Gennari, A | 1 |
| Trabacca, MS | 1 |
| Galimberti, V | 1 |
| Veronesi, P | 1 |
| Martin, M | 1 |
| Marais, R | 1 |
| Scholz, C | 1 |
| Zang, C | 1 |
| Schefe, JH | 1 |
| Habbel, P | 1 |
| Regierer, AC | 1 |
| Schulz, CO | 1 |
| Possinger, K | 1 |
| Eucker, J | 1 |
| Szewczyk, M | 1 |
| Briese, V | 1 |
| Richter, DU | 1 |
| Ambroggio, S | 1 |
| Colombero, R | 1 |
| Kisel'nikov, KS | 1 |
| Zaĭtsev, AN | 1 |
| Cortese, G | 1 |
| Galanti, S | 1 |
| Citro, G | 1 |
| Chlebowski, RT | 2 |
| Wactawski-Wende, J | 1 |
| Manson, JE | 1 |
| Rohan, T | 1 |
| Ipp, E | 1 |
| Kaklamani, VG | 2 |
| Vitolins, M | 1 |
| Gunter, M | 1 |
| Phillips, LS | 1 |
| Strickler, H | 1 |
| Margolis, K | 1 |
| Euhus, DM | 1 |
| Brower, V | 1 |
| Micol, V | 1 |
| Col, NF | 1 |
| Ochs, L | 1 |
| Springmann, V | 1 |
| Komurov, K | 1 |
| Tseng, JT | 1 |
| Muller, M | 1 |
| Seviour, EG | 1 |
| Moss, TJ | 1 |
| Nagrath, D | 1 |
| Ram, PT | 1 |
| Hood, N | 1 |
| Escallon, J | 1 |
| Economopoulou, P | 1 |
| Siziopikou, K | 1 |
| Redaniel, MT | 1 |
| Jeffreys, M | 1 |
| May, MT | 1 |
| Ben-Shlomo, Y | 1 |
| Martin, RM | 1 |
| Murray, JL | 1 |
| Green, MC | 1 |
| Koenig, KB | 1 |
| Salem, AF | 1 |
| Qiu, H | 1 |
| Rhoads, GG | 1 |
| Berlin, JA | 1 |
| Marcella, SW | 1 |
| Demissie, K | 1 |
| Ishibashi, Y | 1 |
| Matsui, T | 1 |
| Takeuchi, M | 1 |
| Yamagishi, S | 1 |
| Holmes, MD | 1 |
| Chen, WY | 1 |
| Ece, H | 1 |
| Cigdem, E | 1 |
| Yuksel, K | 1 |
| Ahmet, D | 1 |
| Hakan, E | 1 |
| Oktay, TM | 1 |
| Sanchez-Alvarez, R | 1 |
| Lamb, R | 1 |
| Hulit, J | 1 |
| Gandara, R | 1 |
| Sartini, M | 1 |
| Rubin, E | 1 |
| Geng, Y | 1 |
| Chandrasekaran, S | 1 |
| Hsu, JW | 1 |
| Gidwani, M | 1 |
| Hughes, AD | 1 |
| King, MR | 1 |
| Williams, CC | 1 |
| Singleton, BA | 1 |
| Llopis, SD | 1 |
| Skripnikova, EV | 1 |
| Dowling, R | 1 |
| Sonenberg, N | 2 |
| Hede, K | 1 |
| Woodgett, JR | 1 |
| Pezzino, V | 2 |
| Trischitta, V | 1 |
| Purrello, F | 1 |
| Vigneri, R | 2 |
| Wong, KY | 1 |
| Goldfine, ID | 1 |
| Mountjoy, KG | 1 |
| Finlay, GJ | 1 |
| Holdaway, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| An Open-labelled Study to Characterise Fluciclovine (18F) Uptake Measured by positRon emissiON Tomography In Breast cancER[NCT03036943] | 40 participants (Actual) | Interventional | 2017-02-15 | Completed | |||
| Obesity-related Mechanisms and Mortality in Breast Cancer Survivors[NCT01302379] | 333 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer[NCT01101438] | Phase 3 | 3,649 participants (Actual) | Interventional | 2010-08-13 | Completed | ||
| A Randomized Phase II, Double Blind Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer Receiving First to Fourth Line Chemotherapy[NCT01310231] | Phase 2 | 40 participants (Actual) | Interventional | 2011-08-22 | Completed | ||
| A Phase 2 Single Arm Study to Examine the Effects of Metformin on Cancer Metabolism in Patients With Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy[NCT01266486] | Phase 2 | 41 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk[NCT02028221] | Phase 2 | 151 participants (Actual) | Interventional | 2014-03-07 | Completed | ||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Endometrial Cancer Recurrence in Patients Taking Metformin[NCT05192850] | 100 participants (Anticipated) | Observational | 2021-12-27 | Active, not recruiting | |||
| Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation[NCT00930579] | Phase 2 | 35 participants (Actual) | Interventional | 2009-10-16 | Completed | ||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer[NCT00897884] | 39 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| Metformin Effect as a Chemotherapeutic Adjuvant on Level of IGF in Non-diabetic Breast Cancer Patients[NCT05840068] | Phase 4 | 107 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemotherapy and a Diet Mimicking FASTing Plus/Minus Metformin in the Preoperative Setting: the BREAKFAST Trial[NCT04248998] | Phase 2 | 30 participants (Actual) | Interventional | 2020-05-05 | Active, not recruiting | ||
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Safety of Lanreotide 120 mg ATG in Combination With Metformin in Patients With Progressive Advanced Well-differentiated Gastro-intestinal (GI) or Lung Carcinoids: A Pilot, One-arm, Open-label, Prospective Study: the MetNET-2 Trial[NCT02823691] | Early Phase 1 | 20 participants (Actual) | Interventional | 2016-04-30 | Active, not recruiting | ||
| Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725] | Phase 2 | 110 participants (Anticipated) | Interventional | 2019-10-15 | Recruiting | ||
| Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia[NCT05326984] | 20 participants (Anticipated) | Interventional | 2021-02-09 | Recruiting | |||
| Effect of the Addition of Metformin Hydrochloride on the Prognosis of Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia With High Expression of ABCB1 Gene[NCT03118128] | 102 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men[NCT01686828] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Pilot Study of Metformin (MF) IN HNSCC (Head and Neck Squamous Cell Carcinoma) as Window Trial Design in Operable HNSCC, to Investigate the Effects of MF, Tumor Genotype and MF Genotype Interactions, on Tumor Metabolism and Anoikis[NCT02402348] | Early Phase 1 | 3 participants (Actual) | Interventional | 2014-12-31 | Terminated (stopped due to Funding not available, PI left institution) | ||
| Screening for Prediabetes and Early Diabetes in Primary Care[NCT00787839] | 1,939 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bioavailable testosterone measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -13.7 |
| Placebo + Lifestyle Intervention | -4.5 |
| Metformin + Standard Dietary Guidelines | -11.1 |
| Placebo + Standard Dietary Guidelines | -1.3 |
C-reactive protein measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -21.4 |
| Placebo + Lifestyle Intervention | -6.7 |
| Metformin + Standard Dietary Guidelines | -9.2 |
| Placebo + Standard Dietary Guidelines | 5.9 |
Glucose measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -1.2 |
| Placebo + Lifestyle Intervention | -2.3 |
| Metformin + Standard Dietary Guidelines | -1.6 |
| Placebo + Standard Dietary Guidelines | 2.0 |
Insulin measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -21.8 |
| Placebo + Lifestyle Intervention | -17.7 |
| Metformin + Standard Dietary Guidelines | -13.2 |
| Placebo + Standard Dietary Guidelines | -1.1 |
Serum hormone binding globulin measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | 12.5 |
| Placebo + Lifestyle Intervention | 7.6 |
| Metformin + Standard Dietary Guidelines | 9.8 |
| Placebo + Standard Dietary Guidelines | -0.1 |
Patients who died from breast cancer (NCT01101438)
Timeframe: 10 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I | 155 |
| Arm II | 160 |
Distant Relapse Free Survival (DRFS) is defined as the percentage of patients without any documented distant recurrence, death from breast cancer, death from a non breast cancer cause or death from an unknown cause. If a subject has not had distant DRFS event nor died at the time of data cut-off for this analysis, DRFS will be censored on the date of last disease assessment. (NCT01101438)
Timeframe: 5 years
| Intervention | percentage of patients without event (Number) |
|---|---|
| Metformin | 88.7 |
| Placebo | 87.8 |
Invasive disease-free survival (IDFS) is defined as the percent of patients without documented development of ipsilateral and contralateral invasive breast tumour, local/regional invasive recurrence, distant recurrence, death from any causes. If a subject has not had invasive disease or died at the time of data cut-off for this final analysis, IDFS was censored on the date of last follow-up. (NCT01101438)
Timeframe: 5 years
| Intervention | percentage of patients without event (Number) |
|---|---|
| Metformin | 84.9 |
| Placebo | 84.1 |
Invasive disease-free survival (IDFS) is defined as percentage of patients without documented development of ipsilateral and contralateral invasive breast tumour, local/regional invasive recurrence, distant recurrence, death from any causes. If a subject has not had invasive disease or died at the time of data cut-off for this final analysis, IDFS was censored on the date of last follow-up. (NCT01101438)
Timeframe: 5 years
| Intervention | percentage of patients without event (Number) |
|---|---|
| Metformin | 86.5 |
| Placebo | 85.9 |
Change in fasting glucose from baseline to Cycle 2 (NCT01310231)
Timeframe: Baseline to Cycle 2
| Intervention | mmol/L (Median) |
|---|---|
| Metformin | -0.2 |
| Placebo | 0 |
Change in fasting insulin from baseline to Cycle 2 (NCT01310231)
Timeframe: Baseline to Cycle 2
| Intervention | pmol/L (Median) |
|---|---|
| Metformin | -7 |
| Placebo | 1 |
HOMA-IR is an index calculated from fasting insulin (pmol/L) and glucose (mmol/L) as insulin/6.9 times glucose/22.5. (NCT01310231)
Timeframe: Baseline to Cycle 2
| Intervention | HOMA-IR score (Median) |
|---|---|
| Metformin | -0.16 |
| Placebo | 0.12 |
"Adverse events graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.~Lower grade (grade 1 and 2) and higher grade (grade 3 and 4) are presented separately.~A detailed breakdown of adverse events are given in the Adverse Events section" (NCT01310231)
Timeframe: Up to 30 days after end of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 15 |
| Placebo | 6 |
"Adverse events graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.~Lower grade (grade 1 and 2) and higher grade (grade 3 and 4) are presented separately.~A detailed breakdown of adverse events are given in the Adverse Events section" (NCT01310231)
Timeframe: Up to 30 days after end of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 7 |
| Placebo | 10 |
Scans will be repeated every 9 weeks. Local follow up for survival will continue until all patients have died or for a maximum total follow up of 3 years, which ever occurs first. The two study arms will be compared in an intent to treat fashion using Cox proportional hazard analysis, with the stratification variables included in the model. Treatment discontinuation for toxicity or other reasons will be considered an event. (NCT01310231)
Timeframe: From date of randomization to first documented progression or death, which ever occurs first, assessed up to 3 years.
| Intervention | months (Mean) |
|---|---|
| Metformin | 5.4 |
| Placebo | 6.3 |
European Organization for Research and Treatment of Cancer (EORTC) quality of life measures: global health status and 5 functioning scales. Baseline and Cycle 2 outcomes are scaled from 0 to 100; higher scores indicate better functioning or better health status. CHANGE in these scales from baseline to cycle 2 is reported for each arm. (NCT01310231)
Timeframe: From baseline to cycle 2 of chemotherapy
| Intervention | EORTC functioning scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Global health Status | Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | |
| Metformin | -12.7 | -6.0 | -18.4 | -2.6 | -0.9 | -12.3 |
| Placebo | 6.3 | 2.1 | -2.1 | 2.3 | 0 | 4.2 |
Change in dense breast volume at 12 months (NCT02028221)
Timeframe: Baseline, 12 months
| Intervention | cm^3 (Mean) |
|---|---|
| Placebo | -12.11 |
| Metformin | -14.75 |
change of dense breast volume at 6 months (NCT02028221)
Timeframe: baseline, 6 months
| Intervention | cm^3 (Mean) |
|---|---|
| Placebo | -5.45 |
| Metformin | -13.71 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | kg (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 101.5 | 99.6 | 99.3 |
| Placebo | 102.3 | 102.1 | 103.2 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | data presented as ratio; no unit (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 0.170 | 0.169 | 0.165 |
| Placebo | 0.178 | 0.178 | 0.171 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | uIU/ml (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 13.5 | 11.9 | 11.7 |
| Placebo | 14.6 | 14.0 | 13.1 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | data presented as ratio; no unit (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 0.028 | 0.025 | 0.026 |
| Placebo | 0.023 | 0.022 | 0.021 |
(NCT02028221)
Timeframe: baseline, 6 months, 12 months
| Intervention | cm (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | 12 months | |
| Metformin | 111.2 | 108.9 | 108.3 |
| Placebo | 110.3 | 111.6 | 111.8 |
This outcome measure examines the changes in tumor proliferation as measured by the amount of Ki-67 protein in the tumor. (NCT00930579)
Timeframe: Baseline, up to 4 weeks
| Intervention | percentage of ki-67 positive cells (Mean) | |
|---|---|---|
| Premetformin Tumor Sample | Post Metformin Tumor Sample | |
| Metformin | 2.17 | 2.165 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
We examined whether differences in lipoprotein lipase expression would be evident across study treatment groups. RNA was isolated from whole adipose tissue gene expression, and complementary DNA (cDNA) was synthesized from 1.5 ug of RNA per sample. Gene expression was measured by polymerase chain reaction (PCR) using predesigned TaqMan® Gene Expression Assays. Standard curves were included on each plate, so Ct values were converted to copy numbers of the target gene. Expression values were normalized to the geometric mean of the housekeeping genes phosphoglycerate kinase and 18s. (NCT01686828)
Timeframe: 4 weeks
| Intervention | gene copy number per ng RNA (Mean) |
|---|---|
| Acyline + Placebo Gel + Placebo Pills | 7493 |
| Acyline + Testosterone Gel (1.25g/d) + Placebo Pills | 8224 |
| Acyline + Testosterone Gel (5g/d) + Placebo Pills | 7885 |
| Acyline + Testosterone Gel (5g/d) + Letrozole | 8320 |
Whole body insulin sensitivity as quantified by Matsuda Index at the end of the treatment period, calculated by the following equation: 10,000/square root of(FPG*FI)*(FPG+PG30*2+PG60*2+PG90*2+PG120)/8*(FPI+PI30*2+PI60*2+PI90*2+PI)/8). FPG=fasting plasma glucose level; FPI=fasting plasma insulin level; PG30,60,90, and 120=plasma glucose levels sampled at 30,60,90, and 120 minutes after oral glucose load; PI30,60,90, and 120=plasma insulin levels sampled at 30,60,90, and 120 minutes after the oral glucose load (NCT01686828)
Timeframe: 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Acyline & Placebo Gel & Placebo Pill | 5.0 |
| Acyline & Testosterone Gel 1.25g/d & Placebo Pill | 9.4 |
| Acyline & Testosterone Gel 5g/d & Placebo Pill | 7.2 |
| Acyline & Testosterone Gel & Letrozole | 7.3 |
Fat mass and lean mass were measured by dual energy X-ray absorptiometry (DEXA) at baseline and at the end of the 4 week treatment period (NCT01686828)
Timeframe: 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Change in fat mass | Change in lean mass | |
| Acyline & Placebo Gel & Placebo Pill | 1.1 | -1.2 |
| Acyline & Testosterone Gel & Letrozole | 0.5 | -0.3 |
| Acyline & Testosterone Gel 1.25g/d & Placebo Pill | 0.7 | -1.4 |
| Acyline & Testosterone Gel 5g/d & Placebo Pill | -0.4 | 0.0 |
"Area under ROC curve (AROC) for prediction of diabetes (based on OGTT) and high-risk dysglycemia (based on OGTT, IGT with 2 hour OGTT glucose 140-199 mg/dl, and/or IFG with fasting glucose 110-125 mg/dl).~ROC curves are plots of (1-sensitivity) vs. (1-specificity) for all possible screening cutoffs, so a higher AROC indicates higher predictive accuracy. A perfect test would have an AROC of 1.00, while a test equivalent to tossing a coin (random) would have an AROC of 0.50; if confidence limits include 0.50, predictive accuracy is no better than chance.~It is important to appreciate that while AROC analysis can show the relative accuracy of different screening tests, and aid the selection of which test to use in clinical practice, such an analysis does not define what the optimal screening test cutoff is. Selection of the optimal cutoff generally requires consideration of other factors, such as costs and/or the clinical importance of having higher or lower sensitivity." (NCT00787839)
Timeframe: 3 years
| Intervention | area under ROC curve (Number) |
|---|---|
| GCTpl - Diabetes | .85 |
| GCTcap - Diabetes | .82 |
| RPG - Diabetes | .76 |
| RCG - Diabetes | .72 |
| A1c - Diabetes | .67 |
| GCTpl - Dysglycemia | .76 |
| GCTcap - Dysglycemia | .73 |
| RPG - Dysglycemia | .66 |
| RCG - Dysglycemia | .64 |
| A1c - Dysglycemia | .63 |
Cost was expressed as cost (dollars) to identify a single case, with cases defined as (i) diabetes or (ii) high-risk dysglycemia. Cost projections for screening were conducted from both Medicare and VA perspectives. All screening projections assumed follow-up testing with an OGTT if the screening test exceeded a 70% specificity cut-off. (NCT00787839)
Timeframe: 3 years
| Intervention | Dollars (Number) |
|---|---|
| GCTpl - Diabetes - VA | 100 |
| GCTcap - Diabetes - VA | 93 |
| GCTpl - Dysglycemia - VA | 42 |
| GCTcap - Dysglycemia - VA | 37 |
| GCTpl - Diabetes - Medicare | 133 |
| GCTcap - Diabetes - Medicare | 125 |
| GCTpl - Dysglycemia - Medicare | 55 |
| GCTcap - Dysglycemia - Medicare | 50 |
62 reviews available for metformin and Breast Neoplasms
| Article | Year |
|---|---|
A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer.
Topics: Breast Neoplasms; Female; Humans; Metformin; Neoplasm Metastasis; Randomized Controlled Trials as To | 2021 |
A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer.
Topics: Breast Neoplasms; Female; Humans; Metformin; Neoplasm Metastasis; Randomized Controlled Trials as To | 2021 |
Effect of metformin on
Topics: Animals; Breast Neoplasms; Carcinoma, Hepatocellular; Colonic Neoplasms; Diabetes Mellitus, Type 2; | 2022 |
Effect of metformin on
Topics: Animals; Breast Neoplasms; Carcinoma, Hepatocellular; Colonic Neoplasms; Diabetes Mellitus, Type 2; | 2022 |
Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis.
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Insulin; Metformin | 2022 |
Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis.
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Insulin; Metformin | 2022 |
Metformin and Breast Cancer: Where Are We Now?
Topics: Animals; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin | 2022 |
Metformin and Breast Cancer: Where Are We Now?
Topics: Animals; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin | 2022 |
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihype | 2022 |
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihype | 2022 |
Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Early Detection of Cancer; Female; Humans; Hypoglycemic | 2023 |
Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Early Detection of Cancer; Female; Humans; Hypoglycemic | 2023 |
Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials.
Topics: Breast Neoplasms; Cancer Survivors; Female; Humans; Metabolomics; Metformin; Obesity; Overweight; Ph | 2022 |
Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trials.
Topics: Breast Neoplasms; Cancer Survivors; Female; Humans; Metabolomics; Metformin; Obesity; Overweight; Ph | 2022 |
Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies.
Topics: Breast Neoplasms; Cohort Studies; Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; P | 2022 |
Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies.
Topics: Breast Neoplasms; Cohort Studies; Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Metformin; P | 2022 |
Metformin and long non-coding RNAs in breast cancer.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Metformin; RNA, Long Noncoding | 2023 |
Metformin and long non-coding RNAs in breast cancer.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Metformin; RNA, Long Noncoding | 2023 |
Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2023 |
Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2023 |
Metformin and Cancer: Solutions to a Real-World Evidence Failure.
Topics: Bias; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin | 2023 |
Metformin and Cancer: Solutions to a Real-World Evidence Failure.
Topics: Bias; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin | 2023 |
Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions.
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin; Obesity; Risk Factors | 2023 |
Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions.
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin; Obesity; Risk Factors | 2023 |
Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Antineoplastic Agents; Antineoplas | 2019 |
Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Antineoplastic Agents; Antineoplas | 2019 |
Controversial association between polycystic ovary syndrome and breast cancer.
Topics: Androgens; Anovulation; Aromatase Inhibitors; Breast Neoplasms; Clomiphene; Contraceptives, Oral, Co | 2019 |
Controversial association between polycystic ovary syndrome and breast cancer.
Topics: Androgens; Anovulation; Aromatase Inhibitors; Breast Neoplasms; Clomiphene; Contraceptives, Oral, Co | 2019 |
Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast N | 2019 |
Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast N | 2019 |
An evolving paradigm of cancer stem cell hierarchies: therapeutic implications.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Br | 2020 |
An evolving paradigm of cancer stem cell hierarchies: therapeutic implications.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Br | 2020 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast | 2020 |
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer.
Topics: Breast Neoplasms; Female; Humans; Metformin; Raloxifene Hydrochloride; Selective Estrogen Receptor M | 2020 |
Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer.
Topics: Breast Neoplasms; Female; Humans; Metformin; Raloxifene Hydrochloride; Selective Estrogen Receptor M | 2020 |
The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials.
Topics: Breast Neoplasms; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hypoglycemic Agents | 2021 |
The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials.
Topics: Breast Neoplasms; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hypoglycemic Agents | 2021 |
Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Metformin; Neoadjuvant Therapy; Neoplasm R | 2022 |
Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Metformin; Neoadjuvant Therapy; Neoplasm R | 2022 |
Metformin and survival of women with breast cancer: A meta-analysis of randomized controlled trials.
Topics: Breast Neoplasms; Disease-Free Survival; Female; Humans; Metformin; Progression-Free Survival; Rando | 2022 |
Metformin and survival of women with breast cancer: A meta-analysis of randomized controlled trials.
Topics: Breast Neoplasms; Disease-Free Survival; Female; Humans; Metformin; Progression-Free Survival; Rando | 2022 |
Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Metform | 2018 |
Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Metform | 2018 |
[Role of metformin in gynaecology and obstetrics].
Topics: Breast Neoplasms; Diabetes, Gestational; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; | 2018 |
[Role of metformin in gynaecology and obstetrics].
Topics: Breast Neoplasms; Diabetes, Gestational; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; | 2018 |
The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Female; Gonadal Steroid Hormones; Humans; Hypoglycemic | 2019 |
The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Female; Gonadal Steroid Hormones; Humans; Hypoglycemic | 2019 |
Metformin and Breast Cancer: Molecular Targets.
Topics: AMP-Activated Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Type | 2019 |
Metformin and Breast Cancer: Molecular Targets.
Topics: AMP-Activated Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Type | 2019 |
The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials.
Topics: Biomarkers; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; | 2020 |
The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials.
Topics: Biomarkers; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; | 2020 |
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
Topics: Benzopyrans; Breast Neoplasms; Cadherins; Cell Plasticity; Cytokines; Disease Progression; Epidermal | 2019 |
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
Topics: Benzopyrans; Breast Neoplasms; Cadherins; Cell Plasticity; Cytokines; Disease Progression; Epidermal | 2019 |
Metformin in breast cancer: preclinical and clinical evidence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Chemoth | 2020 |
Metformin in breast cancer: preclinical and clinical evidence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Chemoth | 2020 |
Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Neoplas | 2013 |
Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Neoplas | 2013 |
The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Diabetes Complications; Endometrial N | 2014 |
The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Diabetes Complications; Endometrial N | 2014 |
Metformin and gynecologic cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Hu | 2014 |
Metformin and gynecologic cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Hu | 2014 |
Update on breast cancer risk prediction and prevention.
Topics: Age of Onset; Aromatase Inhibitors; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Diphosphonates; Fe | 2015 |
Update on breast cancer risk prediction and prevention.
Topics: Age of Onset; Aromatase Inhibitors; Aspirin; Biomarkers, Tumor; Breast Neoplasms; Diphosphonates; Fe | 2015 |
Metformin and breast cancer: basic knowledge in clinical context.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin | 2015 |
Metformin and breast cancer: basic knowledge in clinical context.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin | 2015 |
Recent advances in the use of metformin: can treating diabetes prevent breast cancer?
Topics: Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diabetes C | 2015 |
Recent advances in the use of metformin: can treating diabetes prevent breast cancer?
Topics: Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diabetes C | 2015 |
Diabetes mellitus is associated with breast cancer: systematic review, meta-analysis, and in silico reproduction.
Topics: Breast Neoplasms; Computer Simulation; Databases, Genetic; DEAD-box RNA Helicases; Diabetes Mellitus | 2015 |
Diabetes mellitus is associated with breast cancer: systematic review, meta-analysis, and in silico reproduction.
Topics: Breast Neoplasms; Computer Simulation; Databases, Genetic; DEAD-box RNA Helicases; Diabetes Mellitus | 2015 |
Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.
Topics: Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Hypoglycemic Agents; Me | 2015 |
Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.
Topics: Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Hypoglycemic Agents; Me | 2015 |
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Neoadjuvant Therapy; Prognos | 2015 |
Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Neoadjuvant Therapy; Prognos | 2015 |
Mechanisms of obesity in the development of breast cancer.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Inflammatory Agents; Breast Neoplasms; Disease Progression | 2015 |
Mechanisms of obesity in the development of breast cancer.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Inflammatory Agents; Breast Neoplasms; Disease Progression | 2015 |
Breast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with Metformin.
Topics: Breast Neoplasms; Cell Proliferation; Female; Humans; Metformin; Mitochondria | 2015 |
Breast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with Metformin.
Topics: Breast Neoplasms; Cell Proliferation; Female; Humans; Metformin; Mitochondria | 2015 |
Repurposing metformin for cancer treatment: current clinical studies.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Coho | 2016 |
Repurposing metformin for cancer treatment: current clinical studies.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Coho | 2016 |
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
Topics: Animals; Breast Neoplasms; Drug Repositioning; Endometrial Neoplasms; Female; Humans; Metformin; Ova | 2016 |
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
Topics: Animals; Breast Neoplasms; Drug Repositioning; Endometrial Neoplasms; Female; Humans; Metformin; Ova | 2016 |
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, | 2009 |
mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, | 2009 |
Metformin: a therapeutic opportunity in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Glucose; Humans; | 2010 |
Metformin: a therapeutic opportunity in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Glucose; Humans; | 2010 |
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Compartmentation; Dose-Response Relationship, | 2010 |
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Compartmentation; Dose-Response Relationship, | 2010 |
Epidemiological aspects of neoplasms in diabetes.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Case-Control Studies; Cell Divis | 2010 |
Epidemiological aspects of neoplasms in diabetes.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Case-Control Studies; Cell Divis | 2010 |
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Topics: Adiponectin; AMP-Activated Protein Kinases; Breast Neoplasms; Clinical Trials as Topic; Female; Huma | 2010 |
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Topics: Adiponectin; AMP-Activated Protein Kinases; Breast Neoplasms; Clinical Trials as Topic; Female; Huma | 2010 |
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Typ | 2011 |
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Typ | 2011 |
Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2011 |
Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antin | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antin | 2011 |
Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Diabetes Mellitus, Type 2; Drug Evalua | 2011 |
Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Diabetes Mellitus, Type 2; Drug Evalua | 2011 |
Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Topics: Animals; Breast Neoplasms; Chemoprevention; Cohort Studies; Comorbidity; Disease Models, Animal; Fem | 2011 |
Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Topics: Animals; Breast Neoplasms; Chemoprevention; Cohort Studies; Comorbidity; Disease Models, Animal; Fem | 2011 |
Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Transformation, Neoplastic; Female; Humans; M | 2012 |
Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Transformation, Neoplastic; Female; Humans; M | 2012 |
[Breast cancer subtypes and their endocrine-metabolic basis; practical aspects].
Topics: Age Factors; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Fe | 2011 |
[Breast cancer subtypes and their endocrine-metabolic basis; practical aspects].
Topics: Age Factors; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Fe | 2011 |
Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Diabetes Mellitus, Type 2; Estrogens; Female; Human | 2012 |
Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Diabetes Mellitus, Type 2; Estrogens; Female; Human | 2012 |
Does use of metformin protect against cancer in Type 2 diabetes mellitus?
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Diabetes Mellitus, Typ | 2012 |
Does use of metformin protect against cancer in Type 2 diabetes mellitus?
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Diabetes Mellitus, Typ | 2012 |
Metformin and breast cancer risk: a meta-analysis and critical literature review.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Postmen | 2012 |
Metformin and breast cancer risk: a meta-analysis and critical literature review.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Postmen | 2012 |
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.
Topics: Aldehyde Dehydrogenase 1 Family; Breast Neoplasms; CD24 Antigen; Cell Differentiation; Cell Transfor | 2012 |
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.
Topics: Aldehyde Dehydrogenase 1 Family; Breast Neoplasms; CD24 Antigen; Cell Differentiation; Cell Transfor | 2012 |
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2012 |
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2012 |
Targeting AMPK: a new therapeutic opportunity in breast cancer.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Breast Neoplasms; Female; Humans; Hypoglycemic Agents | 2008 |
Targeting AMPK: a new therapeutic opportunity in breast cancer.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Breast Neoplasms; Female; Humans; Hypoglycemic Agents | 2008 |
Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Neovascularization, Pathologic; Ri | 2009 |
Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Neovascularization, Pathologic; Ri | 2009 |
42 trials available for metformin and Breast Neoplasms
| Article | Year |
|---|---|
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.
Topics: Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Fasting; Female; Humans; Metformin; Middl | 2021 |
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.
Topics: Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Fasting; Female; Humans; Metformin; Middl | 2021 |
Characterising
Topics: Breast Neoplasms; Carboxylic Acids; Cyclobutanes; Female; Humans; Metformin; Neoplasm Grading; Posit | 2022 |
Characterising
Topics: Breast Neoplasms; Carboxylic Acids; Cyclobutanes; Female; Humans; Metformin; Neoplasm Grading; Posit | 2022 |
The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Me | 2022 |
The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Me | 2022 |
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2022 |
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2022 |
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Topics: Breast Neoplasms; Female; Humans; Insulin; Metformin; Mitochondria; Trastuzumab | 2022 |
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Topics: Breast Neoplasms; Female; Humans; Insulin; Metformin; Mitochondria; Trastuzumab | 2022 |
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Topics: Breast Neoplasms; Female; Humans; Insulin; Metformin; Mitochondria; Trastuzumab | 2022 |
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Topics: Breast Neoplasms; Female; Humans; Insulin; Metformin; Mitochondria; Trastuzumab | 2022 |
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Topics: Breast Neoplasms; Female; Humans; Insulin; Metformin; Mitochondria; Trastuzumab | 2022 |
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Topics: Breast Neoplasms; Female; Humans; Insulin; Metformin; Mitochondria; Trastuzumab | 2022 |
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Topics: Breast Neoplasms; Female; Humans; Insulin; Metformin; Mitochondria; Trastuzumab | 2022 |
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Topics: Breast Neoplasms; Female; Humans; Insulin; Metformin; Mitochondria; Trastuzumab | 2022 |
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
Topics: Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Metformin; Progression | 2023 |
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
Topics: Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Metformin; Progression | 2023 |
Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial.
Topics: Breast Neoplasms; Cardiotoxicity; Donepezil; Doxorubicin; Female; Humans; Leukocytes, Mononuclear; M | 2023 |
Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial.
Topics: Breast Neoplasms; Cardiotoxicity; Donepezil; Doxorubicin; Female; Humans; Leukocytes, Mononuclear; M | 2023 |
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Disease-Free Survival; Dou | 2023 |
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Disease-Free Survival; Dou | 2023 |
A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Hypoglyce | 2019 |
A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Hypoglyce | 2019 |
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Breast Neoplasms; Cell Proliferation; Diabetes Mellit | 2020 |
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Breast Neoplasms; Cell Proliferation; Diabetes Mellit | 2020 |
Metformin intervention against ovarian toxicity during chemotherapy for early breast cancer: Study protocol for a randomized double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Su | 2020 |
Metformin intervention against ovarian toxicity during chemotherapy for early breast cancer: Study protocol for a randomized double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Su | 2020 |
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial.
Topics: Biomarkers; Breast Neoplasms; C-Reactive Protein; Colorectal Neoplasms; Combined Modality Therapy; E | 2020 |
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial.
Topics: Biomarkers; Breast Neoplasms; C-Reactive Protein; Colorectal Neoplasms; Combined Modality Therapy; E | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.
Topics: Body Mass Index; Breast Neoplasms; Estradiol; Female; Gonadal Steroid Hormones; Humans; Metformin; M | 2021 |
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.
Topics: Body Mass Index; Breast Neoplasms; Estradiol; Female; Gonadal Steroid Hormones; Humans; Metformin; M | 2021 |
Metformin for the treatment of breast cancer: protocol for a scoping review of randomised clinical trials.
Topics: Breast Neoplasms; Delivery of Health Care; Female; Humans; Metformin; Peer Review; Randomized Contro | 2021 |
Metformin for the treatment of breast cancer: protocol for a scoping review of randomised clinical trials.
Topics: Breast Neoplasms; Delivery of Health Care; Female; Humans; Metformin; Peer Review; Randomized Contro | 2021 |
A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.
Topics: Adiposity; Breast Density; Breast Neoplasms; Feasibility Studies; Female; Humans; Mammography; Metab | 2021 |
A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.
Topics: Adiposity; Breast Density; Breast Neoplasms; Feasibility Studies; Female; Humans; Mammography; Metab | 2021 |
Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial.
Topics: Adolescent; Adult; Breast Neoplasms; Case-Control Studies; Female; Fibroadenoma; Follow-Up Studies; | 2021 |
Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial.
Topics: Adolescent; Adult; Breast Neoplasms; Case-Control Studies; Female; Fibroadenoma; Follow-Up Studies; | 2021 |
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus; Disease-Free Survival; Female; Humans; H | 2017 |
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus; Disease-Free Survival; Female; Humans; H | 2017 |
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Homocysteine; Humans; Metformin; Methylmalon | 2017 |
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Homocysteine; Humans; Metformin; Methylmalon | 2017 |
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic | 2018 |
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic | 2018 |
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2019 |
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2019 |
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients.
Topics: 3-Hydroxybutyric Acid; Breast Neoplasms; Female; Folic Acid Antagonists; Humans; Hypoglycemic Agents | 2019 |
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients.
Topics: 3-Hydroxybutyric Acid; Breast Neoplasms; Female; Folic Acid Antagonists; Humans; Hypoglycemic Agents | 2019 |
The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cancer Survivors; Cognitive Dysfunction; Combined Modalit | 2019 |
The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cancer Survivors; Cognitive Dysfunction; Combined Modalit | 2019 |
The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study.
Topics: Biomarkers; Breast Neoplasms; Cholesterol, HDL; Cholesterol, LDL; Colorectal Neoplasms; Coronary Art | 2019 |
The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study.
Topics: Biomarkers; Breast Neoplasms; Cholesterol, HDL; Cholesterol, LDL; Colorectal Neoplasms; Coronary Art | 2019 |
The effect of metformin on apoptosis in a breast cancer presurgical trial.
Topics: Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Meth | 2013 |
The effect of metformin on apoptosis in a breast cancer presurgical trial.
Topics: Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Meth | 2013 |
Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.
Topics: Aged; Androgens; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Diabetes Mellitus; Estro | 2013 |
Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.
Topics: Aged; Androgens; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Diabetes Mellitus; Estro | 2013 |
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Cell Proliferatio | 2014 |
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Cell Proliferatio | 2014 |
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Female; Humans | 2014 |
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Female; Humans | 2014 |
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Female; Humans; | 2014 |
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Female; Humans; | 2014 |
Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.
Topics: Antineoplastic Agents; Biomarkers; Breast Neoplasms; Caspase 3; Female; Humans; Ki-67 Antigen; Metfo | 2015 |
Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.
Topics: Antineoplastic Agents; Biomarkers; Breast Neoplasms; Caspase 3; Female; Humans; Ki-67 Antigen; Metfo | 2015 |
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Breast Neoplasms; C-Reactive Protein; Combined Modality | 2015 |
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Breast Neoplasms; C-Reactive Protein; Combined Modality | 2015 |
Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Double-B | 2015 |
Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Double-B | 2015 |
Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial.
Topics: Biomarkers; Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasm Staging; Obes | 2015 |
Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial.
Topics: Biomarkers; Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasm Staging; Obes | 2015 |
Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.
Topics: Aged; Aged, 80 and over; Blood Glucose; Breast Neoplasms; C-Reactive Protein; Estradiol; Exercise; F | 2016 |
Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.
Topics: Aged; Aged, 80 and over; Blood Glucose; Breast Neoplasms; C-Reactive Protein; Estradiol; Exercise; F | 2016 |
Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
Topics: Adiponectin; Adult; Body Weight; Breast; Breast Neoplasms; Double-Blind Method; Humans; Hypoglycemic | 2016 |
Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
Topics: Adiponectin; Adult; Body Weight; Breast; Breast Neoplasms; Double-Blind Method; Humans; Hypoglycemic | 2016 |
Insulin-lowering effects of metformin in women with early breast cancer.
Topics: Blood Glucose; Breast Neoplasms; Cholesterol, LDL; Female; Humans; Hypoglycemic Agents; Insulin; Met | 2008 |
Insulin-lowering effects of metformin in women with early breast cancer.
Topics: Blood Glucose; Breast Neoplasms; Cholesterol, LDL; Female; Humans; Hypoglycemic Agents; Insulin; Met | 2008 |
[Influence of metformin and N-acetylcysteine on hormonal and genotoxic effects of estrogens and glucose in convalescent cancer patients].
Topics: Acetylcysteine; Aged; Blood Glucose; Body Mass Index; Breast Neoplasms; Colonic Neoplasms; Drug Admi | 2010 |
[Influence of metformin and N-acetylcysteine on hormonal and genotoxic effects of estrogens and glucose in convalescent cancer patients].
Topics: Acetylcysteine; Aged; Blood Glucose; Body Mass Index; Breast Neoplasms; Colonic Neoplasms; Drug Admi | 2010 |
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cyclic Nucleotide Phosphodiesterases, Type 3; Fema | 2011 |
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cyclic Nucleotide Phosphodiesterases, Type 3; Fema | 2011 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
Topics: Adult; Aged; Algorithms; Breast Neoplasms; Carcinoma; Diabetes Mellitus; Dose-Response Relationship, | 2012 |
Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
Topics: Adult; Aged; Algorithms; Breast Neoplasms; Carcinoma; Diabetes Mellitus; Dose-Response Relationship, | 2012 |
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Apoptosis; Body Mass Index; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemic Agent | 2012 |
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Apoptosis; Body Mass Index; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemic Agent | 2012 |
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response R | 2013 |
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response R | 2013 |
319 other studies available for metformin and Breast Neoplasms
| Article | Year |
|---|---|
Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Aurora Kinase A; Azepines; Breast Neoplasms; | 2021 |
Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Aurora Kinase A; Azepines; Breast Neoplasms; | 2021 |
Metformin may induce ferroptosis by inhibiting autophagy via lncRNA H19 in breast cancer.
Topics: Autophagy; Breast Neoplasms; Female; Ferroptosis; Humans; Metformin; RNA, Long Noncoding | 2022 |
Metformin may induce ferroptosis by inhibiting autophagy via lncRNA H19 in breast cancer.
Topics: Autophagy; Breast Neoplasms; Female; Ferroptosis; Humans; Metformin; RNA, Long Noncoding | 2022 |
Modulatory Effects of Metformin Alone and in Combination with Cimetidine and Ibuprofen on T Cell-related Parameters in a Breast Cancer Model.
Topics: Animals; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cimetidine; Disease Models, Animal; Female; | 2021 |
Modulatory Effects of Metformin Alone and in Combination with Cimetidine and Ibuprofen on T Cell-related Parameters in a Breast Cancer Model.
Topics: Animals; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cimetidine; Disease Models, Animal; Female; | 2021 |
Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report.
Topics: Acidosis, Lactic; Aminopyridines; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; | 2022 |
Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report.
Topics: Acidosis, Lactic; Aminopyridines; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; | 2022 |
The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients.
Topics: Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Neoadjuvant Therapy; Prospective Studies; | 2021 |
The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients.
Topics: Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Neoadjuvant Therapy; Prospective Studies; | 2021 |
An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors.
Topics: Aged; Aging; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Overweight | 2021 |
An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors.
Topics: Aged; Aging; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Overweight | 2021 |
Metformin Treatment or PRODH/POX-Knock out Similarly Induces Apoptosis by Reprograming of Amino Acid Metabolism, TCA, Urea Cycle and Pentose Phosphate Pathway in MCF-7 Breast Cancer Cells.
Topics: Apoptosis; Breast Neoplasms; Chromatography, Liquid; Female; Gene Expression Regulation, Neoplastic; | 2021 |
Metformin Treatment or PRODH/POX-Knock out Similarly Induces Apoptosis by Reprograming of Amino Acid Metabolism, TCA, Urea Cycle and Pentose Phosphate Pathway in MCF-7 Breast Cancer Cells.
Topics: Apoptosis; Breast Neoplasms; Chromatography, Liquid; Female; Gene Expression Regulation, Neoplastic; | 2021 |
Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell S | 2022 |
Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell S | 2022 |
Replacement of hydrochloride in metformin hydrochloride with caprylic acid to investigate its effects on MCF-7 and MDA-MB-231 breast cancer cell lines.
Topics: Breast Neoplasms; Caprylates; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; MCF-7 | 2022 |
Replacement of hydrochloride in metformin hydrochloride with caprylic acid to investigate its effects on MCF-7 and MDA-MB-231 breast cancer cell lines.
Topics: Breast Neoplasms; Caprylates; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; MCF-7 | 2022 |
Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use.
Topics: Adult; Aspirin; Breast Density; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Hydroxyme | 2022 |
Current regular aspirin use and mammographic breast density: a cross-sectional analysis considering concurrent statin and metformin use.
Topics: Adult; Aspirin; Breast Density; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Hydroxyme | 2022 |
A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Diabetes Mellitus, Experimental; Disea | 2022 |
A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Diabetes Mellitus, Experimental; Disea | 2022 |
Effects of metformin on human bone-derived mesenchymal stromal cell-breast cancer cell line interactions.
Topics: Adipokines; Breast Neoplasms; Cell Line, Tumor; Cell Migration Assays; Cell Proliferation; Culture M | 2022 |
Effects of metformin on human bone-derived mesenchymal stromal cell-breast cancer cell line interactions.
Topics: Adipokines; Breast Neoplasms; Cell Line, Tumor; Cell Migration Assays; Cell Proliferation; Culture M | 2022 |
Elucidating the mechanism underlying cognitive dysfunction by investigating the effects of CMF and MET treatment on hippocampal neurons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognitive Dysfunction; Cyclophosph | 2022 |
Elucidating the mechanism underlying cognitive dysfunction by investigating the effects of CMF and MET treatment on hippocampal neurons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognitive Dysfunction; Cyclophosph | 2022 |
Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model.
Topics: Breast Neoplasms; Cell Proliferation; Cell Survival; Female; Humans; In Vitro Techniques; Insulin Re | 2022 |
Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model.
Topics: Breast Neoplasms; Cell Proliferation; Cell Survival; Female; Humans; In Vitro Techniques; Insulin Re | 2022 |
Effects of CMF and MET on glutamate and dopamine levels in the brain, and their impact on cognitive function.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain; Breast Neoplasms; Cognition; Cycloph | 2022 |
Effects of CMF and MET on glutamate and dopamine levels in the brain, and their impact on cognitive function.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain; Breast Neoplasms; Cognition; Cycloph | 2022 |
Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesench | 2022 |
Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesench | 2022 |
Metformin-induced downregulation of c-Met is a determinant of sensitivity in MDA-MB-468 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fema | 2022 |
Metformin-induced downregulation of c-Met is a determinant of sensitivity in MDA-MB-468 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fema | 2022 |
Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
Topics: Breast Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; In | 2022 |
Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
Topics: Breast Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; In | 2022 |
Development and Evaluation of Core-Shell Nanocarrier System for Enhancing the Cytotoxicity of Doxorubicin/Metformin Combination Against Breast Cancer Cell Line.
Topics: Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Female; Humans; Mastectomy; MCF-7 Ce | 2022 |
Development and Evaluation of Core-Shell Nanocarrier System for Enhancing the Cytotoxicity of Doxorubicin/Metformin Combination Against Breast Cancer Cell Line.
Topics: Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Female; Humans; Mastectomy; MCF-7 Ce | 2022 |
Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Humans; Insulin; Metformin; Receptors, CX | 2022 |
Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Humans; Insulin; Metformin; Receptors, CX | 2022 |
The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action.
Topics: Alkylmercury Compounds; Antineoplastic Agents; Apoptosis; Artemisinins; bcl-2-Associated X Protein; | 2022 |
The Effect of Dual Bioactive Compounds Artemisinin and Metformin Co-loaded in PLGA-PEG Nano-particles on Breast Cancer Cell lines: Potential Apoptotic and Anti-proliferative Action.
Topics: Alkylmercury Compounds; Antineoplastic Agents; Apoptosis; Artemisinins; bcl-2-Associated X Protein; | 2022 |
Metformin and Cancer: Is This the End?
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Neopl | 2022 |
Metformin and Cancer: Is This the End?
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Neopl | 2022 |
Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tum | 2022 |
Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tum | 2022 |
Metformin and breast cancer: an opportunity for pharmacogenetics.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Pharmac | 2022 |
Metformin and breast cancer: an opportunity for pharmacogenetics.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Pharmac | 2022 |
Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Medicare; M | 2022 |
Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Medicare; M | 2022 |
Opposing effects of metformin mediated mTORC1 inhibition on IRES possessing anti-apoptotic proteins in breast cancer cell lines.
Topics: Apoptosis; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Inhibitor of Apoptosis Pr | 2022 |
Opposing effects of metformin mediated mTORC1 inhibition on IRES possessing anti-apoptotic proteins in breast cancer cell lines.
Topics: Apoptosis; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Inhibitor of Apoptosis Pr | 2022 |
Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast.
Topics: Breast Neoplasms; Endothelial Cells; Female; Humans; Immunity; Ligands; Lipids; Metformin; PPAR gamm | 2022 |
Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast.
Topics: Breast Neoplasms; Endothelial Cells; Female; Humans; Immunity; Ligands; Lipids; Metformin; PPAR gamm | 2022 |
Assessment of Novel Therapeutics for Individualized Breast Cancer Care in the Modern Era: The Role of Metformin in Breast Cancer Therapy.
Topics: Breast; Breast Neoplasms; Female; Humans; Metformin | 2023 |
Assessment of Novel Therapeutics for Individualized Breast Cancer Care in the Modern Era: The Role of Metformin in Breast Cancer Therapy.
Topics: Breast; Breast Neoplasms; Female; Humans; Metformin | 2023 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.
Topics: Breast Neoplasms; Female; Genomics; Humans; Metformin; Neoplasm Recurrence, Local; Thyroxine | 2022 |
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Estradiol; Female; Humans; Insulin; Leptin; Letrozole; | 2023 |
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Estradiol; Female; Humans; Insulin; Leptin; Letrozole; | 2023 |
Metformin enhances anti-cancer properties of resveratrol in MCF-7 breast cancer cells via induction of apoptosis, autophagy and alteration in cell cycle distribution.
Topics: Autophagy; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Diabetes M | 2023 |
Metformin enhances anti-cancer properties of resveratrol in MCF-7 breast cancer cells via induction of apoptosis, autophagy and alteration in cell cycle distribution.
Topics: Autophagy; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Diabetes M | 2023 |
YAP/TAZ axis was involved in the effects of metformin on breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin; Transcription Factors; Transcrip | 2023 |
YAP/TAZ axis was involved in the effects of metformin on breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin; Transcription Factors; Transcrip | 2023 |
Potentiation of Folate-Functionalized PLGA-PEG nanoparticles loaded with metformin for the treatment of breast Cancer: possible clinical application.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Folic Acid; Humans | 2023 |
Potentiation of Folate-Functionalized PLGA-PEG nanoparticles loaded with metformin for the treatment of breast Cancer: possible clinical application.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Folic Acid; Humans | 2023 |
Co-drug development of gallic acid and metformin targeting the pro-inflammatory cytokines for the treatment of breast cancer.
Topics: Apoptosis; Breast Neoplasms; Cytokines; Drug Development; Female; Gallic Acid; Humans; Metformin | 2023 |
Co-drug development of gallic acid and metformin targeting the pro-inflammatory cytokines for the treatment of breast cancer.
Topics: Apoptosis; Breast Neoplasms; Cytokines; Drug Development; Female; Gallic Acid; Humans; Metformin | 2023 |
Role of metformin in prevention and prognosis of breast cancer.
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Prognosis | 2022 |
Role of metformin in prevention and prognosis of breast cancer.
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Prognosis | 2022 |
Is Metformin effective in Breast Cancer (BC) patients without Type 2 Diabetes (T2D)?
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin | 2023 |
Is Metformin effective in Breast Cancer (BC) patients without Type 2 Diabetes (T2D)?
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin | 2023 |
The efficacy of metformin as adjuvant to chemotherapy on IGF levels in non-diabetic female patients with progressive and non-progressive metastatic breast cancer.
Topics: Adjuvants, Immunologic; Blood Glucose; Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Insuli | 2023 |
The efficacy of metformin as adjuvant to chemotherapy on IGF levels in non-diabetic female patients with progressive and non-progressive metastatic breast cancer.
Topics: Adjuvants, Immunologic; Blood Glucose; Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Insuli | 2023 |
Metformin ameliorates BMP2 induced adipocyte-like property in breast cancer cells.
Topics: Adipocytes; Bone Morphogenetic Protein 2; Breast Neoplasms; Fatty Acids; Female; Humans; Metformin | 2023 |
Metformin ameliorates BMP2 induced adipocyte-like property in breast cancer cells.
Topics: Adipocytes; Bone Morphogenetic Protein 2; Breast Neoplasms; Fatty Acids; Female; Humans; Metformin | 2023 |
Murine Breast Cancer Radiosensitization Using Oxygen Microbubbles and Metformin: Vessels Are the Key.
Topics: Animals; Breast Neoplasms; Female; Humans; Metformin; Mice; Microbubbles; Oxygen; Tumor Hypoxia | 2023 |
Murine Breast Cancer Radiosensitization Using Oxygen Microbubbles and Metformin: Vessels Are the Key.
Topics: Animals; Breast Neoplasms; Female; Humans; Metformin; Mice; Microbubbles; Oxygen; Tumor Hypoxia | 2023 |
Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study.
Topics: Aspirin; Breast Neoplasms; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2023 |
Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study.
Topics: Aspirin; Breast Neoplasms; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2023 |
Metformin Caused Radiosensitivity of Breast Cancer Cells through the Expression Modulation of miR-21-5p/SESN1axis.
Topics: Breast Neoplasms; Female; Humans; MCF-7 Cells; Metformin; MicroRNAs; Radiation Tolerance; Sestrins; | 2023 |
Metformin Caused Radiosensitivity of Breast Cancer Cells through the Expression Modulation of miR-21-5p/SESN1axis.
Topics: Breast Neoplasms; Female; Humans; MCF-7 Cells; Metformin; MicroRNAs; Radiation Tolerance; Sestrins; | 2023 |
Co-Treatment with Sulforaphane and Nano-Metformin Molecules Accelerates Apoptosis in HER2+ Breast Cancer Cells by Inhibiting Key Molecules.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Br | 2020 |
Co-Treatment with Sulforaphane and Nano-Metformin Molecules Accelerates Apoptosis in HER2+ Breast Cancer Cells by Inhibiting Key Molecules.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Br | 2020 |
Implementation of two different experimental designs for screening and optimization of process parameters for metformin-loaded carboxymethyl chitosan formulation.
Topics: Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Compoundin | 2019 |
Implementation of two different experimental designs for screening and optimization of process parameters for metformin-loaded carboxymethyl chitosan formulation.
Topics: Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Compoundin | 2019 |
Enchancement of Toremifene Anti-Tumor Action by Metformin and Unusual Side Effect of Toremifene in Male Transgenic Mice with HER2-Positive Breast Tumor.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Disease Models, Animal; Fe | 2019 |
Enchancement of Toremifene Anti-Tumor Action by Metformin and Unusual Side Effect of Toremifene in Male Transgenic Mice with HER2-Positive Breast Tumor.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Disease Models, Animal; Fe | 2019 |
PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin.
Topics: Antineoplastic Agents; Autocrine Communication; Breast Neoplasms; Cell Line, Tumor; Cell Proliferati | 2019 |
PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin.
Topics: Antineoplastic Agents; Autocrine Communication; Breast Neoplasms; Cell Line, Tumor; Cell Proliferati | 2019 |
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms | 2020 |
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms | 2020 |
Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Diabetes Mell | 2020 |
Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Diabetes Mell | 2020 |
Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Ethnic | 2019 |
Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Ethnic | 2019 |
Metformin alleviates breast cancer through targeting high-mobility group AT-hook 2.
Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulati | 2020 |
Metformin alleviates breast cancer through targeting high-mobility group AT-hook 2.
Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulati | 2020 |
Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Comorbidity; Databases, Factual; Diabetes Mellitus, Type | 2020 |
Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Comorbidity; Databases, Factual; Diabetes Mellitus, Type | 2020 |
Metformin is distributed to tumor tissue in breast cancer patients in vivo: A
Topics: Aged; Biomarkers, Tumor; Breast Neoplasms; Carbon Radioisotopes; Female; Follow-Up Studies; Gene Exp | 2020 |
Metformin is distributed to tumor tissue in breast cancer patients in vivo: A
Topics: Aged; Biomarkers, Tumor; Breast Neoplasms; Carbon Radioisotopes; Female; Follow-Up Studies; Gene Exp | 2020 |
Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell N | 2020 |
Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell N | 2020 |
Tumor microenvironment-responsive polymer with chlorin e6 to interface hollow mesoporous silica nanoparticles-loaded oxygen supply factor for boosted photodynamic therapy.
Topics: Animals; Breast Neoplasms; Catalase; Cell Line, Tumor; Cell Survival; Chlorophyllides; Combined Moda | 2020 |
Tumor microenvironment-responsive polymer with chlorin e6 to interface hollow mesoporous silica nanoparticles-loaded oxygen supply factor for boosted photodynamic therapy.
Topics: Animals; Breast Neoplasms; Catalase; Cell Line, Tumor; Cell Survival; Chlorophyllides; Combined Moda | 2020 |
AMPK Activation by Metformin Promotes Survival of Dormant ER
Topics: AMP-Activated Protein Kinases; Animals; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Ce | 2020 |
AMPK Activation by Metformin Promotes Survival of Dormant ER
Topics: AMP-Activated Protein Kinases; Animals; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Ce | 2020 |
Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Breast Neoplasms; Diabetes Mellitus, Type 2; Female | 2020 |
Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Breast Neoplasms; Diabetes Mellitus, Type 2; Female | 2020 |
Use of metformin and risk of breast and colorectal cancer.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Colorectal Neoplasms; Diabetes Mell | 2020 |
Use of metformin and risk of breast and colorectal cancer.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Colorectal Neoplasms; Diabetes Mell | 2020 |
Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cardiovascular Diseases; Dia | 2020 |
Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cardiovascular Diseases; Dia | 2020 |
Influences of preoperative metformin on immunological factors in early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Biopsy, Large-Core Needle; Breast Neoplasms; CD4-Posi | 2020 |
Influences of preoperative metformin on immunological factors in early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Biopsy, Large-Core Needle; Breast Neoplasms; CD4-Posi | 2020 |
A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Apoptosis; Aspirin; Breast Neoplasms; CD24 A | 2020 |
A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Apoptosis; Aspirin; Breast Neoplasms; CD24 A | 2020 |
Surface modification engineering of two-dimensional titanium carbide for efficient synergistic multitherapy of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Breast Neoplasms; | 2020 |
Surface modification engineering of two-dimensional titanium carbide for efficient synergistic multitherapy of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Breast Neoplasms; | 2020 |
Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer.
Topics: Adenylate Kinase; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Chemokine CXCL1 | 2020 |
Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer.
Topics: Adenylate Kinase; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Chemokine CXCL1 | 2020 |
Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Female; Gene | 2020 |
Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Female; Gene | 2020 |
Effects of metformin on adipose-derived stromal cell (ADSC) - Breast cancer cell lines interaction.
Topics: Adipocytes; Adipose Tissue; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; | 2020 |
Effects of metformin on adipose-derived stromal cell (ADSC) - Breast cancer cell lines interaction.
Topics: Adipocytes; Adipose Tissue; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; | 2020 |
Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Combined Modality T | 2020 |
Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Combined Modality T | 2020 |
Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density.
Topics: Adult; Body Mass Index; Breast; Breast Density; Breast Neoplasms; Cross-Sectional Studies; Drug Ther | 2020 |
Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density.
Topics: Adult; Body Mass Index; Breast; Breast Density; Breast Neoplasms; Cross-Sectional Studies; Drug Ther | 2020 |
Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients.
Topics: Breast Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Met | 2021 |
Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients.
Topics: Breast Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Met | 2021 |
Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling.
Topics: Animals; Breast Neoplasms; Dipeptidyl Peptidase 4; Female; Gene Expression Profiling; Humans; Metfor | 2021 |
Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling.
Topics: Animals; Breast Neoplasms; Dipeptidyl Peptidase 4; Female; Gene Expression Profiling; Humans; Metfor | 2021 |
FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; | 2021 |
FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; | 2021 |
Production of ROS by Gallic Acid Activates KDM2A to Reduce rRNA Transcription.
Topics: Adenylate Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Methylation; F-Box Pro | 2020 |
Production of ROS by Gallic Acid Activates KDM2A to Reduce rRNA Transcription.
Topics: Adenylate Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Methylation; F-Box Pro | 2020 |
Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity.
Topics: Biomarkers; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Coculture Techniques; Female; Gen | 2020 |
Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity.
Topics: Biomarkers; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Coculture Techniques; Female; Gen | 2020 |
Metformin modulates oncogenic expression of HOTAIR gene via promoter methylation and reverses epithelial-mesenchymal transition in MDA-MB-231 cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; | 2021 |
Metformin modulates oncogenic expression of HOTAIR gene via promoter methylation and reverses epithelial-mesenchymal transition in MDA-MB-231 cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; | 2021 |
Association between prior use of anti-diabetic medication and breast cancer stage at diagnosis.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; I | 2021 |
Association between prior use of anti-diabetic medication and breast cancer stage at diagnosis.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; I | 2021 |
Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter.
Topics: A549 Cells; Acidosis, Lactic; Animals; Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus, T | 2021 |
Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter.
Topics: A549 Cells; Acidosis, Lactic; Animals; Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus, T | 2021 |
Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism
Topics: AMP-Activated Protein Kinases; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cy | 2021 |
Metformin promotes apoptosis in primary breast cancer cells by downregulation of cyclin D1 and upregulation of P53 through an AMPK-alpha independent mechanism
Topics: AMP-Activated Protein Kinases; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cy | 2021 |
Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Topics: Animals; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemi | 2021 |
Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Topics: Animals; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemi | 2021 |
Diabetes, metformin and breast cancer: a tangled web.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prospective Stu | 2021 |
Diabetes, metformin and breast cancer: a tangled web.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prospective Stu | 2021 |
A prospective study of type 2 diabetes, metformin use, and risk of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metfo | 2021 |
A prospective study of type 2 diabetes, metformin use, and risk of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metfo | 2021 |
Tangeretin boosts the anticancer activity of metformin in breast cancer cells via curbing the energy production.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; | 2021 |
Tangeretin boosts the anticancer activity of metformin in breast cancer cells via curbing the energy production.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; | 2021 |
The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes.
Topics: Adult; Body Mass Index; Breast Neoplasms; Diabetes Mellitus, Type 2; Disease-Free Survival; Female; | 2021 |
The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes.
Topics: Adult; Body Mass Index; Breast Neoplasms; Diabetes Mellitus, Type 2; Disease-Free Survival; Female; | 2021 |
Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Neoplasm Invasivene | 2021 |
Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Neoplasm Invasivene | 2021 |
Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; Data Analysis; Diab | 2021 |
Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; Data Analysis; Diab | 2021 |
Making sense of associations between type 2 diabetes, metformin, and breast cancer risk.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Prospective Studies; Recepto | 2021 |
Making sense of associations between type 2 diabetes, metformin, and breast cancer risk.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Prospective Studies; Recepto | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies.
Topics: Animals; Apoptosis; Breast Neoplasms; Carotenoids; Cell Proliferation; Disease Progression; Drug The | 2021 |
Crocin and Metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies.
Topics: Animals; Apoptosis; Breast Neoplasms; Carotenoids; Cell Proliferation; Disease Progression; Drug The | 2021 |
Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Middle | 2021 |
Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Middle | 2021 |
ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion.
Topics: AMP-Activated Protein Kinases; Animals; Breast Neoplasms; Estrogens; Female; Humans; Metformin; Mice | 2021 |
ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion.
Topics: AMP-Activated Protein Kinases; Animals; Breast Neoplasms; Estrogens; Female; Humans; Metformin; Mice | 2021 |
Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Mellitus, Experimental; Female; | 2021 |
Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Mellitus, Experimental; Female; | 2021 |
Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Doxorub | 2021 |
Enhanced antitumor activity of doxorubicin by naringenin and metformin in breast carcinoma: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Doxorub | 2021 |
Water-Soluble Gold(III)-Metformin Complex Alters Mitochondrial Bioenergetics in Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response | 2021 |
Water-Soluble Gold(III)-Metformin Complex Alters Mitochondrial Bioenergetics in Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response | 2021 |
Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; | 2021 |
Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; | 2021 |
lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell.
Topics: Apoptosis; Beclin-1; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; En | 2021 |
lncRNA MALAT1 participates in metformin inhibiting the proliferation of breast cancer cell.
Topics: Apoptosis; Beclin-1; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; En | 2021 |
Inhalable Porous Microspheres Loaded with Metformin and Docosahexaenoic Acid Suppress Tumor Metastasis by Modulating Premetastatic Niche.
Topics: Administration, Inhalation; Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Docosahexaenoi | 2021 |
Inhalable Porous Microspheres Loaded with Metformin and Docosahexaenoic Acid Suppress Tumor Metastasis by Modulating Premetastatic Niche.
Topics: Administration, Inhalation; Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Docosahexaenoi | 2021 |
MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose | 2022 |
MPEG-PCL Nanomicelles Platform for Synergistic Metformin and Chrysin Delivery to Breast Cancer in Mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose | 2022 |
AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Carbohydrate Metabolism; Energy Metabolism; Glycoly | 2021 |
AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Carbohydrate Metabolism; Energy Metabolism; Glycoly | 2021 |
Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study.
Topics: Breast; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Republic of Korea | 2021 |
Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study.
Topics: Breast; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Republic of Korea | 2021 |
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Everolimus; | 2017 |
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Everolimus; | 2017 |
Diabetes: Metformin in breast cancer.
Topics: Breast Neoplasms; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin | 2017 |
Diabetes: Metformin in breast cancer.
Topics: Breast Neoplasms; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin | 2017 |
Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Early Detection of Cancer; Female; Humans | 2017 |
Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Early Detection of Cancer; Female; Humans | 2017 |
Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell M | 2017 |
Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell M | 2017 |
Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell | 2017 |
Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell | 2017 |
Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Biphenyl Compounds; Breast Neoplasms; Cel | 2017 |
Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Biphenyl Compounds; Breast Neoplasms; Cel | 2017 |
[Evaluation of primary adherence to medications in patients with chronic conditions: A retrospective cohort study].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chronic Disease; Cohort | 2018 |
[Evaluation of primary adherence to medications in patients with chronic conditions: A retrospective cohort study].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chronic Disease; Cohort | 2018 |
Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells.
Topics: Breast Neoplasms; Capsules; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Carriers; Drug Libe | 2018 |
Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells.
Topics: Breast Neoplasms; Capsules; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Carriers; Drug Libe | 2018 |
Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2017 |
Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2017 |
PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Energy Metabolism; Female; Humans; Hypog | 2017 |
PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Energy Metabolism; Female; Humans; Hypog | 2017 |
Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes.
Topics: Aged; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metfor | 2017 |
Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes.
Topics: Aged; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metfor | 2017 |
Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism.
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers, Tumor; Breast Neoplasms; Carbon; Colonic Neoplas | 2018 |
Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism.
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers, Tumor; Breast Neoplasms; Carbon; Colonic Neoplas | 2018 |
Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neopl | 2017 |
Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neopl | 2017 |
Aspirin and metformin exhibit antitumor activity in murine breast cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Ap | 2018 |
Aspirin and metformin exhibit antitumor activity in murine breast cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Ap | 2018 |
Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes.
Topics: Antineoplastic Agents; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Dr | 2018 |
Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes.
Topics: Antineoplastic Agents; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Dr | 2018 |
Do MCF7 cells cope with metformin treatment under energetic stress in low glucose conditions?
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Galectin 3 | 2018 |
Do MCF7 cells cope with metformin treatment under energetic stress in low glucose conditions?
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Galectin 3 | 2018 |
Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Delayed-Action Preparations; Female; Gels; | 2018 |
Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Delayed-Action Preparations; Female; Gels; | 2018 |
Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents, Immunological; Breast Neoplasms; Caveolin 1; Drug | 2018 |
Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents, Immunological; Breast Neoplasms; Caveolin 1; Drug | 2018 |
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Fibrobl | 2018 |
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Fibrobl | 2018 |
Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; D | 2018 |
Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; D | 2018 |
Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Cyclin D1; Drug Combinations; Drug Synergism; Femal | 2018 |
Synergistic Growth Inhibitory Effects of Chrysin and Metformin Combination on Breast Cancer Cells through hTERT and Cyclin D1 Suppression
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Cyclin D1; Drug Combinations; Drug Synergism; Femal | 2018 |
A size-shrinkable nanoparticle-based combined anti-tumor and anti-inflammatory strategy for enhanced cancer therapy.
Topics: Animals; Anti-Inflammatory Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; | 2018 |
A size-shrinkable nanoparticle-based combined anti-tumor and anti-inflammatory strategy for enhanced cancer therapy.
Topics: Animals; Anti-Inflammatory Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; | 2018 |
Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
Topics: Biomarkers; Breast Neoplasms; Humans; Life Style; Metformin; Obesity; Weight Loss | 2018 |
Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
Topics: Biomarkers; Breast Neoplasms; Humans; Life Style; Metformin; Obesity; Weight Loss | 2018 |
The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
Topics: Biomarkers; Breast Neoplasms; California; Female; Humans; Metformin; Patient Outcome Assessment; Pro | 2018 |
The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
Topics: Biomarkers; Breast Neoplasms; California; Female; Humans; Metformin; Patient Outcome Assessment; Pro | 2018 |
Inhibiting ROS-TFE3-dependent autophagy enhances the therapeutic response to metformin in breast cancer.
Topics: Apoptosis; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Breast Neoplasms; | 2018 |
Inhibiting ROS-TFE3-dependent autophagy enhances the therapeutic response to metformin in breast cancer.
Topics: Apoptosis; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Breast Neoplasms; | 2018 |
Co-delivery of Metformin and Paclitaxel Via Folate-Modified pH-Sensitive Micelles for Enhanced Anti-tumor Efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug | 2018 |
Co-delivery of Metformin and Paclitaxel Via Folate-Modified pH-Sensitive Micelles for Enhanced Anti-tumor Efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug | 2018 |
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
Topics: Animals; Aromatase; Breast; Breast Neoplasms; Disease Progression; Estrogen Receptor alpha; Female; | 2018 |
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
Topics: Animals; Aromatase; Breast; Breast Neoplasms; Disease Progression; Estrogen Receptor alpha; Female; | 2018 |
Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell | 2018 |
Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell | 2018 |
Chinese herbal products and the reduction of risk of breast cancer among females with type 2 diabetes in Taiwan: A case-control study.
Topics: Adult; Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2018 |
Chinese herbal products and the reduction of risk of breast cancer among females with type 2 diabetes in Taiwan: A case-control study.
Topics: Adult; Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2018 |
Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD).
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dow | 2018 |
Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD).
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dow | 2018 |
Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; K | 2018 |
Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; K | 2018 |
In search of the mechanisms of metformin in cancer.
Topics: Breast Neoplasms; Humans; Hypoglycemic Agents; Metformin | 2018 |
In search of the mechanisms of metformin in cancer.
Topics: Breast Neoplasms; Humans; Hypoglycemic Agents; Metformin | 2018 |
Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells
Topics: Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Methylati | 2018 |
Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells
Topics: Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Methylati | 2018 |
Metformin Therapy and Breast Cancer Incidence and Mortality-Letter.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin | 2018 |
Metformin Therapy and Breast Cancer Incidence and Mortality-Letter.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin | 2018 |
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
Topics: Aminopyridines; Antineoplastic Agents, Immunological; Benzimidazoles; Biological Transport; Breast N | 2019 |
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
Topics: Aminopyridines; Antineoplastic Agents, Immunological; Benzimidazoles; Biological Transport; Breast N | 2019 |
Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells.
Topics: Antineoplastic Agents; Antioxidants; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolife | 2018 |
Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells.
Topics: Antineoplastic Agents; Antioxidants; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolife | 2018 |
Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; F | 2019 |
Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; F | 2019 |
Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; | 2019 |
Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; | 2019 |
Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Cell Nucleus; Cytoplasm; Diabet | 2019 |
Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Cell Nucleus; Cytoplasm; Diabet | 2019 |
Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Databa | 2019 |
Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Databa | 2019 |
Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resist | 2019 |
Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resist | 2019 |
Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Hypoxia; Doxorubicin; Drug Compounding; Drug Deliver | 2019 |
Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Hypoxia; Doxorubicin; Drug Compounding; Drug Deliver | 2019 |
PYK2 promotes HER2-positive breast cancer invasion.
Topics: Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; F | 2019 |
PYK2 promotes HER2-positive breast cancer invasion.
Topics: Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; F | 2019 |
Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Disease Models, A | 2019 |
Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Disease Models, A | 2019 |
Glucose Deprivation Enhances the Antiproliferative Effects of Oral Hypoglycemic Biguanides in Different Molecular Subtypes of Breast Cancer: an in Vitro Study.
Topics: Administration, Oral; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Pro | 2018 |
Glucose Deprivation Enhances the Antiproliferative Effects of Oral Hypoglycemic Biguanides in Different Molecular Subtypes of Breast Cancer: an in Vitro Study.
Topics: Administration, Oral; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Pro | 2018 |
Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Topics: AMP-Activated Protein Kinases; Biopsy; Breast; Breast Neoplasms; Cell Movement; Cell Proliferation; | 2019 |
Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Topics: AMP-Activated Protein Kinases; Biopsy; Breast; Breast Neoplasms; Cell Movement; Cell Proliferation; | 2019 |
Highlights from the latest pharmacogenomic genome-wide association studies.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Biomedical Research; Brea | 2013 |
Highlights from the latest pharmacogenomic genome-wide association studies.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Biomedical Research; Brea | 2013 |
Reply to S. Gandini et al.
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin | 2013 |
Reply to S. Gandini et al.
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin | 2013 |
Association between metformin therapy and mortality after breast cancer: a population-based study.
Topics: Aged; Aged, 80 and over; Body Mass Index; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Hypog | 2013 |
Association between metformin therapy and mortality after breast cancer: a population-based study.
Topics: Aged; Aged, 80 and over; Body Mass Index; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Hypog | 2013 |
Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chi-Square Distribution; Diabetes Mellitus; Female | 2013 |
Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chi-Square Distribution; Diabetes Mellitus; Female | 2013 |
Breast and prostate cancer survivors in a diabetic cohort: results from the Living with Diabetes Study.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cohort Studies; Comorbidity; Cross-Sectional Studies; Dia | 2013 |
Breast and prostate cancer survivors in a diabetic cohort: results from the Living with Diabetes Study.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cohort Studies; Comorbidity; Cross-Sectional Studies; Dia | 2013 |
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Topics: Animals; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Class I Phosphati | 2013 |
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Topics: Animals; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Class I Phosphati | 2013 |
[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].
Topics: Adiposity; Antineoplastic Agents; Breast Neoplasms; Energy Metabolism; Exercise; Female; Humans; Hyp | 2013 |
[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].
Topics: Adiposity; Antineoplastic Agents; Breast Neoplasms; Energy Metabolism; Exercise; Female; Humans; Hyp | 2013 |
Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kapla | 2014 |
Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kapla | 2014 |
Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line | 2014 |
Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line | 2014 |
Glucose promotes breast cancer aggression and reduces metformin efficacy.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Glucose; Huma | 2013 |
Glucose promotes breast cancer aggression and reduces metformin efficacy.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Glucose; Huma | 2013 |
Multimodality imaging assessments of response to metformin therapy for breast cancer in nude mice.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diffusion Magnetic Resonance Imagin | 2013 |
Multimodality imaging assessments of response to metformin therapy for breast cancer in nude mice.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diffusion Magnetic Resonance Imagin | 2013 |
Editorial: diabetes and cancer - disease, drugs or deception?
Topics: Breast Neoplasms; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; In | 2013 |
Editorial: diabetes and cancer - disease, drugs or deception?
Topics: Breast Neoplasms; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; In | 2013 |
Use of metformin and survival of diabetic women with breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Comorbidity; Denmark; | 2013 |
Use of metformin and survival of diabetic women with breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Comorbidity; Denmark; | 2013 |
Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle.
Topics: AMP-Activated Protein Kinases; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ce | 2014 |
Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle.
Topics: AMP-Activated Protein Kinases; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ce | 2014 |
Regulation of metformin response by breast cancer associated gene 2.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Breast Neoplasms; | 2013 |
Regulation of metformin response by breast cancer associated gene 2.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Breast Neoplasms; | 2013 |
Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Respiration; Dichloroacetic A | 2014 |
Sensitization of metformin-cytotoxicity by dichloroacetate via reprogramming glucose metabolism in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Respiration; Dichloroacetic A | 2014 |
Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Humans; Hyperthermia, Induced | 2014 |
Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Humans; Hyperthermia, Induced | 2014 |
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; G | 2014 |
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; G | 2014 |
Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Ne | 2014 |
Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Ne | 2014 |
Molecular pathways: preclinical models and clinical trials with metformin in breast cancer.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; | 2014 |
Molecular pathways: preclinical models and clinical trials with metformin in breast cancer.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; | 2014 |
Lack of metformin effects on different molecular subtypes of breast cancer under normoglycemic conditions: an in vitro study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; MCF-7 Cell | 2014 |
Lack of metformin effects on different molecular subtypes of breast cancer under normoglycemic conditions: an in vitro study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; MCF-7 Cell | 2014 |
Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Middle | 2014 |
Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Middle | 2014 |
Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells.
Topics: AMP-Activated Protein Kinases; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Enzyme Activation; Fem | 2014 |
Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells.
Topics: AMP-Activated Protein Kinases; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Enzyme Activation; Fem | 2014 |
The relationship between anticancer effect of metformin and the transcriptional regulation of certain genes (CHOP, CAV-1, HO-1, SGK-1 and Par-4) on MCF-7 cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins | 2014 |
The relationship between anticancer effect of metformin and the transcriptional regulation of certain genes (CHOP, CAV-1, HO-1, SGK-1 and Par-4) on MCF-7 cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins | 2014 |
The effect of metformin on breast cancer outcomes in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2014 |
The effect of metformin on breast cancer outcomes in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2014 |
Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
Topics: Adipocytes; Adipokines; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; C | 2014 |
Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
Topics: Adipocytes; Adipokines; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; C | 2014 |
Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hypoglycemic Agents; Metformin; MicroRNAs; Pheno | 2014 |
Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hypoglycemic Agents; Metformin; MicroRNAs; Pheno | 2014 |
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Campto | 2014 |
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Campto | 2014 |
Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells.
Topics: Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Female; Humans; Matrix Metalloproteinase | 2014 |
Metformin inhibits tumor cell migration via down-regulation of MMP9 in tamoxifen-resistant breast cancer cells.
Topics: Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Female; Humans; Matrix Metalloproteinase | 2014 |
Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression.
Topics: Breast Neoplasms; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Dose-Response Relationship, Drug | 2014 |
Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression.
Topics: Breast Neoplasms; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Dose-Response Relationship, Drug | 2014 |
[Hyperglycaemia during treatment with everolimus].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Hyperglycemia; Hypoglycem | 2014 |
[Hyperglycaemia during treatment with everolimus].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Everolimus; Female; Humans; Hyperglycemia; Hypoglycem | 2014 |
The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Electron Tran | 2015 |
The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Electron Tran | 2015 |
Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dichl | 2014 |
Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dichl | 2014 |
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cel | 2014 |
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cel | 2014 |
Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Diabetes Mellitus, Type 2; F | 2015 |
Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Diabetes Mellitus, Type 2; F | 2015 |
Metformin and erlotinib synergize to inhibit basal breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wes | 2014 |
Metformin and erlotinib synergize to inhibit basal breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wes | 2014 |
Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Carcinoma, Basal Cell; Cell Line, Tumor; Chemoradio | 2014 |
Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Carcinoma, Basal Cell; Cell Line, Tumor; Chemoradio | 2014 |
Metformin and survival in diabetic patients with breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Disease-Free Survi | 2014 |
Metformin and survival in diabetic patients with breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Disease-Free Survi | 2014 |
Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; | 2015 |
Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; | 2015 |
Metformin inhibits 7,12-dimethylbenz[a]anthracene-induced breast carcinogenesis and adduct formation in human breast cells by inhibiting the cytochrome P4501A1/aryl hydrocarbon receptor signaling pathway.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinogenesis | 2015 |
Metformin inhibits 7,12-dimethylbenz[a]anthracene-induced breast carcinogenesis and adduct formation in human breast cells by inhibiting the cytochrome P4501A1/aryl hydrocarbon receptor signaling pathway.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinogenesis | 2015 |
Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relatio | 2015 |
Dual effect of metformin on growth inhibition and oestradiol production in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relatio | 2015 |
The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2015 |
The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2015 |
[Obesity as a factor in the development of cancer in type 2 diabetes].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans | 2015 |
[Obesity as a factor in the development of cancer in type 2 diabetes].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans | 2015 |
Effects of metformin on cell kinetic parameters of MCF-7 breast cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Flow Cytometry; Humans; Hypoglycemic Agents | 2015 |
Effects of metformin on cell kinetic parameters of MCF-7 breast cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Flow Cytometry; Humans; Hypoglycemic Agents | 2015 |
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Female; Humans; Metformin; Middle | 2015 |
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Female; Humans; Metformin; Middle | 2015 |
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Female; Humans; Metformin; Middle | 2015 |
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Female; Humans; Metformin; Middle | 2015 |
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Female; Humans; Metformin; Middle | 2015 |
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Female; Humans; Metformin; Middle | 2015 |
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Female; Humans; Metformin; Middle | 2015 |
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Female; Humans; Metformin; Middle | 2015 |
Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer.
Topics: Animals; Breast Neoplasms; Female; HeLa Cells; Humans; Hypoglycemic Agents; Mammary Neoplasms, Exper | 2015 |
Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer.
Topics: Animals; Breast Neoplasms; Female; HeLa Cells; Humans; Hypoglycemic Agents; Mammary Neoplasms, Exper | 2015 |
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviva | 2015 |
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviva | 2015 |
Association of diabetes and diabetes treatment with incidence of breast cancer.
Topics: Adult; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus; Female; Humans; Incidence; Metform | 2016 |
Association of diabetes and diabetes treatment with incidence of breast cancer.
Topics: Adult; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus; Female; Humans; Incidence; Metform | 2016 |
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.
Topics: Adult; Aged; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Immunohistochemistry; Kaplan-Meier | 2015 |
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.
Topics: Adult; Aged; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Immunohistochemistry; Kaplan-Meier | 2015 |
Associations between diabetes medication use and risk of second breast cancer events and mortality.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Diabetes Mellitus; Fem | 2015 |
Associations between diabetes medication use and risk of second breast cancer events and mortality.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cohort Studies; Diabetes Mellitus; Fem | 2015 |
Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholecalciferol; Drug Synergism; | 2015 |
Synergistic antitumor activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholecalciferol; Drug Synergism; | 2015 |
Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell | 2015 |
Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell | 2015 |
Metformin in breast cancer - an evolving mystery.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin; Receptor, Insulin; Signal Transd | 2015 |
Metformin in breast cancer - an evolving mystery.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin; Receptor, Insulin; Signal Transd | 2015 |
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colorectal Neoplasms; Databases, Factual; Diabetes | 2015 |
No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colorectal Neoplasms; Databases, Factual; Diabetes | 2015 |
p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dose-Respons | 2015 |
p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dose-Respons | 2015 |
Characterization and evaluation of metformin-loaded solid lipid nanoparticles for celluar and mitochondrial uptake.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Calorimetry, Differential Sc | 2016 |
Characterization and evaluation of metformin-loaded solid lipid nanoparticles for celluar and mitochondrial uptake.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Calorimetry, Differential Sc | 2016 |
Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.
Topics: Adenosine Triphosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Ag | 2015 |
Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.
Topics: Adenosine Triphosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Ag | 2015 |
Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions.
Topics: Adjuvants, Pharmaceutic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Culture Media; Down-Regulati | 2015 |
Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions.
Topics: Adjuvants, Pharmaceutic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Culture Media; Down-Regulati | 2015 |
Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Antineoplastic Combine | 2014 |
Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Antineoplastic Combine | 2014 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resis | 2016 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resis | 2016 |
Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Capillaries; Coculture Techniques; Female; Gene | 2015 |
Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Capillaries; Coculture Techniques; Female; Gene | 2015 |
Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; C | 2016 |
Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; C | 2016 |
LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells.
Topics: Aged; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Blotting, Wester | 2016 |
LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells.
Topics: Aged; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Blotting, Wester | 2016 |
Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemo | 2016 |
Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemo | 2016 |
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Topics: Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Asp | 2016 |
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Topics: Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Asp | 2016 |
Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Energy Metabolis | 2016 |
Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Energy Metabolis | 2016 |
Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.
Topics: AMP-Activated Protein Kinases; Aniline Compounds; Animals; Benzamides; Bone Neoplasms; Breast Neopla | 2016 |
Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.
Topics: AMP-Activated Protein Kinases; Aniline Compounds; Animals; Benzamides; Bone Neoplasms; Breast Neopla | 2016 |
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.
Topics: Animals; Breast Neoplasms; Diet, High-Fat; Female; Glucose; Humans; Hypoglycemic Agents; Macrophages | 2016 |
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.
Topics: Animals; Breast Neoplasms; Diet, High-Fat; Female; Glucose; Humans; Hypoglycemic Agents; Macrophages | 2016 |
Metformin may protect nondiabetic breast cancer women from metastasis.
Topics: Adult; Aged; Blood Glucose; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans | 2016 |
Metformin may protect nondiabetic breast cancer women from metastasis.
Topics: Adult; Aged; Blood Glucose; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans | 2016 |
Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cytostatic Agents; Down-Regulation; Female; Gene | 2016 |
Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cytostatic Agents; Down-Regulation; Female; Gene | 2016 |
Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Choline; Female; Humans; Metformin; Phosphatidylcholines; Phosph | 2016 |
Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Choline; Female; Humans; Metformin; Phosphatidylcholines; Phosph | 2016 |
Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Dr | 2016 |
Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Dr | 2016 |
Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Hypoglycemic Ag | 2016 |
Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Hypoglycemic Ag | 2016 |
Impact of metformin on metastases in patients with breast cancer and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Germany; Humans; Hypog | 2016 |
Impact of metformin on metastases in patients with breast cancer and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Germany; Humans; Hypog | 2016 |
Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Proteomics | 2016 |
Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Proteomics | 2016 |
Medium Renewal Blocks Anti-Proliferative Effects of Metformin in Cultured MDA-MB-231 Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2016 |
Medium Renewal Blocks Anti-Proliferative Effects of Metformin in Cultured MDA-MB-231 Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2016 |
Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer.
Topics: Animals; Breast Neoplasms; Butyrates; Cell Line, Tumor; Cell Proliferation; Female; Humans; Metformi | 2016 |
Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer.
Topics: Animals; Breast Neoplasms; Butyrates; Cell Line, Tumor; Cell Proliferation; Female; Humans; Metformi | 2016 |
Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Carcinoma, Intraductal, Noninfilt | 2017 |
Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Carcinoma, Intraductal, Noninfilt | 2017 |
[Lily polysaccharide 1 enhances the effect of metformin on proliferation and apoptosis of human breast carcinoma cells].
Topics: AMP-Activated Protein Kinases; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; F | 2016 |
[Lily polysaccharide 1 enhances the effect of metformin on proliferation and apoptosis of human breast carcinoma cells].
Topics: AMP-Activated Protein Kinases; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; F | 2016 |
[Metformin impact on purine metabolism in breast cancer].
Topics: Aged; Breast Neoplasms; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Metformin; Middle | 2016 |
[Metformin impact on purine metabolism in breast cancer].
Topics: Aged; Breast Neoplasms; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Metformin; Middle | 2016 |
The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclins; DNA-Binding Proteins; Female; | 2016 |
The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclins; DNA-Binding Proteins; Female; | 2016 |
TRAIL restores DCA/metformin-mediated cell death in hypoxia.
Topics: Breast Neoplasms; Cell Death; Cell Hypoxia; Dichloroacetic Acid; Enzyme Activation; Humans; JNK Mito | 2016 |
TRAIL restores DCA/metformin-mediated cell death in hypoxia.
Topics: Breast Neoplasms; Cell Death; Cell Hypoxia; Dichloroacetic Acid; Enzyme Activation; Humans; JNK Mito | 2016 |
Metformin induces degradation of mTOR protein in breast cancer cells.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Metformin; Protei | 2016 |
Metformin induces degradation of mTOR protein in breast cancer cells.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Metformin; Protei | 2016 |
Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin G2; Cyclin-Dependen | 2016 |
Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin G2; Cyclin-Dependen | 2016 |
miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7.
Topics: 3' Untranslated Regions; AMP-Activated Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; | 2016 |
miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7.
Topics: 3' Untranslated Regions; AMP-Activated Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; | 2016 |
Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Topics: Adult; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Me | 2017 |
Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Topics: Adult; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Me | 2017 |
Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models.
Topics: Animals; Antihypertensive Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2017 |
Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models.
Topics: Animals; Antihypertensive Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2017 |
Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding | 2017 |
Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding | 2017 |
Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women.
Topics: Aged; Breast Neoplasms; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; | 2017 |
Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women.
Topics: Aged; Breast Neoplasms; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; | 2017 |
Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.
Topics: Animals; Antibodies, Neoplasm; Antigens, CD; Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; | 2017 |
Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.
Topics: Animals; Antibodies, Neoplasm; Antigens, CD; Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; | 2017 |
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
Topics: AMP-Activated Protein Kinase Kinases; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell S | 2009 |
The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
Topics: AMP-Activated Protein Kinase Kinases; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell S | 2009 |
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Hypoglycemic | 2009 |
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Hypoglycemic | 2009 |
Is it time to test metformin in breast cancer clinical trials?
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Diabetes Mellitus, Type 2; H | 2009 |
Is it time to test metformin in breast cancer clinical trials?
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Diabetes Mellitus, Type 2; H | 2009 |
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells.
Topics: AMP-Activated Protein Kinases; Aurora Kinases; Breast Neoplasms; Cell Cycle Proteins; Cell Division; | 2009 |
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells.
Topics: AMP-Activated Protein Kinases; Aurora Kinases; Breast Neoplasms; Cell Cycle Proteins; Cell Division; | 2009 |
Metformin induces unique biological and molecular responses in triple negative breast cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspases | 2009 |
Metformin induces unique biological and molecular responses in triple negative breast cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspases | 2009 |
Metformin in breast cancer: time for action.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Female; Humans; | 2009 |
Metformin in breast cancer: time for action.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Female; Humans; | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Fe | 2009 |
Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Humans; Hypoglycemic Agents; Insuli | 2009 |
Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Humans; Hypoglycemic Agents; Insuli | 2009 |
Metformin, diet and breast cancer: an avenue for chemoprevention.
Topics: Breast Neoplasms; Chemoprevention; Diet; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged | 2009 |
Metformin, diet and breast cancer: an avenue for chemoprevention.
Topics: Breast Neoplasms; Chemoprevention; Diet; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged | 2009 |
Expanding the arsenal: metformin for the treatment of triple-negative breast cancer?
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Breast Neoplasms; ErbB Receptors; F | 2009 |
Expanding the arsenal: metformin for the treatment of triple-negative breast cancer?
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Breast Neoplasms; ErbB Receptors; F | 2009 |
Is it time to test metformin in breast cancer prevention trials? A reply to the authors.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin | 2009 |
Is it time to test metformin in breast cancer prevention trials? A reply to the authors.
Topics: Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Growt | 2009 |
LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.
Topics: AMP-Activated Protein Kinase Kinases; Breast Neoplasms; Female; Humans; Metformin; Neoadjuvant Thera | 2009 |
LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.
Topics: AMP-Activated Protein Kinase Kinases; Breast Neoplasms; Female; Humans; Metformin; Neoadjuvant Thera | 2009 |
If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Clinical Trials as Topic; Drug Deli | 2009 |
If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Clinical Trials as Topic; Drug Deli | 2009 |
Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; | 2010 |
Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; | 2010 |
Metformin as an addition to conventional chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Diabetes M | 2009 |
Metformin as an addition to conventional chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Diabetes M | 2009 |
Metformin, B(12), and enhanced breast cancer response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Female; Humans; | 2010 |
Metformin, B(12), and enhanced breast cancer response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diabetes Mellitus; Female; Humans; | 2010 |
[Glargine insulin and cancer risk].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Complications; Diabe | 2009 |
[Glargine insulin and cancer risk].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Complications; Diabe | 2009 |
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Prolif | 2010 |
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Prolif | 2010 |
Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy.
Topics: Adipokines; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Biomarkers; Bl | 2010 |
Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy.
Topics: Adipokines; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Biomarkers; Bl | 2010 |
Long-term metformin use is associated with decreased risk of breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemi | 2010 |
Long-term metformin use is associated with decreased risk of breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemi | 2010 |
Long-term metformin use is associated with decreased risk of breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemi | 2010 |
Long-term metformin use is associated with decreased risk of breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemi | 2010 |
Long-term metformin use is associated with decreased risk of breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemi | 2010 |
Long-term metformin use is associated with decreased risk of breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemi | 2010 |
Long-term metformin use is associated with decreased risk of breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemi | 2010 |
Long-term metformin use is associated with decreased risk of breast cancer.
Topics: Aged; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemi | 2010 |
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Topics: Breast Neoplasms; Estrogens; Estrogens, Catechol; Female; Gas Chromatography-Mass Spectrometry; Gene | 2010 |
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Topics: Breast Neoplasms; Estrogens; Estrogens, Catechol; Female; Gas Chromatography-Mass Spectrometry; Gene | 2010 |
The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; | 2011 |
The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; | 2011 |
More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2011 |
More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2011 |
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.
Topics: AMP-Activated Protein Kinases; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle | 2010 |
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.
Topics: AMP-Activated Protein Kinases; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle | 2010 |
Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Topics: Adenylate Kinase; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase; Aromatase Inhibitors; Breas | 2011 |
Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Topics: Adenylate Kinase; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase; Aromatase Inhibitors; Breas | 2011 |
Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Blood Glucose; Breast Neoplasms; Diabetes Mell | 2010 |
Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Blood Glucose; Breast Neoplasms; Diabetes Mell | 2010 |
[Effect of previous diabetes therapy on tumor receptor phenotype in breast cancer: comparison of metformin and sulphonylurea derivatives].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diabetes Mellitus; Femal | 2010 |
[Effect of previous diabetes therapy on tumor receptor phenotype in breast cancer: comparison of metformin and sulphonylurea derivatives].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diabetes Mellitus; Femal | 2010 |
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
Topics: Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Humans; | 2010 |
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
Topics: Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Humans; | 2010 |
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; | 2011 |
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; | 2011 |
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; | 2011 |
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; | 2011 |
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; | 2011 |
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; | 2011 |
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; | 2011 |
Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; | 2011 |
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Topics: Animals; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cellular Senescence; Dogs; Epithelial-Mesenc | 2010 |
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
Topics: Animals; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cellular Senescence; Dogs; Epithelial-Mesenc | 2010 |
The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.
Topics: Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Female; Flow Cytometry; Fluorescent Antibody Techn | 2011 |
The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.
Topics: Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Female; Flow Cytometry; Fluorescent Antibody Techn | 2011 |
Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Denmark; Diabetes Mellitus; Female; | 2011 |
Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Denmark; Diabetes Mellitus; Female; | 2011 |
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; AMP-Activated Protein Kinase Kinases; AMP-Activated | 2011 |
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; AMP-Activated Protein Kinase Kinases; AMP-Activated | 2011 |
Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation; H | 2011 |
Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation; H | 2011 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Car | 2011 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Car | 2011 |
[Effects of antidiabetic drug metformin on human breast carcinoma cells with different estrogen receptor expressing in vitro].
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relatio | 2011 |
[Effects of antidiabetic drug metformin on human breast carcinoma cells with different estrogen receptor expressing in vitro].
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relatio | 2011 |
Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells.
Topics: Apoptosis; Apoptosis Inducing Factor; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Cycle; Ce | 2011 |
Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells.
Topics: Apoptosis; Apoptosis Inducing Factor; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Cycle; Ce | 2011 |
Gerosuppressant metformin: less is more.
Topics: Adenylate Kinase; Aging; Animals; Breast Neoplasms; Cellular Senescence; Disease Progression; Enzyme | 2011 |
Gerosuppressant metformin: less is more.
Topics: Adenylate Kinase; Aging; Animals; Breast Neoplasms; Cellular Senescence; Disease Progression; Enzyme | 2011 |
Therapeutic effects of metformin in breast cancer: involvement of the immune system?
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Metformin; Mice | 2011 |
Therapeutic effects of metformin in breast cancer: involvement of the immune system?
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Metformin; Mice | 2011 |
Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling.
Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cycl | 2011 |
Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling.
Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cycl | 2011 |
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma; Case-Control Studies; Diabetes Mellitus | 2012 |
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma; Case-Control Studies; Diabetes Mellitus | 2012 |
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell | 2011 |
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell | 2011 |
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Topics: Alloxan; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell | 2011 |
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Topics: Alloxan; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell | 2011 |
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, | 2011 |
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, | 2011 |
5'-AMP-activated protein kinase (AMPK) regulates progesterone receptor transcriptional activity in breast cancer cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Breast Neoplasms; Cell Line, Tumor; Femal | 2011 |
5'-AMP-activated protein kinase (AMPK) regulates progesterone receptor transcriptional activity in breast cancer cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Breast Neoplasms; Cell Line, Tumor; Femal | 2011 |
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; F | 2012 |
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Case-Control Studies; Diabetes Mellitus, Type 2; F | 2012 |
Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression.
Topics: Antioxidants; Breast Neoplasms; Cell Proliferation; Estradiol; Female; Flow Cytometry; Humans; Metfo | 2011 |
Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression.
Topics: Antioxidants; Breast Neoplasms; Cell Proliferation; Estradiol; Female; Flow Cytometry; Humans; Metfo | 2011 |
Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Electron Transport Com | 2011 |
Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Electron Transport Com | 2011 |
Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.
Topics: Aminosalicylic Acids; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Ben | 2012 |
Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.
Topics: Aminosalicylic Acids; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Ben | 2012 |
Metabolic compartments in tumor tissue: implications for therapy.
Topics: Breast Neoplasms; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Metformi | 2012 |
Metabolic compartments in tumor tissue: implications for therapy.
Topics: Breast Neoplasms; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Metformi | 2012 |
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2012 |
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic A | 2012 |
Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation.
Topics: Breast Neoplasms; Cell Line, Tumor; Electron Transport Complex IV; Female; Histocompatibility Antige | 2012 |
Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation.
Topics: Breast Neoplasms; Cell Line, Tumor; Electron Transport Complex IV; Female; Histocompatibility Antige | 2012 |
Phenformin as prophylaxis and therapy in breast cancer xenografts.
Topics: Adenylate Kinase; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Cell Li | 2012 |
Phenformin as prophylaxis and therapy in breast cancer xenografts.
Topics: Adenylate Kinase; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Cell Li | 2012 |
Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Chem | 2012 |
Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Chem | 2012 |
Cracking open window of opportunity trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Diabetes Mellitus; Female; Humans; Hypo | 2012 |
Cracking open window of opportunity trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Diabetes Mellitus; Female; Humans; Hypo | 2012 |
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast N | 2012 |
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast N | 2012 |
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Autophagy; Breast Neoplasms; Carboplatin; Ce | 2012 |
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Autophagy; Breast Neoplasms; Carboplatin; Ce | 2012 |
A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Blood Glucose; Breast Neoplasms; Cell Line, Tumo | 2012 |
A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Blood Glucose; Breast Neoplasms; Cell Line, Tumo | 2012 |
[The influence of metformin and N-acetylcysteine on mammographic density in postmenopausal women].
Topics: Acetylcysteine; Aged; Apoptosis; Breast; Breast Neoplasms; Cell Proliferation; DNA Repair; Female; H | 2012 |
[The influence of metformin and N-acetylcysteine on mammographic density in postmenopausal women].
Topics: Acetylcysteine; Aged; Apoptosis; Breast; Breast Neoplasms; Cell Proliferation; DNA Repair; Female; H | 2012 |
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.
Topics: Animals; Antitubercular Agents; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2012 |
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.
Topics: Animals; Antitubercular Agents; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2012 |
Diabetes, metformin, and breast cancer in postmenopausal women.
Topics: Aged; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Incidence; Metformin; Middle Aged; Postme | 2012 |
Diabetes, metformin, and breast cancer in postmenopausal women.
Topics: Aged; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Incidence; Metformin; Middle Aged; Postme | 2012 |
Diabetes, metformin, and breast cancer: lilac time?
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin | 2012 |
Diabetes, metformin, and breast cancer: lilac time?
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin | 2012 |
[Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
Topics: Aged; Aromatase; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation, En | 2012 |
[Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
Topics: Aged; Aromatase; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation, En | 2012 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Illuminating the diabetes-cancer link.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic | 2012 |
Metformin is synthetically lethal with glucose withdrawal in cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Li | 2012 |
Metformin is synthetically lethal with glucose withdrawal in cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Li | 2012 |
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Ataxia Telangiectasia Mutated P | 2012 |
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Ataxia Telangiectasia Mutated P | 2012 |
The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flow C | 2012 |
The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flow C | 2012 |
Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women.
Topics: Adult; Aged; Breast Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Insulin; M | 2012 |
Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women.
Topics: Adult; Aged; Breast Neoplasms; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Insulin; M | 2012 |
Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance.
Topics: Animals; Autophagy; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; DNA-Directed RNA Polymeras | 2012 |
Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance.
Topics: Animals; Autophagy; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; DNA-Directed RNA Polymeras | 2012 |
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; | 2013 |
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; | 2013 |
Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulat | 2013 |
Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulat | 2013 |
Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels?
Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Blood Glucose; Breast Neoplasms; Case-Control Stu | 2012 |
Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels?
Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Blood Glucose; Breast Neoplasms; Case-Control Stu | 2012 |
Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin.
Topics: Antineoplastic Agents; Autophagy; Breast Neoplasms; Caveolin 1; Cell Line; Cell Proliferation; Cocul | 2013 |
Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin.
Topics: Antineoplastic Agents; Autophagy; Breast Neoplasms; Caveolin 1; Cell Line; Cell Proliferation; Cocul | 2013 |
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Transformation | 2013 |
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Transformation | 2013 |
Metformin and breast cancer risk.
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin | 2013 |
Metformin and breast cancer risk.
Topics: Breast Neoplasms; Diabetes Mellitus; Female; Humans; Metformin | 2013 |
Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion.
Topics: Anti-Inflammatory Agents; Breast Neoplasms; Cell Adhesion; Cell Aggregation; Cell Line, Tumor; Cell | 2013 |
Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion.
Topics: Anti-Inflammatory Agents; Breast Neoplasms; Cell Adhesion; Cell Aggregation; Cell Line, Tumor; Cell | 2013 |
Metformin induces a senescence-associated gene signature in breast cancer cells.
Topics: Breast Neoplasms; Cell Culture Techniques; Cellular Senescence; Female; Gene Expression Regulation, | 2013 |
Metformin induces a senescence-associated gene signature in breast cancer cells.
Topics: Breast Neoplasms; Cell Culture Techniques; Cellular Senescence; Female; Gene Expression Regulation, | 2013 |
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Topics: Adenylate Kinase; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Fem | 2006 |
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Topics: Adenylate Kinase; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Fem | 2006 |
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene | 2007 |
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene | 2007 |
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Enzyme Activat | 2009 |
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Enzyme Activat | 2009 |
Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?
Topics: Breast Neoplasms; Exercise; Female; Humans; Hypoglycemic Agents; Insulin; Life Style; Metformin; Mus | 2008 |
Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?
Topics: Breast Neoplasms; Exercise; Female; Humans; Hypoglycemic Agents; Insulin; Life Style; Metformin; Mus | 2008 |
Doctors seek to prevent breast cancer recurrence by lowering insulin levels.
Topics: Adenylate Kinase; Antineoplastic Agents; Breast Neoplasms; Canada; Clinical Trials as Topic; Exercis | 2008 |
Doctors seek to prevent breast cancer recurrence by lowering insulin levels.
Topics: Adenylate Kinase; Antineoplastic Agents; Breast Neoplasms; Canada; Clinical Trials as Topic; Exercis | 2008 |
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Topics: AMP-Activated Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; | 2009 |
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Topics: AMP-Activated Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; | 2009 |
Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells.
Topics: Breast Neoplasms; Cells, Cultured; Cycloheximide; Humans; Insulin; Lymphocytes; Metformin; Phenformi | 1982 |
Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells.
Topics: Breast Neoplasms; Cells, Cultured; Cycloheximide; Humans; Insulin; Lymphocytes; Metformin; Phenformi | 1982 |
Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding of its receptors in target cells.
Topics: Animals; Biguanides; Breast Neoplasms; Cell Line; Female; Fibroblasts; Humans; Insulin; Liver Neopla | 1982 |
Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding of its receptors in target cells.
Topics: Animals; Biguanides; Breast Neoplasms; Cell Line; Female; Fibroblasts; Humans; Insulin; Liver Neopla | 1982 |
Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro.
Topics: Breast Neoplasms; Colonic Neoplasms; Fibroblasts; Glyburide; Humans; In Vitro Techniques; Insulin; M | 1987 |
Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro.
Topics: Breast Neoplasms; Colonic Neoplasms; Fibroblasts; Glyburide; Humans; In Vitro Techniques; Insulin; M | 1987 |